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Abstract 
The Joint United Nations Program on HIV/AIDS (UNAIDS) over the past two decades has 
documented the heavy burden and impact of HIV on mothers and infants living in resource-
limited settings. The sub-Saharan Africa (SSA) region still faces a challenge of significant 
numbers of pregnant women who acquire HIV infection during pregnancy or postpartum but 
who are not diagnosed and offered antiretroviral medicines. The achievement of the UNAIDS 
goal relies on a successful implementation of a set of prevention of mother-to-child 
transmission (PMTCT) of HIV interventions called the PMTCT cascade. The goal of 
elimination of new paediatric infections has not been met, so there is a need to investigate 
why some programs are not effective. Routinely collected clinic data can provide much 
needed information on the prevalence of HIV among pregnant women and the uptake of 
services for PMTCT of HIV. In Zambia there is a substantial amount of data that has been 
collected through the SmartCare electronic health record system over the years, but the 
database has never been used to analyse the implementation of PMTCT programs. 
A mixed method study design was used which included a systematic review of literature, 
quantitative and qualitative methods. A systematic review of literature was conducted to 
identify, evaluate and summarise the findings from analysis of quantitative retrospective and 
prospective cohort studies that utilised routinely collected data with a focus on provision and 
utilisation of post 2010 PMTCT services in SSA. The quantitative analysis of SmartCare 
routinely collected data provided an overview of PMTCT coverage and the performance of 
early infant diagnosis (EID) services. Qualitative data was collected using in-depth 
interviews, observations and focus groups discussions (FGD) to understand the 
implementation procedures of SmartCare. 
 
The findings from the systematic review of literature showed a decrease in the mother to child 
transmission (MTCT) rate but poor quality routinely collected data. The quantitative analysis 
of 104, 155 pregnant women seeking antenatal care (ANC) services in 886 health facilities 
indicated an increase from 2010 to 2015 in the proportion of HIV- infected women who were 
already on treatment. The analysis of data comprising 32, 593 HIV-infected infants born in 
the pre (2006-2009) and post (2010-2016) Option B+ periods revealed that there has been 
progress in the EID program implementation. The results from the two quantitative studies 
were characterised by missing data which introduced bias and affected the external validity of 
the findings. The findings from SmartCare data analysis were triangulated with the Health 
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Management Information System (HMIS), which further confirmed the conclusion drawn. 
The SmartCare database has structural challenges which can be traced to its development and 
in addition it has faced a lot of implementation challenges which include funding gaps, lack 
of feedback from the system and the absence of uniform data collection and verification 
procedures. 
 
The thesis is the first study to have attempted to evaluate the implementation of PMTCT 
guidelines using routinely collected data from the SmartCare electronic health record (EHR) 
system database.  Recommendations arising from the thesis include upgrading of SmartCare 
into a networked Open Medical Record System. The Zambia MoH with its partners could 
also implement a SmartCare performance-based financing initiative in order to improve the 
implementation of EHR system. Further studies are needed to investigate the impact of 
implementing PMTCT guidelines particularly on the retention in care and adherence to 
treatment and EID. 
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Chapter 1: Introduction 
 
The Joint United Nations Program on HIV/AIDS (UNAIDS) over the past two decades has 
documented the heavy burden and impact of HIV on mothers and infants living in resource-
limited settings. Globally, AIDS-related illnesses are the leading cause of death among 15–
49-year-old females who are in their reproductive stage(1). The sub-Saharan Africa (SSA) 
region still faces a challenge of significant numbers of pregnant women who acquire HIV 
infection during pregnancy or postpartum but who are not diagnosed and offered 
antiretroviral medicines (2). The 2011 Global Plan towards the elimination of new HIV 
infections among children and keeping mothers alive aimed to reduce new childhood 
infections by 90% and HIV‐related maternal death by 50% by 2015(3). The drive to eliminate 
mother-to-child transmission of HIV continues to yield results, with 93% of pregnant women 
living with HIV in the eastern and southern African region receiving antiretroviral 
prophylaxis in 2017(2). The target of elimination of new paediatric infections has not been 
met, so there is a need to investigate why some programs are not effective. 
 
A commonly used surrogate marker for program effectiveness is program coverage.  For 
prevention of mother-child-transmission of HIV (PMTCT) this would be the proportion of 
HIV-infected women and exposed infants in a population who access the different 
components of the PMTCT programmatic cascade(4). Estimates of coverage with PMTCT 
services among all HIV-infected pregnant women are vital to monitor progress relative to 
targets (5).  
1.1 Rationale of the Study 
Routinely collected clinic data can provide much needed information on the prevalence of 
HIV among pregnant women and the uptake of services for PMTCT of HIV(5). The use of 
routinely collected data can be timely and cost-efficient for decision making as data are 
already available for analysis (6). However in Zambia there is underutilization of routinely 
collected data in the HIV programs (7). An important component of this study is to 
investigate how routine program data can be used for assessing the outcome of a PMTCT 
program and by doing so, help adjust or fine-tune program implementation in an evidence-
informed way. 
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1.2 Study Aim and Objectives  
Zambia has been using ‘SmartCare’, an electronic health records (EHR) system for the 
routine collection of HIV data since 2004, and currently most facilities wishing to dispense 
ART are required to use this system. This means there is a substantial amount of data that has 
been collected over the years, but the database has never been used to analyse the 
effectiveness of implementing PMTCT programs. The study aimed to use routinely collected 
data to give an overview of the effectiveness of post 2010 World Health Organisation (WHO) 
PMTCT guidelines implementation and improve decision making in the Zambia health care 
system. The main objectives were: 
1. To synthesise and evaluate the impact of implementing post-2010 WHO PMTCT 
guidelines on attainment of PMTCT targets in Sub-Saharan Africa through a 
systematic review of literature. 
2. To describe trends in the coverage of PMTCT services from 2010 to 2015 using the 
SmartCare database of routine clinical information collected in Zambia. 
3. To evaluate the performance of Zambia’s early infant diagnosis services using 
routinely collected data of HIV-infected infants in the SmartCare database for the 
period January 2006 to December 2016. 
4. To use qualitative research to understand the implementation procedures of the 
SmartCare system. 
 
1.3 Structure of the Thesis 
This thesis is presented in nine chapters and follows the format of the “research paper style” 
dissertation.  It is made up of manuscripts that have been published, or under review together 
with introductory, methods, triangulation and discussion chapters. Each of the four 
manuscripts, written in the format of the journals where they are published or intended to be 
published, establishes an independent chapter. Each chapter that contains a journal 
manuscript is prefaced by the required LSHTM cover sheet. The references for each of the 
published papers are presented at the end of each chapter whilst the references for the 
unpublished sections are presented at the end of the thesis.  The outline of the chapters is as 
follows: 
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Chapter 1- Introduction  
This chapter presents an overview of the research through a brief description of the 
knowledge gap, study rationale and the research aims and objectives. The roles of the 
candidate in the research are also outlined. 
 
Chapter 2 – Background  
The chapter gives the background of the global commitment to elimination of new paediatric 
infections through the use of antiretroviral therapy (ART). The post-2010 WHO PMTCT 
guidelines are also described. A particular focus was made to the literature from Sub-Saharan 
Africa and the 22 priority countries, including Zambia, with a high burden of HIV. 
 
Chapter 3 – Methods 
The chapter highlights the methods used for the study and includes overall study design, 
study location and the ethical considerations during the conduct of the study.  
 
Chapter 4 - Systematic Literature Review Paper  
The chapter is a published article in the Journal of Medicine and is titled Implementation 
Effectiveness of Revised (post- 2010) World Health Organisation Guidelines on 
Prevention of Mother to Child Transmission of HIV using routinely collected Data in 
sub-Saharan Africa: A Systematic Literature Review. 
 
Chapter 5: Quantitative paper using antenatal services data set  
This paper is an analysis of a dataset of pregnant woman seeking antenatal (ANC) services in 
health facilities using the SmartCare electronic health record system. The article is under 
review with the Frontiers in Public Health journal. The manuscript is titled: Evidence that an 
Increasing Proportion of HIV-infected Pregnant Zambian Women attending ANC are 
already on ART: Analysis using Routinely Collected Data (2010-2015). 
 
Chapter 6: Quantitative paper using data set of HIV- infected infants  
The manuscript outlines the progress of the early infant diagnosis program in Zambia using 
the data of HIV-infected infants extracted from the SmartCare database. The paper was first 
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authored by an MSc student, Jasleen Singh, who analysed the dataset under my supervision 
for her summer project.  The manuscript was published by the BMC Public Health journal 
and is titled Progress in the performance of HIV Early Infant Diagnosis services in 
Zambia using routinely collected data from 2006 to 2016. 
 
Chapter 7 – Qualitative paper on implementation challenges of the SmartCare 
electronic health record system 
The chapter is a qualitative manuscript under review with the Health Informatics Journal. The 
paper presents the findings from investigating the implementing procedures of SmartCare and 
unearths the reasons for missing data in the two quantitative papers presented above. It is 
titled A Qualitative Inquiry into Implementing an Electronic Health Record System 
(SmartCare) for Prevention of Mother-to-Child Transmission data in Zambia. 
 
Chapter 8: Health Management Information System (HMIS) Data 
The purpose of this chapter was to present aggregate HMIS data and triangulate findings from 
the SmartCare database on outcomes similar to those discussed in Chapter 5.  
Chapter 9 - Discussion  
The implications of the study findings from the four papers and triangulating findings are 
outlined as well as the strengths and limitations of this work. Conclusions and 
recommendations are also drawn. 
1.4 Conceptualisation and Disciplinary Approach 
The purpose of this research was to inform practice; hence the candidate adopted a pragmatic 
approach with an aim to guide the delivery of PMTCT health services from the lessons learnt 
in the study. The candidate has training in international public health and is a public health 
practitioner with more than 15 years experience in strategic management of research 
operations and population-based surveys, designing and implementing research operations 
system. The candidate has also extensive research exposure through working with donors, 
government entities and the private sector. Through this work she had noted that there is a lot 
of data that is collected but not adequately analysed specifically for maternal and child health 
programs, which she has great interest in.  The candidate would have included in her research 
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the infant feeding practices of HIV-exposed infants; however, it seemed that data in this area 
are not adequately collected.  During the last three years, the candidate has worked for the 
School of Public Health, University of Zambia as a research fellow in a project whose aim 
was to support the utilisation of routinely-collected data for strengthening services and 
transparency in delivering services to people living with HIV. 
 
The candidate had the ambition to develop her quantitative research skills in analysing big 
data. In addition, the qualitative segment was added as a result of the initial analysis of the 
routinely collected data which had a lot of missing data requiring explanation regarding to the 
completeness, accuracy and representativeness of the findings. It was therefore crucial to have 
a mixed method study which provided added value to the candidate. The systematic literature 
review skills ensured the candidate justification for further research as this identified gaps in 
utilisation of routinely collected data for evaluation PMTCT programs. 
 
This research was built on the realisation that there is a dearth of evidence on implementing 
electronic health systems in developing countries.  The results show the value of using these 
data, which give a potential for a greater role in understanding patient health. The routine 
health information systems are often overlooked in the African health systems and the 
candidate now aspires to venture into further research in health informatics.  
 
1.5 Role of the Candidate 
I conceived the ideas, designed the studies and developed them further with my supervisors, 
Professor Suzanne Filteau and Mr Jim Todd, together with Dr Paul Mee the advisory 
committee member. Mrs Tendai Munthali and Dr Patrick Musonda appraised the quality of a 
portion of the included studies for the systematic review of literature study. I extracted all the 
data from the SmartCare database with the assistance of Ministry of Health ICT department. I 
cleaned and analysed the data with the assistance from the two supervisors and advice from 
Mr Ab Schaap and Dr Paul Mee for the quantitative studies.  I supervised Dr Jasleen Singh 
for her MSc Summer project to analyse the EID data set which I had already extracted, from 
the SmartCare database and cleaned, in preparation for analysis.  I also assisted her to draft 
the early infant diagnosis paper. I conducted all the in-depth interviews and observations for 
the qualitative study. The focus group discussions with women seeking PMTCT services 
were moderated by a trained field assistant who was fluent in the local languages (Bemba and 
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Nyanja).  Dr. Virginia Bond assisted in analysis of the qualitative data and the construction of 
the manuscript. I am also the corresponding author for all the manuscripts presented in this 
thesis. 
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Chapter 2: Background 
2.1 Global Commitment to eliminate new paediatric HIV infections 
The use of ART by HIV-positive pregnant and breastfeeding women is the cornerstone of the 
strategy to PMTCT (8, 9) of HIV. The global community in June 2011 committed to 
accelerate progress for PMTCT through an initiative whose goals were to eliminate new 
paediatric HIV infections by 2015 and improve maternal, new-born and child health and 
survival in the context of HIV(3). The Global Plan emphasized the expansion of 
comprehensive, integrated, and efficacious interventions for PMTCT within a maternal and 
child health (MCH) framework, to achieve targets by 2015 (3, 10). Subsequently the 2016 
United Nations United Nations General Assembly Political Declaration on ending the AIDS 
epidemic by 2030 committed, among other things, to reduce the number of children newly 
infected with HIV annually to less than 40 000, and to reach and sustain 95% of pregnant 
women living with HIV with lifelong HIV treatment by 2018 (11).  
The achievement of high coverage and uptake of services along the PMTCT cascade is 
crucial for national and international mother-to-child  transmission (MTCT) elimination goals 
(3).  Twenty-two countries in sub-Saharan Africa with a high burden of MTCT were 
identified as priority countries for intensified support to achieve the UNAIDS HIV 
elimination goal (3, 12). These countries are Botswana, Cameroon, Chad, Côte d’Ivoire, 
Democratic Republic of the Congo, Ethiopia, Ghana, Kenya, Lesotho, Malawi, Mali, 
Mozambique, Namibia, Nigeria, South Africa, South Sudan, Swaziland, Uganda, United 
Republic of Tanzania, Zambia, Zimbabwe (13).   As of October 2016, the WHO 
recommendation for lifelong ART for all pregnant and lactating women (Option B+) was 
being nationally implemented in the 22 priority countries (14). In 2017, the global coverage 
of pregnant women living with HIV had access to ARV medicines to prevent transmission of 
HIV to their babies was  80% [61–95%] (15).  
 As a result of increased coverage and improved regimens, rates of HIV transmission from 
mothers to infants during pregnancy and breastfeeding have decreased around the world (8). 
The largest decline was in eastern and southern Africa, where it fell from 18% of infants born 
to mothers living with HIV in 2010 to 6% in 2015(16). In 2017, 210 000 new infections were 
averted due to PMTCT(15). Some countries in the SSA like South Africa are approaching the 
very low MTCT rates achieved in high- income countries, but several others such as Zambia, 
Angola, DRC, Nigeria, Lesotho and Kenya lag far behind at the moment (17). In Zambia 
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coverage of pregnant women living with HIV accessing antiretroviral medicines was 92% [78 
- >95] in 2017, a decrease from 95% in 2015(15). 
Although the use of antiretroviral therapy (ART) for the prevention of mother-to-child 
transmission (PMTCT) is essential, effective programmes to achieve early infant diagnosis 
(EID) are critical when that prevention fails (18). There is strong evidence that the early 
initiation of ART in HIV-infected children can substantially reduce HIV-related morbidity 
and mortality (19). To ensure timely HIV diagnosis and access to ART, the WHO 
recommends that HIV-exposed children are regularly followed-up, tested for HIV and 
initiated on ART (20). However EID coverage in Zambia was 46 % in 2017 (15), which is far 
below the target although new HIV infections among children reduced from over 10 000 in 
2010 to 8 900 in 2016 (21). 
2.2 Timing of mother to child transmission 
MTCT occurs as a continuum across three time periods; in-utero, perinatal and postnatally 
through breastfeeding  (22). Without intervention, the risk of mother-to-child transmission of 
HIV (MTCT) can be as high as 45%, however successful implementation of PMTCT 
programs can reduce this risk to around 2% in non-breastfeeding populations and less than 
5% in breastfeeding populations (10, 23).  Maternal risk factors for in utero transmission 
include high plasma HIV viral load, low CD4 count and late stage of HIV disease. The risk of 
transmission ranges from 1% with plasma viral load of less than 400copies /l. to 32% with 
plasma viral load of 100,000copies /l. At delivery risk factors include: mode of delivery, 
premature delivery, long duration of membrane rupture, and infection in the birth canal. Post-
natal risk factors include mixed feeding, recent maternal HIV infection and mastitis (24).  
Interventions for PMTCT can either take a programmatic or individualised approach (25). 
 
Preventive interventions need to be considered within the context of the environment of the 
mother-infant pair. Lack of any breastfeeding or termination of breastfeeding before 6 months 
of age increases the risk of gastro-enteritis, and mortality as well as increasing the risk of 
malnutrition in the absence of safe and nutritious feeding alternatives. Hence, in usually 
resource-poor countries, risks of gastroenteritis and malnutrition outweigh the risk of 
transmission of HIV (26). Randomised controlled studies have demonstrated the low risk of 
breast milk transmission where the mother is on ART, or the infant is on pre-exposure 
prophylaxis (23). Therefore in African settings PMTCT programs should be designed around 
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breastfeeding together with provision of ART (26). The combined effect of maternal ART 
and infant post-exposure prophylaxis has been adopted into programs in Africa to reduce 
MTCT, and so, despite breastfeeding, the risk of transmission is ≤ 5%; this compares to the 
UK where the risk of transmission is as low as 0.1% with maternal ART and formula feeding 
(27).  
 
An estimated 3.3 million children are infected with HIV globally, with 90% of them residing 
in sub-Saharan Africa (28). Children aged 0-4 are among the most vulnerable to HIV, facing 
the highest risk of AIDS-related deaths compared to any other age group (29). New paediatric 
infections declined by 66% between 2010 and 2015(8), in 2017 210, 000 new infections were 
averted due to PMTCT(15). Without treatment approximately 50% of HIV-infected infants 
die before the age of two (30). One of the main factors for low coverage among children is 
the large number of infants who remain undiagnosed but would be eligible for treatment 
under current treatment guidelines (31). In Zambia the estimated percentage of children (aged 
0–14 years) living with HIV receiving ART, in 2015 was 61%, 3% lower than the adult 
coverage (8). Therefore, there is an urgent need to address the important programmatic 
2.3. Origins of PMTCT 
In 1982 United States of America reported the first case of paediatric HIV (32), 18 months 
after the first report of HIV in adults (33). Parental risk for HIV transmission to child was 
identified in 1983, confirming that most paediatric HIV infections occurred via transmission 
from mother-to-child and that one in four HIV-infected mothers transmitted HIV to their 
infants (32). No specific prevention interventions existed at that time other than identification 
of HIV status and, if infected, to avoid pregnancy. By 1985, the first guidance on paediatric 
HIV in the United States recommended that pregnant women in high-risk groups be offered 
counselling and voluntary HIV testing, and that HIV-infected women should avoid 
breastfeeding (33). In 1987, the approval of AZT for adults was subsequently proposed as a 
MTCT preventive strategy. The 67% reduction in MTCT in the ‘076 AZT trial’ was the first 
demonstration of ‘treatment as prevention’. Unfortunately, these interventions were too 
complex to administer (e.g., the protocol required both oral and intravenous AZT, the need 
for a sustainable infrastructure, and sustained attendance of women to ANC, which was not 
the norm) and, therefore, not feasible for most deliveries in LMICs at that time. Subsequent 
researches focused on simpler options to achieve similar results were initiated (34). Between 
1997 and 1999, the HIVNET 012 randomised trial conducted in Uganda concluded that 
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Nevirapine lowered the risk of HIV-1 transmission during the first 14-16 weeks of life by 
nearly 50% in a breastfeeding population (34).   
Recommendations expanded from selective testing of high-risk pregnant women in February 
1995, to HIV education and voluntary routine testing for all pregnant women in the United 
States, leading to the universal routine ‘opt-out’ antenatal HIV testing with patient 
notification. 
  By the late 1990s, enhanced affordability of AZT enabled Botswana to launch Africa’s first 
PMTCT program with short-course AZT while new research added a simple, sdNVP for 
enhanced efficiency, nearly halving transmission risk (35). In 1997, the recommendation to 
stop breastfeeding as soon as replacement feeds were available was the first programmatic 
acknowledgement that HIV transmission extends into the breastfeeding period. This 
recommendation became problematic in LMICs, as adequate supplies of safe infant formula 
could not be assured. The realization that the risk of transmission must be balanced against 
optimal feeding practices became important in PMTCT programs, and growing consideration 
was given to infant survival beyond the risk of transmission (36) 
In 2000, a 5-year NVP donation to developing countries expanded the availability of PMTCT 
for most LMICs. Additional research indicated that combining AZT and sdNVP was highly 
effective and capable of reducing MTCT to rates seen with triple ARV in resource-rich 
countries, which became the global standard for PMTCT. However, delays in program 
implementation, in part due to supply chain management problems of AZT and sdNVP, 
resulted in the majority of HIV-infected pregnant women in LMICs never receiving 
prophylaxis. 
Further, emerging concerns about rapidly developing resistance from sdNVP were becoming 
clear. Recognition of breastfeeding as the cornerstone of infant survival in LMICs spurred 
research on safe breastfeeding (37, 38). In 2003, the concept of rapid weaning of 
breastfeeding with targeted testing to minimize transmission risks during breastfeeding was 
introduced. Subsequently, calls for exclusive breastfeeding for 6 months with gradual 
weaning and an increased emphasis on ARV prophylaxis during breastfeeding were expanded 
in 2006. Although this represented a clear progression in thinking, correct programmatic 
implementation and messaging around this strategy was mired in confusion. Only when 
normative bodies began incorporating not only HIV, but also child survival into consideration 
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of reducing risks did this issue progress. By 2008, clinical trials examined varying 
prophylactic approaches of expanded ARV during breastfeeding and led to implementation of 
such programs by 2010 (39-41) 
The 2010 WHO PMTCT guidelines recommended eliminating the use of single-drug 
regimens, favouring longer duration of ARVs during pregnancy and breastfeeding, including 
ART for ineligible pregnant/breastfeeding women under Option B, in resource-limited 
settings (42). 
The 2010 guidelines also recommended extending ARV coverage through duration of 
breastfeeding exposure, now recommended for at least 12 months. In 2011, ‘Option B+, or 
lifelong ART for all HIV-positive pregnant/ breastfeeding women regardless of CD4 cell 
count, was adopted by Malawi in response to difficulties implementing CD4 cell testing. 
Preliminary data from Malawi’s B+ programs reported a rapid increase in the number of 
pregnant and breastfeeding women on ART (43). More so, MTCT rates have decreased 
considerably in many resource-limited areas (44, 45). 
2.4 post 2010 World Health Organisation PMTCT guidelines 
Global PMTCT guidelines have evolved from short-course antiretroviral (ARV) prophylaxis 
for mothers and infants to prevent HIV transmission, towards longer and more potent ARV 
regimens with the potential to improve maternal health (46-49) (Figure 2.1). WHO in 2010 
revised its PMTCT guidelines (48). This was in an effort to achieve the goal of reducing 
mother-to-child transmission to less than 5% by 2015 (50). These guidelines offered two 
options: Option A and Option B. Under Option A, pregnant women with a CD4≥350 cells/µL 
receive ART prophylaxis including daily Zidovudine from 14 weeks gestation through one 
week postpartum, single-dose Nevirapine at delivery, and daily Lamivudine from delivery 
through one week postpartum. Their infants receive daily Nevirapine from birth through one 
week after the cessation of breastfeeding. Women with CD4≤ 350 cells/µL or WHO clinical 
stage 3 or 4 disease are put permanently on triple-drug ART regardless of symptoms.  Under 
Option B, all women receive triple-drug ART from 14 weeks gestation through the cessation 
of breastfeeding, and infants receive a daily Nevirapine or Zidovudine dose from birth to 4–6 
weeks. (49). This recommendation replaced earlier guidelines that endorsed combination 
ART for women who met criteria for treatment based on CD4 cell count or disease stage (47). 
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Figure 2.1: Origins of PMTCT  
 
Refer to section 2.3 on PMTCT origins 
In 2013, WHO revised its guidelines for the treatment and prevention of HIV and 
recommended that all pregnant and breastfeeding HIV-infected women, regardless of CD4 
cell count, should continue ART for life known as "Option B+" whilst their infants receive 
daily Nevirapine or Zidovudine from birth to 4–6 weeks. Among women on ART prior to 
pregnancy, early MTCT in Malawi’s Option B+ programme compares favourably to 
transmission rates observed in developed countries (51).  
Zambia revised its national PMTCT guidelines in 2010 in accordance with the new WHO 
guidelines and, along with many other developing countries, adopted Option A(52). In 2013, 
after more than two years implementing Option A, Zambia announced that it would revise its 
PMTCT guidelines again and adopt Option B+(53). 
 
Effective PMTCT programs require women and their infants to receive a cascade of 
interventions (Figure 2.2) including uptake of antenatal services and HIV testing during 
pregnancy, use of ART by pregnant women living with HIV, appropriate infant feeding, 
uptake of infant HIV testing and other post–natal health care services (54). Several factors 
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could influence uptake of the PMTCT cascade services including health system factors that 
affect service uptake, user-related or individual factors and broader socio-cultural factors (55-
57). Health system or structural issues such as staffing level, availability and cost of ART, 
capacity of health personnel to prescribe appropriate regimens; shortage of supplies in 
facilities, failure to follow up mothers’ or infants’ status, and giving wrong information or 
suboptimal quality of counselling could lead to loss or dropout from the PMTCT cascade (57-
62). Individual factors such as mothers’ knowledge of PMTCT, socioeconomic and 
demographic characteristics, pregnancy history, as well as broader socio-cultural factors such 
as fear of stigma, lack of interest, cultural, family and social barriers are factors that influence 
successful completion of the PMTCT cascade services (63-65). There is evidence that 
performance based financing (an incentive scheme directed to health providers) has improved 
the quality and quantity of antenatal care interventions in Rwanda (66) and Mozambique (67) 
. Other SSA countries could explore financing initiative in order to improve the 
implementation the implementation of PMTCT guidelines  
Figure 2.2: PMTCT Cascade 
 
 
Zambia adapted the implementation of Option B+ based on a health outcome and cost 
implication analytic model on the national health system perspective (68) rather than based on 
participant consultation. In Tanzania where the acceptability of Option B+ was explored, 
women’s views on Option B+ were divided and those in favour of B+ were highly determined 
to prolong life for their own sake and were concerned for the welfare of their children. Others 
 
28 
 
questioned their own ability to adhere to life-long ART, thinking that they would be less 
motivated to take drugs after protecting their child, and fearing the drug side effects and the 
challenges of chronic daily medication (69). In addition preliminary data from Malawi the 
first country to introduce Option B+, a nation-wide cohort of women on Option B+ showed 
that 17% of Option B+ clients were lost to follow-up within 6 months after delivery (70).  
 
Acceptability and adherence to Option B+ has not been investigated in Zambia. However 
Kamuyango et al (71) and Ngarina et al (72)  reported that default and incomplete adherence 
were more common in the Option B+ cohort compared to the pre-Option B cohort in Malawi 
and Tanzania respectively. In a recent Swaziland study, on challenges and successes in the 
implementation of Option B+,   the risk of attrition was higher among women initiated on 
ART during the later enrolment phase which had a higher proportion of same-day ART 
initiations (73) . Adherence to PMTCT options especially to Option B+ will therefore need 
massive public education as women are particularly vulnerable to disruptions in adherence 
during pregnancy and breastfeeding.  
2.4.1 Evolution of the PMTCT Cascade 
The PMTCT cascade (Figure 2.2) is a series of key stepwise activities that constitute a 
critical pathway to successful PMTCT that begins with all pregnant women and ends with the 
detection of a final HIV status in HIV-exposed infants (HEIs) (74). The PMTCT cascade, 
with defined indicators to measure each step, has evolved over time with each advance in the 
science of PMTCT and the release of revised World Health Organization (WHO) guidelines 
(Figure 1). Model-based analyses suggest that reaching elimination of MTCT targets is 
feasible, but only with dedicated efforts to support medication adherence and retention in care 
for women and infants throughout the PMTCT cascade, as well as interventions targeting 
maternal-child health care and safer breastfeeding practices (75).  
Before the use of antiretroviral medicines for PMTCT, early WHO guidelines focused on 
counselling, offering and acceptance of HIV testing, and receiving HIV antibody test results 
for pregnant women and HEIs at 18 months of age (47). Steps along the cascade expanded as 
interventions to prevent transmission were introduced and access to antiretroviral therapy 
improved. Indicators changed as recommendations evolved from single-dose Nevirapine 
prophylaxis to initiation of lifelong antiretroviral therapy for all pregnant and lactating 
women (Option B+) (48, 76, 77). Also, development of early infant diagnosis (EID) capacity 
led to the addition of HIV testing at 6 weeks to the cascade (78). The final HIV outcome in 
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children cannot be determined until the end of exposure through breastfeeding. The antenatal 
and early infant follow-up (6–8 weeks) steps of the cascade have received more attention than 
the later postnatal period (74). 
 
2.4.2 Efficacy and Effectiveness of PMTCT Options 
Options A and B have to date not been directly compared in a trial, though indirect evidence 
from Chasela et al, suggests similar efficacy (37). The only head-to-head comparison thus far 
has been of the postpartum components in the BAN study, where no differences in 
proportions of HIV transmission were noted between maternal and infant prophylaxis 
regimens at 28 weeks of life (2.9% vs. 1.7%; p=0.10)(37). Across multiple sites in South 
Africa, Kenya, and Burkina Faso, the Kesho Bora study showed lower rates of HIV 
transmission at 12 months when combination maternal regimens (antenatal, intrapartum, 
postpartum through 6 months of breastfeeding) were compared to antenatal ZDV and 
peripartum NVP (5.4% vs. 9.5%; log-rank p=0.029). Interestingly, the transmission rates 
between the two arms were comparable at birth (1.8% vs. 2.5%), suggesting similar efficacy 
between the antenatal components of Option A and Option B among women who are not 
eligible for ART (38). In their comparison of three combination antiretroviral regimens, 
Shapiro and colleagues demonstrated high rates of virologic suppression (defined as < 400 
copies/mL) at delivery and throughout the breastfeeding period (>92%). Only 8 of 709 (1.1%; 
95% CI: 0.5–2.2) of infants were infected - among the lowest transmission rates ever reported 
in breastfeeding infants, with the majority acquiring HIV in utero (79). 
Although efficacy of Options A and B is believed to be similar, there are limited data on 
effectiveness outside clinical trials. Low early (4–8 weeks) MTCT rates have been reported 
for the South African national program under Option A conditions suggesting good overall 
effectiveness in a relatively well-resourced health system (57). However, several 
observational studies under Option A have reported paradoxically lower early MTCT rates 
among ART-eligible pregnant women receiving ART compared with non-eligible women 
receiving short-course Zidovudine (AZT) prophylaxis (62, 80). Several studies have 
demonstrated that the lowest rates of transmission occur among women on ART at the time of 
conception (62, 80, 81). Therefore, particularly in settings with high rates of unplanned 
pregnancies and poor penetration of family planning, B+ is likely to be superior to A and B 
for PMTCT in subsequent pregnancies. Our systematic review of literature (Chapter 4 and 
(45)), showed a continued decline in the incidence of HIV among children, as indicated by 
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low MTCT rates, and an average rate of mother-to-child transmission of approximately 9.9% 
was achieved in East and Southern Africa in 2017 (2). 
 
Research data have suggested that Options A, B, or B+ may be associated with important 
adverse outcomes, including drug resistance, congenital anomalies, preterm delivery, and 
impaired infant growth (82-86). The results from a recent systematic review of literature on 
use of ARVs during pregnancy and adverse birth outcomes among women living with HIV-1 
in  low and middle income countries  (LMICs) revealed  mixed evidence suggesting both 
potential harm and potential benefit for most regimens (87). The harmful or protective effects 
of certain regimens varies depending on the drug backbone (87). Women who received 
Zidovudine-based ART (Zidovudine, Lamivudine, and Lopinavir/Ritonavir) had the lowest 
HIV-1 MTCT prevalence of 0.5% and the highest low birth weight prevalence of 20%,  
whereas,  women who received Zidovudine plus single-dose NVP had the highest HIV-1 
MTCT prevalence of 2%  and the lowest low birth weight prevalence of  9% (88). The most 
recent regimens based on Option B+ and Test and Treat policies are more likely to be 
effective at reducing MTCT rates but are associated with likelihood of increased low birth 
weight and preterm birth. 
2.4.3 Cost effectiveness of PMTCT Options 
Cost-effectiveness is a formal methodology to assess value for money. Two discrete 
outcomes: 1) healthcare costs, in dollars or other currency, and 2) health benefits, in life-years 
saved (LYS), quality-adjusted life-years (QALYs), or disability-adjusted life-years (DALYs)  
are calculated (89, 90). Several studies have evaluated Options A, B, or B+, with wide 
variations in the costs and outcomes considered, as well as the choice of comparator 
strategies. The greatest number of recent reports have examined Option B, and found it to be 
either cost-saving or very cost-effective when compared to no PMTCT, single dose of 
Nevirapine (sdNVP), or dual antenatal ARV prophylaxis. (89, 91-97). A Zimbabwean study 
comparing Options A and B indicated that Option B led to greater life-years gained for both 
mothers and infants, and was also less expensive (92). 
Fasawe et al (93) in Malawi examined maternal and infant outcomes for Options A, B and B+ 
separately and concluded that, if implemented as recommended, Options A, B and B+ are 
equivalent in preventing new infant infections, yielding cost effectiveness ratios between 
USD 37 and USD 69 per disability adjusted life year averted in children. However, Option 
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B+ also yielded favourable incremental cost effectiveness ratios (ICER) of USD455 per life 
year gained over the current practice.(93). A study that examined health outcomes and cost 
impact of the shift to WHO 2013 recommendations in Zambia, suggested that the shift from 
2010 Option A to the 2013 guidelines (Option B+) would result in a 33% reduction of the risk 
of HIV transmission among exposed infants (68). The risk of transmission to sero-discordant 
partners for a period of 24 months would be reduced by 72% with ARVs during pregnancy 
and breastfeeding and further reduced by 15% with lifelong ART. The probability of HIV-
infected pregnant women initiating ART would increase by 80%. It was also suggested that 
while the shift would generate higher PMTCT costs, it would be cost-saving in the long term 
as it spares future treatment costs by preventing infections in infants and partners (68). 
2.5. Early Infant Diagnosis 
EID of HIV is a critical step in ensuring infant survival. The landmark CHER (Children with 
HIV Early Antiretroviral Therapy) study in South Africa demonstrated that starting ART 
before 12 weeks of age reduced mortality by 76% and disease progression by 75% in HIV-
infected infants as compared to delayed ART (98). As a result of this trial and a growing body 
of evidence, in 2008 the WHO updated its paediatric HIV guidelines to recommend 
immediate ART for all HIV-infected infants under 12 months, irrespective of clinical or 
immune status (48). In 2013 this was extended to all HIV-infected children under 5 years 
(49). An effective EID service should achieve the following: identify all HIV-exposed 
infants, provide HIV testing and ensure return of results in a timely manner; retain HIV-
exposed infants and their mothers in care; and identify all HIV-infected infants and link them 
to treatment services to ensure timely initiation of ART (99). A recent study in Malawi 
revealed that children born to women who received ART are less likely to be lost to follow-
up and more likely to be tested for HIV (100). 
 
In our review of literature (Chapter 4 (45)), the uptake of  EID (less than 2 months) ranged 
from less than 60% in Nigeria (101) and Zambia (62) to 100% in 2012 according to South 
African national data where it increased from 87% in 2010 (102). The age at which 
polymerase chain reaction (PCR) test for HIV was done ranged from 4 weeks to 18 months. 
In South Africa, 80% of exposed infants had PCR results at 6 weeks (103), whereas in 
Malawi 52% underwent testing at 6–12 weeks and 28% tested at 12 months(104).  
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Age at first PCR had an impact on the MTCT of HIV-exposed infants (45). In Tanzania, the 
proportion of HIV-infected infants was higher among infants who appeared later for HIV 
testing (18% at 3–6 months) than among those who presented earlier (6.4% at 1–2 months) 
under Option A implementation (105). An Ethiopian study reported that late enrolment to the 
exposed infant follow-up clinic was significantly and independently associated with increased 
MTCT of HIV (AOR= 2.89, 95% CI: 1.35, 6.21) (106).  
2.6 Adherence to PMTCT options 
Adherence to ART is essential for maximal suppression of viral replication and avoidance of 
drug resistance (107, 108) As such, good adherence is believed to be a critical determinant of 
long-term survival among HIV-infected individuals (109). In a systematic review and meta- 
analysis from over 20 countries, adequate adherence (>80%) was shown to drop from 75% 
(CI 71.5-79.7) during pregnancy to 53% (CI 32.8-72.7) postpartum among women on ART 
(109). Tracing women on Option B+ who default in Uganda, Malawi and Zimbabwe was 
recently reported to be difficult as women implicitly choose not to be traced by providing a 
false address at enrolment (110).  In addition, the need to begin treatment is not yet urgent for 
less seriously ill women with more recent Option B+ and Test and Treat policies as  they  
consider themselves  “healthy” without treatment (111). 
    
In Zambia (112), self reported adherence rate to Option A was 82.5 % during pregnancy, 
84.2 % at one week postpartum, 81.5 % at six weeks postpartum, and 70.5 % at 24 weeks 
postpartum, whilst in Ethiopia self reported  adherence rate to Option B+ was 87%  during 
pregnancy (113).  The quality of counselling was indicated as a predictor of adherence as 
mothers who were counselled on the correct intake of ARV medications had 4.7 (95% CI) 
1.98 – 11.36) times’ higher odds of adherence than those who were not counselled properly.  
 
2.7 Routinely collected data   
Routinely collected health data (RCD) are data collected for purposes other than research or 
without specific a priori research questions developed before collection (114). It includes 
clinical information from electronic health records, health administrative data, disease 
registries and epidemiologic surveillance systems.  Data quality from RCD systems remain in 
question (115), as research and evaluation have traditionally been termed ‘secondary’ uses of 
these data, because the data are used for purposes other than those for which they were 
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originally collected (116).  The perceived advantages of RCD should be viewed cautiously, 
because of the inevitable biases of observational research and specific biases due to the nature 
of these data (117). 
Extensive resources have been invested in the field of routinely collected data: these include 
the set-up of disease registries and clinical databases at regional, national or international 
levels; the promotion of the use of electronic health records; and making use of wearable 
devices for the collection of health data (117-119). However, in resource-limited settings with 
the limited resources and capacities, most of the electronic systems are still side by side to the 
paper documentation (120-123). RCD in electronic form can be linked over time, and across 
data sources, to create longitudinal records for individuals and multilevel data structures 
(116).  
In spite of the demands for quality data, routine health information systems in many resource-
limited settings continue to perform below expectations. Often the systems are unable to be 
used for their intended purposes of generating accurate and reliable data. Where data is 
collected and generated, the information is often not used for planning and management (124, 
125). Other reasons for poor quality data include design/structural issues relating to 
inappropriate data collection tools and procedures (125, 126), poor recording due to 
inadequate skills(125, 127, 128) inadequate resources(125, 127) leading to poor capturing and 
reporting of data (129, 130), elements, staff attrition (127-129) and lack of use of already 
generated data, which may hinder constructive feedback to data producers (125, 127, 128, 
130). 
 
Recent studies which have attempted to use routinely collected data have recommended the 
importance of evaluating the availability, quality and completeness of data from routine ANC 
data systems before recommending that these data be used to replace data collected in ANC 
surveillance surveys (131-135). Hence there is a need to optimize quality systems to ensure 
robust routine HIV testing for programmatic and surveillance purposes. 
 
Routine data can either be patient or aggregate data. Patient data is data relating to a single 
patient, such as his/her diagnosis, name, age, earlier medical history etc. Patient based data is 
important when you want to track longitudinally the progress of a patient over time. On the 
other hand, aggregated data is the consolidation of data relating to, multiple patients, and 
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therefore cannot be traced back to a specific patient. Aggregate data cannot provide the type 
of detailed information which patient level data can, but is crucial for planning and guidance 
of the performance of health systems. Patient data is highly confidential and therefore must be 
protected, whereas security concerns for aggregated data are not as crucial as for patient data, 
as it is usually impossible to identify a particular person to an aggregate statistic. Routinely 
collected data is should not be distributed without adequate data dissemination policies in 
place as it misused and misinterpreted. 
 
2.8 Conclusion 
The global initiative to eliminate new paediatric HIV infection by 2015 and improve 
maternal, newborn and child health and survival in the context of HIV has resulted in increase 
in the PMTCT coverage and reduction in HIV infections among children. However, the 
targets set have not been reached in most of the 22 priority countries with a high burden of 
HIV, which also includes Zambia. The PMTCT cascade has evolved in line with the 
introduction of various post 2010 WHO PMCT of guidelines. My research intended to use the 
PMTCT cascade points as a framework for analysis specifically in ART initiation points for 
both HIV-infected mothers and infants.    
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Chapter 3: Overview of Methods 
3.0 Introduction 
This chapter present the methods used in this study which included: the systematic review of 
literature, quantitative analysis of routinely collected data and qualitative data collection and 
handling. The ethical considerations are also outlined. 
3.1 Study location  
Zambia is a landlocked country in south-central Africa, neighbouring the Democratic 
Republic of the Congo to the north, Tanzania to the north-east, Malawi to the east, 
Mozambique, Zimbabwe, Botswana and Namibia to the south, and Angola to the west 
(Figure 3.1). As of 1 January 2018, the population of Zambia was estimated to be 17,470,471 
people (136). Zambia is classified as a lower middle income country. 
Figure 3.1: Location of Zambia in Africa 
                           
 
Zambia is experiencing a generalized and mature HIV/AIDS epidemic, with a national HIV 
prevalence rate of 11.6 percent among adults ages 15 to 49 in 2016 (137). The primary modes 
of HIV transmission are through heterosexual sex and mother-to-child transmission (138). 
The prevalence of HIV among females aged 15 to 49 years in Zambia is 14.5 % higher than 
in their male counterparts which is 8.6% (139). The HIV prevalence in the 15-49 years age 
group varies geographically across Zambia, ranging from 5.9 percent in Muchinga Province 
to 16.0 percent in Western Province and 16.1 percent in Lusaka (Figure 3.2). (139) . 
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Infection rates are highest in cities and towns along major transportation routes and lower in 
rural areas with low population density (138). In 2016, Zambia adopted the WHO guidelines 
on offering all people living with HIV antiretroviral therapy regardless of their CD4 
count(140). Of the estimated 1.2 million people living with HIV in Zambia, only 67% know 
their status as of 2016 (8, 141). Among people living with HIV (PLHIV) ages 15-59, who 
know their status 85.4% self-report current use of ART: 84.9 percent of HIV-positive females 
and 86.2 percent of HIV-positive males.  
Figure 3.2: HIV Prevalence among adults by province 
 
Adapted from the Zambia Population-based HIV Impact Assessment (2015-16)(139) 
3.1.1 PMTCT Program in Zambia 
Zambia has been implementing a rigorous PMTCT program which has seen the percentage of 
children born HIV-positive drop by 51% between 2011 and 2012, a decline from 19, 000 to 9, 
500 (142). In 2015, 87% of pregnant women living with HIV were receiving effective 
antiretroviral treatment, just under universal health targets of 90% (8), by end of 2017 the 
coverage percentage was 92%(15).  The SmartCare database includes a dedicated module for 
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collecting the PMTCT data, and is designed to be used in all health facilities providing the 
PMTCT services.  
Zambia launched its PMTCT initiative as a three-year pilot program in 1999.  In 2003, the 
first national PMTCT of HIV program was initiated. In 2007, an updated version was 
published, followed by another in 2008 and another in 2010. There has been a remarkable 
expansion in the release of prophylactic medication regimens to mothers and infants between 
the years 1999 and 2010. The current policy (2013) recommends that all pregnant women 
living with HIV who are Zambian citizens are provided with free ARV drugs for life, 
regardless of their CD4 count (53). It also guides health care workers to follow a family-
centred approach in testing and counselling for HIV, as well as in care and treatment. 
Zambia also adopted a provider-initiated HIV testing and counselling model in 2006. New 
ANC clients are informed about PMTCT during group pre-test counselling. Unless a client 
opts out, providers perform a rapid HIV test that produces results within one hour. Individual 
post-test counselling is offered as part of the standard package of ANC and delivery services 
(143). Ninety-six percent of mothers received antenatal care from a skilled provider and 91% 
of women had an HIV test either during antenatal care or during labour for their most recent 
birth and received the test results (144). 
3.1.2 EID program in Zambia 
The latest 2016 Zambian MoH guidelines, in line with WHO guidelines, recommend HIV 
PCR testing for HIV-exposed infants by 6 weeks of age and again at 6 months (145).
 
In 
Zambia only 3 public-sector laboratories currently perform HIV early infant diagnosis, with 
two of them located in the capital Lusaka, so rural areas face significant delays in receiving 
results (146). The cost of infant PCR assays (which are more expensive than antibody tests) is 
another limiting factor, as well as the need to repeat PCRs in infants who are breastfed (147).
 
HIV-infected women and their exposed infants receive HIV counselling from clinic staff and 
are advised to have infants tested by HIV PCR at 6 weeks and 6 months of age. Blood is 
collected from infants by heel stick and stored as dried blood spots (DBS) in the laboratory at 
the HIV clinic. Batches of specimens are transported by road to the central laboratories for 
testing by PCR.  If the HIV PCR test is negative or invalid at 6 months of age, the infant is 
recommended to return at 12 and 18 months of age or 6 weeks after cessation of 
breastfeeding. If the results are available and the infant is HIV PCR positive, the caregiver is 
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counselled to have their child begin ART and another DBS specimen is collected for 
confirmatory testing (145).  
Project Mwana was an innovative health initiative implemented by the Zambian Ministry of 
Health with the support of UNICEF and its collaborating partners: the Zambia Centre for 
Applied Health Research and Development (ZCHARD), a Boston University affiliate; the 
Zambia Prevention, Care and Treatment Partnership (ZPCT); and the Clinton Health Access 
Initiative (CHAI). Through the use of RapidSMS mobile technology, the project delivers test 
results for diagnosis of HIV in infants in real time to rural clinics and facilitates 
communications between clinics and community health workers communities(148). The 
community health workers then inform mothers that the results are ready for their collection. 
The project begun as a pilot in 13 districts of Zambia in June 2010, and is now being 
implemented across all 10 provinces of Zambia across a total of 1,030 health facilities. 
3.2 Study Setting 
3.2.1 The SEARCH Project  
The PhD research was nested in the project called SEARCH (Sustainable Evaluation 
through Analysis of Routinely Collected HIV data) whose aim was to support the utilisation 
of routinely-collected HIV data for strengthening services, and provide transparency about 
the benefits and equity in delivering services to people living with HIV. The Bill & Melinda 
Gates Foundation funded the collaboration between the London School of Hygiene & 
Tropical Medicine and the Ministries of Health in Tanzania and Zambia. The SmartCare 
Database was the source of routinely collected data in Zambia. 
3.2.1 SmartCare Electronic Health System 
SmartCare is one of the largest electronic patient monitoring systems in Africa. It is a 
Zambian Ministry of Health led project funded from the United States Centre for Disease 
Control and Prevention (CDC). Its implementing partners include Jhpiego, U.S. Agency for 
International Development; the Centre for Infectious Disease Research in Zambia; Zambia 
HIV/AIDS Prevention, Care and Treatment Partnership; Zambia National AIDS Network; the 
Elizabeth Glaser Paediatric AIDS Foundation (EGPAF); John Snow International 
(JSI)/DELIVER; Aids Relief/Catholic Relief Services; the Zambia Defence Force (ZDF) 
Medical Services; the Zambia Police Medical Services; the Churches Health Association of 
Zambia and Chreso ministries. 
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SmartCare was developed to improve continuity of care and provide timely data on maternal 
and child health, HIV/AIDS, tuberculosis and malaria interventions for public health 
purposes, including Health Management Information System (HMIS) trend reporting and 
analysis for health officials and clinicians (149). SmartCare is now also required for any 
facility in Zambia desiring accreditation to dispense ARV drugs for HIV clients. Since 2005, 
SmartCare has been deployed in over 800 facilities (Western Province - 72; Southern 
Province - 153; North-western Province – 38; Lusaka Province - 106; Central Province – 65; 
Copper belt Province – 151; Eastern Province – 113; Northern Province – 26; Luapula 
Province - 39 and, Muchinga – 71) in 94 districts and has an enrolment of more than 900,000 
HIV positive patients. Approximately 61% of those enrolled are female. Although this 
represents only 40% of all clinics in Zambia, these include the biggest and busiest clinics. The 
MoH does not have precise records of the specific numbers of facilities implementing 
SmartCare per year owing to inadequate resources to enable close monitoring and 
documentation of the implementation. 
3.2.1.1 SmartCare Model Structure  
SmartCare is organised into comprehensive modules and sub-modules (Figure 3.3). This was 
mainly influenced by its funders depending on the information they wanted at that particular 
time. The main module groups (Table 3.1) are: clinical group comprising the following 
modules – ANC, Delivery, Postnatal, ART, Paediatric ART, PMTCT follow up, Under 5 
among others – ( these are mainly of interest for this research); logistic group which 
constitute information on drug dispensing and orders; monitoring and evaluation groups 
which includes health management information system reports, graphing, data analysis, data 
merge from facilities for MOH; and the continuity of care group which had data from across 
facilities and within facilities. Through the data merge the SmartCare information can be used 
to obtain data for the monthly reports to MOH, including the HMIS-HIA report. 
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Table 3.1: Smart Care Module Groups 
SN Module Group Components 
1 Clinical Includes the following modules – ANC, Delivery, Postnatal, 
ART, Paediatric ART, PMTCT follow up, Under 5 among 
others – ( these are mainly of interest for this research)  
2 Logistic Consists of information on drug dispersion and orders 
3 Monitoring and 
Evaluation 
Includes health management information system reports, 
graphing, data analysis, data merge from facilities for MOH 
4 Continuity of 
Care 
Data from across facilities and within facilities 
 
All patients in SmartCare have a unique identity (ID) number, and information from various 
modules is linked through the unique ID number (149).  Infants are registered as separate 
individuals with unique numbers different from their mothers. Thus it proved impossible to 
link mother-infant pairs for the present study.  
Figure 3.3: SmartCare Model Structure 
 
Adapted from Ministry Health HMIS workshop Presentation 
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3.2.1.2 Data capturing process 
Data is captured under a number of ‘modules’ across a range of health issues. Records are 
updated at every point of clinical service. SmartCare enables the capture of all patient data 
into one centralised database that can be accessed from any supported health facility. Patients 
enrolled in the system can have their records accessed at whichever SmartCare-supported 
facility they present to in the country. Patients are issued with Smartcards at their initial 
consultation which contains all their clinical information and treatment details. When they 
present at another facility the health worker simply plugs the Smartcard into the online 
system and can access all the patients’ details (Appendix 2).  
Data on a range of HIV and pregnancy related outcomes are collected during the patient 
consultation with the clinician, who records the information on paper forms in facilities that 
are paper-based and directly on the computer in the few facilities which are computer-based. 
These forms are then entered into the SmartCare database by data entry clerks who have been 
trained in using the SmartCare database. Data is collected from each facility on a monthly 
basis and submitted to a District Health Information Officer, who aggregates and sends the 
data to the province level Senior Health Information Officers. From here the data are wired to 
a national server at MoH headquarters. 
3.3 Study design 
In order to achieve the stated aim and objectives, a mixed-methods approach was used.  The 
quantitative and qualitative methods were chosen to complement each other in addressing the 
objectives (Table 3.2). Through the use of systematic review of literature, the researcher was 
able to review evidence available on the implementation of the post 2010 WHO PMTCT 
guidelines in Sub Saharan Africa. The quantitative routinely collected data from the 
SmartCare Database provided an overview of coverage of PMTCT and performance of EID 
services. An inquiry of implementation procedures of SmartCare was carried out using 
qualitative methods. The research methods employed under the objective to which they 
contributed are outlined below and details are provided in the individual chapters. 
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 Objective 1: To synthesise and evaluate the impact of implementing post-2010 World 
Health Organisation (WHO) prevention of mother-to-child transmission (PMTCT) 
guidelines on attainment of PMTCT targets in Sub Saharan Africa through a systematic 
review of literature. 
 
Systematic reviews aim to identify, evaluate, and summarize the findings of all relevant 
individual studies over a health-related issue, thereby making the available evidence more 
accessible to decision makers (150). The systematic review involved analysis of quantitative 
retrospective and prospective cohort study designs that utilised routinely collected data with a 
focus on provision and utilisation of the cascade of PMTCT services, and evaluated 
implementation of post 2010 PMTCT guidelines. The systematic review provided 
justification for further research, in addressing the overall aim of the study as it identified 
gaps in the use of utilisation of routinely collected data for evaluation PMTCT programs. The 
detailed systematic review methods are presented in Journal of Medicine manuscript format 
in Chapter 4. 
Objective 2: To describe trends in the coverage of PMTCT services from 2010 to 2015 
using the SMART Care database of routine clinical information collected in Zambia. 
Quantitative methods were used to analyse routinely collected data from the Ministry of 
Health electronic SmartCare database for a cohort of all pregnant women attending antenatal 
care (ANC) from January 2010 to December 2015 in health facilities. Descriptive analysis 
was employed to quantify the proportion of HIV-positive pregnant women attending ANC, 
percentage of HIV pregnant women initiated on ART and time from diagnosis to treatment 
initiation. Further details are presented in Chapter 5 of the thesis in the Frontiers in Public 
journal manuscript format. 
Objective 3: To evaluate the performance of Zambia’s early infant diagnosis services 
routinely collected data from the SmartCare database was performed for the period 
January 2006 to December 2016. 
Similar to objective 2, quantitative methods were used to analyse routinely collected data 
from the Ministry of Health electronic SmartCare database for a cohort of HIV-infected 
infants from January 2006 to December 2016. Univariable logistic regression was conducted 
 
43 
 
to identify factors associated with later infant testing and treatment initiation. A detailed 
presentation of analysis is in Chapter 6 in the BMC Public Health manuscript format. 
Objective 4: To understand the implementation procedures of SmartCare 
Qualitative methods were used to understand the implementation procedures of SmartCare. 
Data was collected using in-depth interviews, observations and focus groups discussions 
(FGD) between September and November 2016. Seventeen in-depth interviews were held 
with a range of key informants from the Ministry of Health and local and international 
organisations implementing SmartCare. Four data entry observations and three FGDs with 22 
pregnant and lactating women seeking PMTCT services were conducted. Data was analysed 
using a thematic content approach. A detailed report of the study is presented in Chapter 7 of 
the thesis. 
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Table 3.2: Overview of Objectives and Methods 
 
Where 
Results are 
presented 
Objective Study Design Main Outcome  Analysis 
Paper 1  
(Chapter 4) 
To synthesise and 
evaluate the impact of 
implementing post-2010 
World Health 
Organisation (WHO) 
prevention of mother-to-
child transmission 
(PMTCT) guidelines on 
attainment of PMTCT 
targets in Sub Saharan 
Africa. 
 
Systematic 
review of 
literature 
Quantitative 
retrospective and 
prospective cohort 
study designs that 
utilised routinely 
collected data with a 
focus on provision and 
utilisation of the 
cascade of PMTCT 
services, and evaluated 
implementation of post 
2010 PMTCT 
guidelines. 
Preferred Reporting 
Items for 
Systematic and 
Meta-Analysis 
(PRISMA) 
Paper 2 
(Chapter 5) 
To describe trends in the 
coverage of PMTCT 
services from 2010 to 
2015 using the SMART 
Care database of routine 
clinical information 
collected in Zambia. 
 
Retrospective 
cohort study 
Proportion of HIV-
positive pregnant 
women attending ANC, 
percentage of HIV 
pregnant women 
initiated on ART and 
time from diagnosis to 
treatment initiation 
Descriptive 
analysis 
 
Paper 3 
(Chapter 6) 
To evaluate the 
performance of Zambia’s 
early infant diagnosis 
services routinely 
collected data from the 
SmartCare database was 
performed for the period 
January 2006 to 
December 2016 
Retrospective 
cohort study 
Age at infant HIV test 
and time from 
diagnosis to treatment 
initiation. 
 
Univariable and 
multivariable 
logistic regression 
Paper 4 
(Chapter 7) 
To understand the 
implementation 
procedures of SmartCare  
Qualitative study 
using in-depth 
interviews, 
observations and 
focus groups 
discussions 
(FGD) between 
September and 
November 2016. 
Challenges in 
implementing a 
Zambian EHR system 
labelled ‘SmartCare’ in 
order to improve 
PMTCT data 
Thematic content 
analysis 
Chapter  8  To triangulate data from 
an independent source 
with findings from 
Chapter 5 
Retrospective 
analysis of ANC 
HMIS data from 
2013 to 2016 
Routine aggregate 
surveillance ANC data 
from the HMIS 
Descriptive 
analysis 
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3.3.1 Sequence of study design implementation 
The components of a mixed methods study can be undertaken at the same time or sequentially 
with either the quantitative study undertaken first followed by the qualitative study or vice 
versa (151). The mixed methods of this study were undertaken in a sequential manner. The 
systematic review of literature was done first. The systematic review of literature allowed for 
further research as it indicated underutilisation of routinely collected for PMTCT programs 
(45). This was then followed by data extraction, cleaning and quantitative analysis of 
routinely collected data from the SmartCare data. The quantitative data from a cohort of 
pregnant women attending ANC and HIV-positive infants were cleaned and analysed 
separately.  
 
The findings from the two quantitative studies required extracting surveillance data from a 
Zambian EHR system, SmartCare. The work highlighted some deficiencies including large 
amounts of missing data, especially in more recent years, and variable performance across the 
country. This confirmed the need for a qualitative study to understand the implementation 
procedures of SmartCare. Thematic content analysis was carried out to give an account of 
challenges in implementing the SmartCare Electronic health system and recommendations 
drawn to improve PMTCT data. 
The findings of these studies were presented in individual paper for publications in various 
journals. The summaries of findings were then triangulated for interpretation in order to draw 
conclusions and recommendations. Timelines for the study are presented in (Appendix 1). 
3.4 Quantitative Data Extraction and Cleaning  
3.4.1 Data Access 
To access the MOH SmartCare data, an access agreement with the Policy Directorate in MoH 
was developed with the support of SEARCH management team. Removal of personal 
information of the recipients was done by the MoH ICT team and the unique identifier for the 
data was the SmartCare ID number. The individual level data from the ANC and EID datasets 
were extracted and cleaned separately.  The extraction and cleaning of the data for all 
modules was undertaken by the candidate in 2017, prior to combining the data for analysis. 
3.4.2 ANC Data extraction 
Data from the ANC module was linked to the HIV Client Summary module and the ARV 
Eligibility Interaction Module to identify HIV-positive women. Data from the Obstetric 
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History Module was then used to segregate PMTCT clients from general ART clients. The 
oldest date of HIV testing and ANC visit date were used to determine whether women had 
known their HIV status before the ANC visit. 
3.4.3 ANC Outcomes of Interest 
1. Proportion of HIV positive pregnant women  (i.e. the number of pregnant women with 
a new HIV test result documented in ANC clinic plus pregnant women with known 
status but not on ART and pregnant women who are already on ART / the total 
number of pregnant women presenting to ANC clinic per calendar 
2. Proportion of women on ART was calculated from the number of HIV-infected 
pregnant women receiving combination ART during ANC and those already on ART 
(i.e. the number of HIV-infected pregnant women documented to have received 
combination ART during ANC or ART clinic / the total number of pregnant women 
enrolled in ANC clinic with either newly documented HIV infection or known prior. 
3.4.4 ANC Data cleaning 
These following steps were taken to ensure the data which was analysed was clean: 
 Removing of duplicate visits – this was done for every individual woman, with the 
same gravida and parity as this was assumed that it was the same pregnancy. 
 Removal of implausible parity and gravida mothers i.e. mother who had very odd 
gravida and parity for their age. 
 Parity profile by age groups histograms were also plotted in Stata 14 to determine 
whether they were normal distributed. The age groups were in five year intervals.  
 Removal of any records of mothers whose age was not within the reproductive age 
using the WHO standard of 15-49 year distribution. During this exercise, they were 
also enough mothers in the dataset that were highly implausible as they were a lot 
mothers under the age of 12 with more than 5 children and mothers above 50 years of 
age. It was also difficult otherwise to distinguish garbage data and therefore, the use 
the WHO standard was opted. The final sample age distribution profiles of mothers 
were similar to the Demographic Health Survey (DHS) data. 
 The final data set were inspected on a year by year basis, and 2016 was excluded for 
analysis as number of mothers recorded during the year dropped to 2500, from above 
10, 000 of the previous years. 
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3.4.5 EID Data extraction 
The EID dataset was extracted from Under 5 Registration module and the Paediatric ART 
module. The following variables were extracted for all infants on ART: sex, date of birth, 
year of birth, province where infant was registered to start ART, date of HIV positive test, age 
at HIV test, date of ART initiation, year of ART initiation.  
The main outcomes of interest were age at first infant HIV test (which was determined from 
infant date of birth and age at HIV test) and time from diagnosis to treatment initiation 
(determined from date of HIV positive and date of ART initiation 
3.4.6 EID data cleaning 
 Removal of 1,648 entries for infants born before 2006, as these was not in our targeted 
sample. 
 For the outcome ‘age at infant HIV testing’, 317 entries were erroneously entered as 
having age at testing<0 months of age and were excluded from the analysis. 
 For the outcome ‘time from diagnosis to ART initiation’, a total of 21,712 (66.62%) 
entries had missing data as there was no date of HIV test for most infants. 
3.5. Data management  
The data was stored separately on the LSHTM computer, personal laptop and H drive. The 
data were organised in files and folders on these devices. All the devices were secured with a 
password. Since the data were for educational purposes, they were shared with LSTHM 
supervisors and the SEARCH project team members. After completion of studies the data 
will be held in the LSHTM Research Data Repository and retrieved as needed for academic 
and publishing purposes. 
Throughout the qualitative data collection period the researcher kept a field diary, where she 
documented areas she needed to explore further during the interview or interesting. She also 
documented any new ideas and insights coming out of interviews held that required additional 
exploration in subsequent interviews. 
3.6 Research ethics 
Permission to use SmartCare data was granted by the Zambia Ministry of Health. Permission 
to collect data from the health facilities was granted by the MoH district offices (Appendix 4). 
The study was approved by the Zambia Biomedical Ethical Board (Ref 101-04-16) (Appendix 
5) and the LSHTM Research Ethics Committee (Ref 12086) (Appendix 6). An Amendment to 
 
48 
 
add the qualitative component was also approved when the initial quantitative analysis 
showed a lot of missing data (Appendix 7).  The researcher met the costs associated with 
travel and refreshments for the FDGs. 
Written informed consent was obtained from all in-depth interview participants including 
their consent to record the interviews and publish anonymous quotations. Verbal consent was 
sought for FGD participant upon receipt for a waiver from the Zambia Biomedical Ethical 
Board (Appendix 8). Participation in the study was entirely voluntary and participant 
anonymity was maintained throughout the processes of interview transcription, data analysis 
and presentation by using pseudonyms.   
 
  
 
49 
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Abstract 
Objective: To synthesise and evaluate the impact of implementing post-2010 World Health 
Organisation (WHO) prevention of mother-to-child transmission (PMTCT) guidelines on 
attainment of PMTCT targets. 
Methods: Retrospective and prospective cohort study designs that utilised routinely collected 
data with a focus on provision and utilisation of the cascade of PMTCT services were 
included. The outcomes included the proportion of pregnant women who were tested during 
their antenatal clinic (ANC) visits; mother-to-child transmission (MTCT) rate; adherence; 
retention rate; and loss to follow-up (LTFU). 
Results: Of the 1210 references screened, 45 met the inclusion criteria. The studies originated 
from 14 countries in sub-Saharan Africa. The highest number of studies originated from 
Malawi (10) followed by Nigeria and South Africa with 7 studies each. More than half of the 
studies were on Option A whilst the majority of Option B+ studies were conducted in 
Malawi. These studies indicated a high uptake of HIV testing ranging from 75% in Nigeria to 
over 96% in Zimbabwe and South Africa. High proportions of CD4 count testing were 
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reported in studies only from South Africa despite that in most of the countries CD4 testing 
was a prerequisite to access treatment. MTCT rate ranged from 1.1% to 15.1% and it was 
higher in studies where data was collected in the early days of the WHO 2010 PMTCT 
guidelines. During the postpartum period, adherence and retention rate decreased, and LTFU 
increased for both HIV-positive mothers and exposed infants. 
 Conclusion: Irrespective of which Option was followed, uptake of antenatal HIV testing was 
high but there was a large drop off along later points in the PMTCT cascade. More research is 
needed on how to improve later components of the PMTCT cascade, especially of Option B+ 
which is now the norm throughout Sub-Saharan Africa. 
 
LIST OF ABBREVIATIONS  
AIDS    Acquired immunodeficiency syndrome 
ANC    Ante Natal Care  
ART   Antiretroviral therapy 
ARV    Antiretroviral 
DRC   Democratic Republic of Congo 
EID   Early Infant Diagnosis 
HAART  Highly active antiretroviral therapy 
HIV    Human immunodeficiency virus 
LTFU   Lost to Follow-up 
MTCT   Mother-to-child transmission of HIV 
NVP    Nevirapine 
PMTCT  Prevention of mother-to-child transmission of HIV 
UNAIDS   Joint United Nations Program on AIDS 
UNFPA   United Nations Population Found 
UNICEF  United Nations International Children’s Emergency Fund 
WHO   World Health Organisation 
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4.1 Introduction 
The Joint United Nations Program on HIV/AIDS (UNAIDS) over the past two decades has 
documented the heavy burden and impact of HIV on mothers and infants living in resource-
limited settings. Among the 260,000 new paediatric infections of HIV worldwide in 2012, 90% 
of new cases occurred in Sub-Saharan Africa [1]. The use of antiretroviral therapy (ART) by 
HIV-positive mothers is the cornerstone of strategies to prevent mother-to-child transmission 
(PMTCT) during the ante-partum and peri-partum periods and for the duration of breastfeeding 
[2] . 
The World Health Organization (WHO) in 2010 revised guidelines and offered two options: 
Option A and Option B. Under Option A, pregnant women with a CD4≥350 cells/µL receive 
ART prophylaxis from 14 weeks gestation through one week postpartum, single-dose 
Nevirapine at delivery, and daily Lamivudine from delivery through one week postpartum. 
Their infants receive daily Nevirapine from birth through one week after the cessation of 
breastfeeding. Women with CD4≤ 350 cells/µL or WHO clinical stage 3 or 4 disease are put 
permanently on triple-drug ART.  Under Option B, all women receive triple-drug ART from 
14 weeks gestation through the cessation of breastfeeding, and infants receive a daily 
Nevirapine or Zidovudine dose from birth to 4–6 weeks [2]. In 2013, WHO revised its 
guidelines for the treatment and prevention of HIV and recommended that all pregnant and 
breastfeeding HIV-infected women, regardless of CD4 cell count, should continue ART for 
life known as "Option B+" whilst their infants receive daily Nevirapine or Zidovudine from 
birth to 4–6 weeks [3]. Option B+ is now a norm in Sub-Saharan Africa, with all the 21 
Global Plan countries implementing it except for Nigeria as of October 2015  [4]. 
 Effective PMTCT programmes require women and their infants to receive a cascade of 
interventions including uptake of antenatal services and HIV testing during pregnancy, use of 
ART by pregnant women living with HIV, safe child birth practices and appropriate infant 
feeding uptake, with infant prophylaxis, HIV testing and other postnatal health care services 
following delivery [5]. The global community committed to accelerate progress for PMTCT 
through an initiative whose goals were to eliminate new paediatric HIV infection by 2015 and 
improve maternal, newborn and child health and survival in the context of HIV [6]. 
Elimination of new paediatric infections has not been met, so there is a need to investigate 
why some programs are not effective. This systematic review of the literature was performed 
to evaluate the impact of implementing the WHO post-2010 PMTCT guidelines in order to 
inform practices which could help reach PMTCT targets. 
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4.2 Methods 
Data Sources: The following databases were searched for articles published from January 
2010 to October 2016:  Africa Wide Information, Medline, Embase; and reference lists from 
publications provided additional articles. The search was limited to English language journals 
for studies in sub-Saharan Africa. The following search terms and their variations were 
combined: prevention of mother to child transmission of HIV; PMTCT cascade; PMTCT 
options; effectiveness of PMTCT; PMTCT Option A; PMTCT Option B; PMTCT Option B+; 
antiretroviral treatment; ART; antenatal care; Human Immunodeficiency Virus; HIV-exposed 
infants’ health outcomes; infant feeding; early infant diagnosis, adherence; retention in care; 
loss to follow-up (LTFU). 
 Study Selection: The searched results were exported using reference management software 
Endnote 7.3 and duplicates were removed. The titles, abstracts and full texts of potentially 
relevant studies were reviewed for eligibility. An adapted Preferred Reporting Items for 
Systematic and Meta-Analysis (PRISMA) flow chart was drawn (Flow Diagram). The 
selected studies had to include data collected post the WHO 2010 PMTCT guidelines. The 
inclusion criteria were: retrospective and prospective cohort study designs that utilised 
routinely collected data with a focus on provision and utilisation of the cascade of PMTCT 
services; studies with particular interest in WHO Option A, B or B+ implementation; studies 
from countries which had adopted WHO post-2010 PMTCT guidelines during the data 
collection period, and studies which evaluated implementation of post 2010 PMTCT 
guidelines. Qualitative studies, randomized controlled trials, reviews, commentaries, 
editorials and modelling studies were excluded. Two independent reviewers (SGM and TM) 
reviewed the full text articles for inclusion, exclusion and extracted data on outlined 
outcomes. Ethical approval was granted from London School of Tropical Medicine and 
Hygiene Research Ethics Committee (Ref: 12086). 
 Data Extraction: Data was extracted using a standardised data extraction form which 
summarised key information from relevant studies. The following information was extracted: 
proportion of pregnant women who were tested during their antenatal clinic (ANC) visits; 
proportion of women who tested HIV-positive; proportion of women who were already on 
ART before pregnancy; proportion of women who received their HIV test results; proportion 
of women tested for CD4 cell count; type of PMTCT option for mothers and their infants; 
adherence of women to ART; infant feeding methods; infant age when polymerase chain 
reaction (PCR) was done; MTCT rate; proportion of infants reported to die or be LTFU as 
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missing three consecutive clinic visits; and retention rate which is  the continuous 
engagement from diagnosis in a package of prevention, treatment, support and care services.  
In case of studies where data collection began before 2010 only post 2010 data was extracted. 
4.3 Summary of Results 
Study Characteristics: A total of 944 potentially eligible full text articles out of 2913 studies 
based on titles and abstracts were identified. Forty-five met the inclusion criteria (Flow 
Diagram – Figure 4.1) and they originated from 14 countries in sub-Saharan Africa, (Table 
4.1). The highest number of studies originated from Malawi (10) followed by Nigeria and 
South Africa with 7 studies each. The period of data collection was from 2010 to April 2015. 
The sample sizes for the selected studies ranged from 113 to 2, 215, 090 participants; the 
largest sample sizes were from the studies that utilized national data from South Africa and 
Ghana. 
Uptake of ANC services: The data on HIV testing during ANC visits was extracted from 8 
studies (Table 4.1) conducted in Malawi [7-9], Nigeria [10, 11], Ghana [12], Zimbabwe [13] 
and South Africa [14]. These studies indicated a high uptake of HIV testing ranging from 
75% in Nigeria to over 96% in Zimbabwe and South Africa. The high uptake of HIV testing 
could have been attributable to policy changes in integrating HIV testing in ANC and shifting 
from opt-in to opt-out testing 
The proportion of women who were already on ART prior to ANC visits, was reported in six 
studies, from Malawi [7-9], Zimbabwe [13], Kenya [15] and Zambia [16]. In Zimbabwe only 
7% of the women were already on ART during their ANC visits whilst in Malawi, 
implementation of option B+, resulted in an increase of women who were already on ART 
before pregnancy [7-9] from 30% before Option B+ to 48% after Option B+ adaptation. In a 
matched cohort study of Option A and B, in four sites receiving external technical support for 
the provision of PMTCT-related care in Zambia, 48% of women were already on ART prior 
to their first ANC visit [16]. Findings are not representative of PMTCT service delivery in 
Zambia as a whole, since the sites receive technical support for the provision of PMTCT-
related care from the Boston University PMTCT Integration Project through the President’s 
Emergency Plan for AIDS Relief (PEPFAR). External support can also influence health 
facility characteristics and operational aspects of a facility such as capacity, location, staffing 
and services provided. 
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Four  out of the seven studies that had information on CD4 count testing were from South 
Africa[17-20] and the rest from Kenya [15], Zambia [16] and Mozambique [21]. The 
proportion of women who had CD4 testing during ANC visits from Kenya, Zambia and 
Mozambique was below 60% despite that over the data collection period of these studies, 
CD4 testing was supposed to be a prerequisite to access care. In South Africa the proportion 
of women tested for CD4 count increased from 66% in 2010 to 76% in 2012 according to a 
study that utilised national data. [19]   
Exposure to PMTCT options: Thirty-five (78%) studies reported on Option A (Tables 1and 
2) and they were from the 14 representative countries with South Africa contributing seven 
studies [14, 17-19, 22-24].  Implementation of Option B+ was investigated in Nigeria [25, 26] 
, Malawi [7-9, 27-32], Mozambique [33], Zimbabwe [34] and Ethiopia [35, 36] in 16 studies 
which were synthesised. The two studies which reported on all three Options (A, B and B+) 
were conducted in Malawi [29] and Nigeria [25] where the data collection covered a longer 
period. 
Infant outcomes: The MTCT rate was reported in 29 studies (Table 1) and ranged from 1.1% 
to 15.1%. MTCT rate was high  (above 10%) mainly in studies where data was collected in 
the early days [37-42] of the WHO 2010 PMTCT guidelines although South Africa reported a 
low MTCT rate of 2% during the same period [20] . In Zambia there was a reduction in 
MTCT rate from 12% in 2010 [37] to 3% in a retrospective study conducted from 2011 to 
2014 [43]. The lowest MTCT rate of 1.1% was reported from Nigeria [26]; however, the 
author indicated that the study involved HIV-positive women who booked for antenatal care 
in a tertiary institution, and were likely to be wealthier and more educated than the general 
population and perhaps more likely to adhere to ART and other PMTCT interventions 
 
Exposure to PMTCT options and MTCT rate: In a study from Cameroon, under option A, 
the MTCT rate  was 3.7% for infant mother pairs who both received prophylaxis; 16.2% 
when only the mothers  received prophylaxis; 12% for mothers without prophylaxis whose 
infants received Nevirapine, and 31.3% when neither mother or infant received prophylaxis 
[44]. In Zambia, lower rates of MTCT were associated with both mother and infant receiving 
prophylaxis: 4.2% compared to 20.1% in a no intervention group at 0-6 weeks [37]. In South 
Africa, in-utero transmission rate was highest among women who required ART but did not 
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initiate treatment (8.5%) compared to 2.7% and 0.4% among women who received ART and 
women who were not eligible for ART and received prophylaxis under option A [14].  
In Ethiopia, absence of maternal ART was significantly and independently associated with 
maternal to child transmission of HIV (AOR = 5.02, 95% CI: 2.43, 10.4) [45].  
 
Results from two studies that compared option A and B+ from Ethiopia [36] and  Malawi[8], 
both confirmed supremacy of option B+ over A in terms of MTCT rate. In Ethiopia, none of 
the infants whose mothers received option B+ had a positive PCR result whilst the MTCT 
rate for those under option A was 3.9% [36]. In Malawi the MTCT rate was 2.9% under  
Option A, 1.9% under Option B+, and 1.1% for infants whose mothers received ART for their 
own health [8]. 
 
Figure 4.2 shows MTCT rates at the end of data collection year and according to which 
option was used; only studies showing overall MTCT rates, not rates at younger ages when 
HIV transmission may have been ongoing in a breastfeeding population, are shown. Option A 
had higher MTCT rates in most of the studies under review; however, most Option A studies 
preceded the Option B+ studies. The general functions of the PMTCT programs have been 
improving over time with studies carried out after 2013 showing lower MTCT rates even 
under Option A. 
 
Timing of ART initiation and MTCT: In Kenya where an MTCT rate of 8.9% was 
reported, lack of maternal use of ART at the time of delivery was associated with increased 
risk of MTCT for infants of women who were on Option A and B [15]. In Nigeria MTCT 
(0.4%) was lower among women on ART before pregnancy compared to women who started 
ART during pregnancy or delivery which was at 2% [46].    
 
Impact of infant feeding on MTCT: The impact of infant feeding mode was not explored in 
the analysis of most studies under this review with only 13 studies providing results (Table 
4.2). Exclusive breastfeeding is commonly measured through household surveys by asking 
mothers/caregivers of sample infants less than 6 months of age regarding intake in the 
previous day and night. However there is a lack of uniformity of methods used for collecting 
exclusive breastfeeding data in the countries under review. Infant feeding methods were 
reported in studies from Zambia [37] Malawi [7], DRC [40], Ethiopia [36, 45], Cameroon 
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[42, 47], Nigeria [26, 46, 48, 49], South Africa [18] and Tanzania[39]. High levels of 
exclusive breastfeeding were reported, with Malawi reporting that 99% of HIV-exposed 
infants exclusively breastfed in the first 6 months.  
MTCT of HIV was significantly higher with mixed feeding (adjusted odds ratio (aOR): 6.7, 
95% CI 1.6-28.3; p=0.009) in Cameroon under Option A exposure [42]. Similarly in Nigeria 
MTCT was higher for mixed fed infants at 14.2%, compared to 3.73% for exclusively 
breastfed infant and 2.43% for exclusively formula-fed infants at 18 months [49]. This was 
consistent with a study in Ethiopia where mixed infant feeding practices were significantly 
and independently associated with MTCT of HIV (AOR = 4.18, 95% CI: 1.59, 10.99) [45].  
Lower rates of MTCT were found in children who never breastfed in Zambia at 2.5% at 0-6 
weeks compared to 6.5% those who had been breastfed under Option A exposure [37].  
 
Early Infant diagnosis: Early Infant diagnosis (EID) of HIV by PCR was reported in 20 
studies from 8 countries (Table 4.). The uptake of  EID ranged from less than 60% in Nigeria 
[25] and Zambia [37] to 100% in 2012 according to South African national data where it 
increased from 87% in 2010 [19]. The age at which PCR was done ranged from 4 weeks to 18 
months. In South Africa, 80% of exposed infants had PCR results at 6 weeks [24], whereas in 
Malawi 52% underwent testing at 6–12 weeks and 28% tested at 12 months[31].  
 
Impact of age at first PCR on MTCT: Age at first PCR had an impact on the MTCT of 
HIV-exposed infants. In Tanzania, the proportion of HIV-infected infants was higher among 
infants who appeared later for HIV testing (18% at 3–6 months) than among those who 
presented earlier (6.4% at 1–2 months) under Option A implementation [39]. The Tanzanian 
observations were in agreement with the Ethiopian study which reported that late enrolment 
to the exposed infant follow-up clinic  was significantly and independently associated with 
MTCT of HIV (AOR= 2.89, 95% CI: 1.35, 6.21) [45].  
 
ART initiation of HIV-positive infants: ART initiation of HIV-positive infants is a key 
stage of the PMTCT cascade. In this review it was reported in three studies from DRC[40], 
Zambia[41] and Nigeria[11]. Among HIV-infected infants in DRC, 97% enrolled in 2011-
2012 were initiated on ART; this was an increase from 61% for infants enrolled in 2007-2008 
[40].  Lower rates were reported in Zambia where 67% of infants who tested positive started 
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ART by the end of the study[41] and Nigeria where 75% of HIV-positive infants were 
initiated on ART[11]. 
Retention in care: Retention in routine maternal-infant HIV care of HIV exposed infants was 
explored in three studies from Zambia, Malawi and Rwanda. In Zambia the retention rate of 
HIV-exposed infants under Option A, at 6 months after delivery was 62% compared to 30% 
of HIV-unexposed infants under the same ongoing routine care conditions [16]. In Malawi 
72% of HIV-exposed infants remained in care after 12 months under Option B+[31], whereas 
in Rwanda under Option B, infants’ 12-month retention was 81% (95% CI: 76%, 86%) [50].  
In Malawi, the retention in HIV care of women initiated on Option B+ was 85%, compared to 
93% after 2 years among those initiated on ART because of clinical or CD4 cell count criteria 
[29]. These results were consistent with the findings from Rwanda where mothers eligible for 
ART for their own health were better retained across all the time periods, 66% (CI: 59%, 
73%), compared with those not eligible and receiving ART solely for PMTCT, 47% (CI: 
37%, 57%), at 12 months, p<0.001 [50]. Another Malawian study  highlighted that initiation 
of ART on the same day as HIV diagnosis was independently associated with reduced 
retention in the first 6 months (aOR 2.27; 95% CI: 1.34–3.85; p=0.002) under Option B+ [9]. 
 In a retrospective record review of women presenting to antenatal care or maternal and child 
health services at 34 health facilities in rural Zimbabwe, retention in ART care after 6 months 
of Option B+ initiation was 83% [34].  In contrast, retention for Rwandan mothers exposed to 
option B was 68% at 6 weeks post-delivery, decreasing to 58% by 12 months [50]. 
Lost to follow up: Data on the magnitude of LTFU (missing three consecutive clinic visits) 
along the PMTCT cascade was reported in nine studies  (Table 4.2)  from Malawi [27, 28, 
51], Tanzania [38], Kenya [15], Nigeria [10, 25] and Ethiopia [35, 36]. In the studies from 
Malawi and Ethiopia this was explored in the context of Option B+ whilst in the other 
countries it was explored under Option A.  
 In Tanzania [38], 61% of infants receiving treatment were lost to follow up at the time of 
review, despite the high proportion of guardians and parents who returned for PCR results 
(92% in 2010 and 98% in 2011). The results were consistent with a study from Malawi where 
48% of the HIV-exposed infants were declared LTFU in the database although 96% of the 
them in the cohort had their PCR test done at 24 months [52]. However, Nigeria reported low 
rates of LTFU for HIV-infected infants of less than 15% [11, 46] despite that the studies 
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evaluated different PMTCT options. In Kenya LTFU increased with the age of infants with 
9.6 % of enrolled infants not returning for any follow-up care, 26.4 % dropping out by 9 
months and 39 % by 18 months of age [15].  
In Ethiopia under option B+ implementation, the cumulative proportions of women LTFU at 
6, 12 and 24 months were 12%, 15% and 23%, respectively [35]. Similar results were 
reported in Malawi where cumulative incidence of LTFU by year 2 was 24.5% (95%CI, 
23.2%–25.8%) among women who started ART during pregnancy, 20.2% (95% CI, 18.3%–
22.2%) among those who started ART while breastfeeding, and 17.0% (95% CI, 15.2%–
18.8%) among those who were neither pregnant nor breastfeeding when they started 
treatment [30]. 
The independent risk factors for LTFU were younger maternal age at ART initiation, missing 
CD4 cell count at ART initiation, ART initiation on the same day of diagnosis, and starting 
ART at hospital [35].  The risk of being LTFU was higher in ‘B+ pregnant’ (adjusted hazard 
ratio [asHR]: 2.77; 95% CI: 2.18–3.50; P < 0.001) and ‘B+ lactating’ (asHR: 1.94; 95% CI: 
1.37–2.74; P < 0.001) compared to women on ART for their own health in Mozambique [33]. 
 
Adherence: Adherence to ART drugs for PMTCT by the mothers, was reported in two 
studies (Table 4.2) from Malawi [51] and Zambia [43]. Adherence during the postpartum 
period in Zambia [43] ranged from 71% to 84% at different times postpartum. The results of 
the study were consistent with the Malawian study where 70% of women exposed to option 
B+,  who started ART during pregnancy and breastfeeding adhered adequately during the first 
2 years of ART [30]. However, default and incomplete adherence were more common in the 
option B+ compared to the Option A in Malawi [51], where 4% of women in the option B+ 
cohort had less than 95% adherence compared to 2% for the-option A cohort. 
4.4 Discussion 
The Global Plan towards the elimination of new HIV infections among children by 2015 and 
keeping their mothers alive prioritized 21 countries in Sub-Saharan Africa. The studies in the 
review originated from 14 of the priority countries. The studies show a continued decline in 
the incidence of HIV among children, as indicated by low MTCT rates, but the target of a 
90% reduction by 2015 was not met, reduction in incidence being only 76% in the 21 priority 
countries (54).  South Africa reported low MTCT rates under Option A implementation[24] 
even from the results of the facility-based cross-sectional study conducted in 2010 [53]. This 
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could have been as a result of their health system which is better resourced than most of the 
countries under review. 
Many of the studies on the impact of infant feeding methods and exposure to various ART 
regimens were conducted before the 2010 WHO PMTCT [54, 55]. Although infant feeding 
results were available from only a minority of studies in this review, the results of the review 
are in agreement with the findings which led to the current guidelines. In the countries under 
review breastfeeding is very common, and breastfed infants have an increased risk of MTCT 
of HIV [56]. Mixed feeding is also a common practice in Sub-Saharan Africa and is an 
additional risk for postnatal HIV transmission [57]. As revealed by the studies from Tanzania 
[39] and Ethiopia [45], where there was increase in MTCT over time, continued breastfeeding 
in the face of low adherence to ART treatment, is a risk. 
 
Option B+ which initiates lifelong ART to all pregnant and breastfeeding women is now 
widespread in Sub-Saharan Africa, with all the 22 Global Plan countries implementing it 
except for Nigeria. As of October 2015, Option B+ was being nationally implemented in 14 
(Angola, Burundi, Cameroun, Chad, Ethiopia, Kenya, Lesotho, Malawi, South Africa, 
Swaziland, Tanzania, Uganda, Zambia and Zimbabwe) out of the 21 Countries in Sub-
Saharan Africa, and scale-up continues in 6 countries (Botswana, Cote d’Ivoire, DRC, Ghana, 
Mozambique and Namibia) [4]. In this review, Implementation of Option B+ was 
investigated in Nigeria [25, 26] , Malawi [7-9, 27-32], Mozambique [33], Zimbabwe [34] and 
Ethiopia [35, 36]. Most studies came from Malawi since they were the pioneers of this option; 
hence there is a need to explore the impact of implementing the Option B+ guidelines and 
identifying missed opportunities along the PMTCT cascade in other countries which have 
adopted it.  
 
The implementation of Option B+ in Malawi resulted in a five-fold increase in the numbers of 
pregnant women being enrolled on ART. Nonetheless, default and incomplete adherence 
were more common in Option B+ implementation [43, 51]. These results were consistent with 
a qualitative study conducted in Tanzania among mothers who were put on Option B+ during 
pregnancy who indicated various reasons for poor adherence to ART, which included lack of 
motivation to continue ART after weaning the child and protecting the child from becoming 
infected, stigma and poverty [58]. There is also a need to adjust operational practices related 
to quality of counselling as it has been indicated to be a predictor of adherence to 
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treatment[59]. Moreover a recent study suggested that retention in all postnatal programs, 
including those outside the context of HIV is poor globally, elaborating the need for evidence 
based intervention strategies and further research on the drivers of disengagement.[60] 
  
The retention in care of HIV-infected and lactating mothers under Option B+ was poor and 
driven by early losses [9, 27-29, 34, 50]. Hence implementation of Option B+ requires that 
policy makers rethink ways of ensuring optimal adherence to ART for maximal suppression 
of viral replication and avoidance of drug resistance. One possibility is to explore the use of 
cell phone SMS which has been found to be useful in Africa for improving the quality of care 
and follow-up of people with HIV/AIDS [61, 62]. 
The consolidated guidelines recommend that HIV-exposed infants be tested for HIV between 
6-8 weeks, at the end of breastfeeding, and at any point they present with illness[3]. However 
in the studies under review the retention rate tended to decrease during the post-partum period 
[16, 27-29, 32]. This reduction in post-partum retention rate implies that HIV-exposed infants 
will be detached from the health system, thus missing opportunities for PCR testing. A 
systematic review of mostly Sub-Saharan countries found that about a third of HIV-exposed 
children in standard PMTCT programs fall out of care in 3 months after delivery and a further 
45% stop care after their first HIV test [63]. Furthermore, low rates of infected infants are 
initiated on ART despite being PCR-tested [32, 38], raising concerns on the benefits of EID 
and the referral to care and treatment of these infected infants. Similar results were reported 
by Chatterjee et al, in their descriptive analysis of national EID programs in four countries 
where only 22% to 38% of infected infants were initiated on ART[64]. There is a need for 
strategic and technical developments for ensuring that drop-out rates along the PMTCT 
cascade are minimal. 
Limitations of the study 
The major limitation of the review is that the results of most of the study findings may not be 
representative of the general health care systems in the countries reviewed as only two studies 
from Ghana and South Africa used national data for analysis. There are also profound 
variations in the implementation of PMTCT programs across countries. For instance, in 
Nigeria MTCT was reported to be 1.1%  [26] which was largely attributed to the study 
population which comprised wealthier and more educated women than the general 
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population. There is a research gap of evaluating PMTCT interventions using large cohorts 
that can be generalizable to the whole population.   
 
The limitations of the data sources of this review are mainly due to the retrospective nature 
posing problems of incomplete recordings. Moreover, the data used in these studies was 
originally collected for different purposes from this review and therefore hard to compare 
data when a lot of time points differ because of different timings of key outcomes  However, 
the advantage of using routinely collected data is that research will be conducted in a timely 
and cost-efficient manner as data are already collected and available for analysis [65]. 
 All the studies reported challenges in the documentation of routine services, linkage of HIV 
diagnosis to care and active follow-up of those enrolled in care. The data collection systems 
often lack immediacy as many are paper-based with records completed at each facility and 
collated centrally. This is likely to be a challenge in most Sub-Saharan countries and therefore 
there is a need to improve management of health information systems through the use of 
modern technology. 
4.5 Conclusion 
Irrespective of which Option was followed, uptake of antenatal HIV testing was high but 
there was a large drop off along later points in the PMTCT cascade. More research is needed 
on how to improve later components of the PMTCT cascade, especially of Option B+ which 
is now the norm throughout Sub-Saharan Africa. 
 
There is research gap for studies that investigated the full cascade of interventions that 
include uptake of antenatal services and HIV testing during pregnancy, use of ART by 
pregnant women living with HIV, appropriate infant feeding, uptake of infant HIV testing and 
other post–natal health care services in the context of the PMTCT Option B+ interventions. In 
view of the gap there is a need for implementation research evaluating real world 
effectiveness of the 2010 WHO PMTCT guidelines specifically Option B+. 
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4.7 Table and Figure Legends 
Table 4.1 
Abbreviations used: ANC = antenatal clinic; EID = early infant diagnosis; MTCT = mother 
to child HIV transmission; LTFU = lost to follow-up  
Option A - pregnant women with a CD4≥350 cells/µL receive ART prophylaxis including 
daily Zidovudine from 14 weeks gestation through one week postpartum, single-dose 
Nevirapine at delivery, and daily Lamivudine from delivery through one week postpartum. 
Their infants receive daily Nevirapine from birth through one week after the cessation of 
breastfeeding. Women with women with CD4≤ 350 cells/µL or WHO clinical stage 3 or 4 
disease are put permanently on triple-drug ART regardless of symptoms. 
 
Option B-  all women receive triple-drug ART from 14 weeks gestation through the cessation 
of breastfeeding, and infants receive a daily Nevirapine or Zidovudine dose from birth to 4–6 
weeks. 
 
Option B+ - all pregnant and breastfeeding HIV-infected women, regardless of CD4 cell 
count, should continue ART for life. 
 
Table 4.2  
Abbreviations used:  ART=antiretroviral therapy; LTFU=lost to follow-up 
Retention rate - the continuous engagement from diagnosis in a package of prevention, 
treatment, support and care services; 
Lost to follow-up - missing three consecutive clinic visits;  
 
Figure 4.1 
Abbreviations used; MTCT = mother to child HIV transmission;  
Key – The numbers in brackets are study references and the points are the MTCT rate. 
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Figure 4. 1: PRISMA Chart 
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Figure 4. 2: Comparison of MTCT Rate and PMTCT Option 
 
Key – The numbers in brackets are study references and the points are the MTCT rate across 
different time periods. The country of study origin of the studies are indicated in Table 4.1 
NB// some of the studies such as reference 8 and 36 reported MTCT rates of more than 1 
PMTCT options 
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Table 4.1: Uptake of PMTCT services and Infant outcomes
1 
Author 
Data 
collection 
Period Country 
Tested for 
HIV during 
ANC Visit 
Infant Feeding 
methods Early Infant Diagnosis (EID) Infant outcomes 
Option A Studies 
Temgoua et al 
[47] 2010-2011 Cameroon 23% 
31.9% were exclusively 
breastfed, 
35.9% were formula 
fed, 
14.4% were mixed fed. 
12. 6% at ≤6 weeks,  
61.1% at  >6 weeks -6 months, 
26.3% at >6 months,  
Overall MTCT rate was 11.5% 
MTCT rate was 3.7% for infant mother pairs 
who received prophylaxis; 16.2% for mothers 
who received prophylaxis and baby without 
ART; 12% for mother without prophylaxis 
and infant with Nevirapine and 31.3% for 
mother baby pair without prophylaxis and 
Nevirapine  
Noubiap et al 
[42] 2010 Cameroon  
44.6% were exclusively 
breastfed,  
33% were formula fed, 
22.4% were mixed fed. 
 
71.4% at  ≤ 6 months 
28.8 % at >6 months. 
Overall MTCT rate 11.6%. 
MTCT increased with mixed feeding (aOR: 
6.7, 95% CI 1.6-28.3; p=0.009 
MTCT increased if EID at > 6 months 
compared with <=6 months (aOR: 6.5, 95% 
CI 1.4-29.3; p=0.014).  
 
Feinstein et al 
[40] 2007-2012 DRC  
94.4% were exclusively 
breastfed in 2011-2012 63%  by 2 months  in 2011–2012 
MTCT rate 11%.               
3% dead by 18 months.  
Among HIV-infected infants, 97% were 
initiated on ART.             
Dako-Gyeke et 
al [12] 2011-2013 Ghana 
2011 -  83% 
2012 - 76% 
2013 - 75%  
   
Banwat, et al 
[48] 2009 - 2010 Nigeria  
80.3% were exclusively 
breastfed    
MTCT rate 9.6%. 
 
Okusanya et al 
[10] 2010 - 2011 Nigeria 97.3%     MTCT rate 6.3%.  
Anigilaje et al 
[49] 2008 - 2011 Nigeria  
24.5% were exclusively 
breastfed,  
67.9% were formula 
fed, 
7.6 % were mixed fed 
  
MTCT rates at 18 months were 3.73% for 
exclusively breastfed infants, 2.43%  for 
exclusively formula fed infants and 14.2% for 
mixed fed and MF respectively. 
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Author 
Data 
collection 
Period Country 
Tested for 
HIV during 
ANC Visit 
Infant Feeding 
methods Early Infant Diagnosis (EID) Infant outcomes 
Moodley et al 
[22] 2004 - 2012 South Africa    97.4% at 4-8 weeks MTCT rate was 2.9% by 2012 
Bhardwaj et al 
[19] 2010 - 2012 South Africa  
 
87% in 2010, 
93% in 2011, 
100% in 2012. 
 
Hussain et al 
[14] 2010 South Africa 99.2% 
 
58.9% at birth 
MTCT rate  2.4% 
in-utero transmission rate was highest among 
women who required ART but did not initiate 
treatment (8.5%) compared to 2.7% and 0.4% 
among women who received ART and 
women who were not eligible for ART and 
received PMTCT 
Schnippel et al 
[17] 2012 - 2013 South Africa        
Technau et al 
[18] 2011 South Africa 92% 
 51% were exclusively 
breastfed;  
13% were formula fed 
36% were mixed fed   
 
Sherman et al 
[23] 2003 - 2012 South Africa  
 
73% at 6 weeks 
 
MTCT rate was 2.4% 
 
Ibeto et al [24] 2012 - 2013 South Africa  
 
80%  at 6 weeks MTCT rate was 1.6%  
Chiduo et al 
[38] 2009-2011 Tanzania    
91.5% in 2010, 
97.8%  in 2011 
MTCT rate of  9.21 %   in 2010  and 10.1% 
in 2011 
Mwendo et al 
[39] 2009- 2012 Tanzania  
88.6% were exclusively 
breastfed;  
7.1% were formula fed 
3.9% were mixed fed 
77.7% at 1-2months, 
16.8% at 3-6 months, 
5% at 7-12 months, 
Overall MTCT rate  9.6%   
The proportion of HIV-infected infants was 
higher among infants who appeared later for 
HIV testing (18% at 3–6 months) than among 
those who presented earlier (6.4% at 1–2 
months). 
Bannik- Mbazzi 
et al [66]  2002 - 2011 Uganda 
2010 - 95.5% 
2011 - 96%     MTCT rate of 5.7% in 2010, and 6.1% 2011  
Scott et al [16] 2011 Zambia          MTCT rate was 3%  
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Author 
Data 
collection 
Period Country 
Tested for 
HIV during 
ANC Visit 
Infant Feeding 
methods Early Infant Diagnosis (EID) Infant outcomes 
Torpey et al 
[37] 2007- 2010 Zambia  
86.4%  were ever 
breastfed;  
56.8%  were 
exclusively  breastfed;     
22%  were mixed fed  
22.4% between  0-6 weeks, 
59.1% between 6 weeks- 6months, 
59.1% between 6 12months. 
MTCT rate was 11% in 2010                  
Lower rates of positive PCR results were 
associated with 1) both mother and infant 
receiving prophylaxis, 2) children never 
breastfed and 3) mother being 30 years old or 
greater 
 
Gonese et al 
[13] 2012 Zimbabwe 96% 
   
Option A and B Studies 
Koye and 
Zeleke [45] 2012 Ethiopia  
78.8% were exclusively 
breastfed; 
 13.3% were formula 
fed;  
7.9% were mixed fed   
MTCT rate was 10 %   
Late enrolment to the exposed infant follow 
up clinic (AOR = 2.89), rural residence (AOR 
= 5.05), home delivery (AOR = 2.82), 
absence of maternal ART(AOR = 5.02) and 
mixed infant feeding practices (AOR = 4.18, 
95) were significantly and independently 
associated with maternal to child transmission 
of HIV  
Nduati et al [15] 2006 - 2012 Kenya      
MTCT rate  was  8.9 % in 2012 
Age at enrolment, nutritional status, 
residential distance from the hospital and 
mothers’ HAART status at the time of 
delivery were independently associated with 
MTCT of HIV infection. 
Sutcliffe et al 
[41] 2010 - 2012 Zambia     98% of the infants MTCT rate 12%  
Okawa et al 
[43] 2011 - 2014 Zambia    80.4 % of infants MTCT rate of 3.4 %  
Option A, B and B+ Studies 
Rawizza et al 
[25] 2004 - 2014 Nigeria    
Median age - 1.6 months;  was 
available for 53% of their infants 
MTCT for infants whose mothers received 
any antenatal and/or delivery care was 2.8% 
versus 20.0% if their mother received none. 
Option  A and B+ Studies 
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Author 
Data 
collection 
Period Country 
Tested for 
HIV during 
ANC Visit 
Infant Feeding 
methods Early Infant Diagnosis (EID) Infant outcomes 
Olana et al[36] 
 
 
 
 
 
2006 - 2014 Ethiopia  
79% were exclusively 
breastfed  
14.6% exclusive 
replacement 
4.7 % were mixed fed  Done for 66.7% 
Overall MTCT rate of 4.3% 
MTCT rate for infants who received Option 
B+  - 0 % 
MTCT rate for mother and infant receiving 
prophylaxis was 3.9℅.  
Kamuyango et 
al [51] 2009 - 2013 Malawi 94%   
82 %  at 7.6 weeks  under Option 
A; 
Under Option B+,  86.5 % at 6.9 
weeks  
MTCT rate was 4.6 % under Option A, and 
2.6 % under Option B+. 
Kim et al [8] 2010 - 2013 Malawi  
  
MTCT rate under Option A - 2.9, 1.9% in 
infants born to mothers who received Option 
B+ and 1.1% for infants with mothers 
received ART for their own health. 
Option B Studies 
Mugerwa et al 
[67] 2010 - 2014 Uganda  
73.4% exclusively 
breastfed;  
26.6% exclusive 
replacement 
   
MTCT rate of 2.6%;      
MTCT was lower among women on ART 
before pregnancy compared to women who 
started ART during pregnancy or delivery           
Option B+ Studies 
Price et al [7] 2011 -  2013 Malawi 90% 98.8% were breastfed 
6.4% at 6-8 weeks;           
9.5% of at 9 weeks;        
Not done for 73%  of the infants 
and unknown for 11.1% 
 
Chan et al [9] 2011- 2012 Malawi 81% 
   
Martínez Pérez 
et al [31] 2011 - 2012 Malawi  
 
80.3% underwent  
52.0%  at 6–12 weeks,  
28.1% at 12 months 
MTCT rate was 4.1% and all had been started 
on ART by the age of 12 months 
Ngambi et al 
[32] 
 2012-2014 Malawi  
43% were   exclusively 
breastfed; 
50% were mixed fed;  
89% at 6 weeks,  
and 96% at 24 months 
MTCT rate was 5%  for tested at 6 weeks and 
8% for those tested at 24 months 
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Author 
Data 
collection 
Period Country 
Tested for 
HIV during 
ANC Visit 
Infant Feeding 
methods Early Infant Diagnosis (EID) Infant outcomes 
4%  stopped 
breastfeeding before 
registration 
Okafor et al 
(24) 2009-2011 Nigeria  
91.8% were   
exclusively breastfed; 
5.5% were mixed fed;  
2.7%  formula fed 
 
MTCT rate of 1.1% at 18 months 
Pharr et al [11] 2013 Nigeria 75% 
 
 Done for 71% of infants 
 Dzangare et al 
[34] 2014. 
Zimbabwe 95% 
   1 Abbreviations used: ANC, antenatal clinic; EID, early infant diagnosis; MTCT, mother to child HIV transmission; LTFU, lost to follow-up 
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Table 4.2: Retention rate, Adherence and Magnitude of Loss to follow up (LTFU)
 1, 2
 
Author 
Data 
collection 
Period Country Retention Rate Loss to Follow Up (LTFU) 
 
 
Adherence to ART 
Option A Studies 
Okusanya et al 
[10] 2010 – 2011 Nigeria   
30% of HIV infected mothers and 25% of 
exposed infants LTFU  
 
Chiduo et al 
[38] 2009-2011 Tanzania   61% of infants LFTU 
 
Scott et al [16] 2011 Zambia 
62% of HIV exposed were retained in care 
compared to 30% of comparison unexposed  
 
 
Option A and B Studies 
Nduati et al [15] 2006 – 2012 Kenya   
9.6 % of enrolled infants did not return for any 
follow-up care, 39.0% were lost to follow-up 
before 18 months of age;  26.4% LTFU at 
9 months, 39% at 18 months  
 
Sutcliffe et al 
[41] 2010 – 2012 
 
 
 
 
Zambia 
86% of caregivers returned for results and 67% 
of infants who tested positive started ART by 
the end of the study 
 
 
Okawa et al [43] 2011 – 2014 Zambia     
ART adherence 82.5 % during 
pregnancy, 84.2 % at 1 week 
postpartum, 81.5 % at 6 weeks, 
and 70.5 % at 24 weeks. 
Option A, B and B+ Studies 
Koole et al [29] 2005 – 2012 
 
 
 
 
Malawi 
Women who started ART because of Option 
B+ had retention rate of 85% compared to 93%  
among women of child bearing age initiated on 
ART because of clinical or CD4 cell count 
criteria. 
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Author 
Data 
collection 
Period Country Retention Rate Loss to Follow Up (LTFU) 
 
 
Adherence to ART 
Rawizza et al 
[25] 2004-2014 
 
 
 
Nigeria 
66% of the women completed the entire 
cascade of services including antenatal, 
delivery and at least one infant follow up visit.  
21% prior to delivery care with a further 16% 
lost prior to first infant visit. 
 
Option A and B+ Studies 
Kamuyango et 
al [51] 2009 – 2013 Malawi   
 Pregnant women were likely to be lost to 
follow up compared to non pregnant women 
initiating therapy  for disease stage  or CD4 
count 
Default and incomplete adherence 
were more common in the Option 
B+ cohort than under Option A 
Kim et al [8] 2010 – 2013 Malawi 
 
High LTFU rate at 6-8weeks; 22℅ were lost to 
follow-up care and treatment. 
 
Option B Studies 
Sagay et al [46] 2009 -  2011 
 
Nigeria 
 
14.1% of the HIV exposed infants were LTFU 
between birth and 18 months 
 
Woelk et al [50] 2010 – 2012 
 
 
 
 
Rwanda 
 Women 58% (95% CI: 52%, 64%) were 
retained 12 months post-delivery,  
Infants’ 12-month retention was 81% (95% CI: 
76%, 86%). 
Overall, the majority of loss to retention was 
observed in the 30 days after antenatal 
registration.  
 
Option B+ Studies 
Mitiku et al [35] 2013-2015 
 
 
 
 
Ethiopia 
 
The cumulative proportion of patients LFU at 6, 
12 and 24 months after ART initiation was 
11.9% (95% CI: 8.9, 16.0%), 15.7% (95% CI: 
12.0, 20.4%) and 22.5% (95%CI: 17.3, 29.2%), 
respectively. Overall 16.5% were LTFU 
 
Tenthani et al 
[28] 2011- 2012 
 
 
Malawi 82.2 % at 6 months postnatal 
17.1% LTFU,  Six months after initiation 23.9 
% in all Option B+ patients who started ART 
while pregnant  
 
Chan et al [9] 2011- 2012 
 
 
 
Malawi 
Initiation of ART on the same day as HIV 
diagnosis was independently associated with 
reduced retention in the first six months (aOR 
2.27; 95% CI: 1.34–3.85; p=0.002). 
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Author 
Data 
collection 
Period Country Retention Rate Loss to Follow Up (LTFU) 
 
 
Adherence to ART 
Haas et al [30] 2011 – 2013 
 
 
 
 
 
 
 
Malawi 
 
The cumulative incidence of LTF by year 2 was 
24.5% (95%CI, 23.2%–25.8%) among women 
who started ART during pregnancy, 20.2% 
(95% CI, 18.3%–22.2%) among those who 
started ART while breastfeeding, and 17.0% 
(95% CI, 15.2%–18.8%) among those who 
were neither pregnant nor breastfeeding when 
they started treatment. 
70% of women who started ART 
during pregnancy and 
breastfeeding adhered adequately 
during the first 2 years of ART 
Tweya et al [27] 2011 – 2013 
 
 
 
Malawi 85% at 3mths; 82% at 6mths; 79% at 12mths 
20% of these 47% collected ARVs and did not 
return; 12% collected at 2 visits; 9% at 3 visits 
and 32% at 4  or more visits 
 
Martínez Pérez 
et al [31] 2011 – 2012 Malawi 
71.7% of the exposed infants remained in care 
at 12 months. 
 
 
Ngambi et al 
[32] 
 2012-2014 Malawi 
 
Overall, 48% of HIV-exposed infants were 
declared lost-to-follow-up in the database. 
 
Llenas-García et 
al[33] 2013 – 2014 
 
 
 
 
 
 
 
Mozambique 
 
48.5% of Option B+ women were LTFU. The 
risk of being lost to follow-up was higher in 
pregnant’(adjusted sub hazard ratio [asHR]: 
2.77; 95% CI: 2.18–3.50; P < 0.001) and 
lactating’ (asHR:1.94; 95% CI: 1.37–2.74; P < 
0.001 
 
Pharr et al [11] 2013 Nigeria 
 
13% of the enrolled infants were LTFU 
 
Dzangare et al 
[34] 2014 Zimbabwe 
Retention in ART care after 6 months of Option 
B+ initiation was 82.6%  
 
 
1
 definitions: retention rate - the continuous engagement from diagnosis in a package of prevention, treatment, support and care services; lost to 
follow-up - missing three consecutive clinic visits;  
1 ART=antiretroviral therapy; LTFU=lost to follow-up.
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Chapter 5: Quantitative paper using ANC services data set 
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Abstract 
Introduction: Accurate estimates of coverage of prevention of mother-to-child (PMTCT) 
services among HIV-infected pregnant women are vital for monitoring progress towards HIV 
elimination targets. The achievement of high coverage and uptake of services along the 
PMTCT cascade is crucial for national and international mother-to child transmission 
(MTCT) elimination goals.  In eastern and southern Africa, MTCT rate fell from 18% of 
infants born to mothers living with HIV in 2010 to 6% in 2015. This paper describes the 
degree to which World Health Organization (WHO) guidelines for PMTCT services were 
implemented in Zambia between 2010 and 2015. 
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Method: The study used routinely collected data from all pregnant women attending 
antenatal clinics (ANC) in SmartCare health facilities from January 2010 to December 2015. 
Categorical variables were summarized using proportions while continuous variables were 
summarized using medians and interquartile ranges. 
Results: There were 104,155 pregnant women who attended ANC services in SmartCare 
facilities during the study period. Of these, 9% tested HIV-positive during ANC visits whilst 
43% had missing HIV test result records. Almost half (47%) of pregnant women who tested 
HIV-positive in their ANC visit were recorded in 2010. Among HIV-positive women, there 
was an increase in those already on ART at first ANC visit from 9% in 2011 to 74% in 2015. 
The overall mean time lag between starting ANC care and ART initiation was 7 months, over 
the six year period, but there were notable variations between provinces and years. 
Conclusion: The implementation of the WHO post 2010 PMTCT guidelines has resulted in 
an increase in the proportion of HIV-infected pregnant women attending ANC who are 
already on ART. However, the variability in HIV infection rates, missing data, and time to 
initiation of ART suggests there are some underlying health service or database issues which 
require attention. 
(296 words) 
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5.1 Introduction 
The use of antiretroviral therapy (ART) by HIV-positive pregnant and breastfeeding women 
is the cornerstone of the strategy to prevent mother-to-child HIV transmission (PMTCT) (1, 
2). Global PMTCT guidelines have evolved from short-course antiretroviral (ARV) 
prophylaxis for mothers and infants to prevent HIV transmission, towards longer and more 
potent ARV regimens with the potential to improve maternal health (3-6). The World Health 
Organization (WHO) recommendation for lifelong ART for all pregnant and lactating women 
(Option B+) is nearly universally adopted in the 22 priority countries with a high burden of 
HIV and moving towards full implementation (7). In 2017, the global coverage of pregnant 
women living with HIV had access to ARV medicines to prevent transmission of HIV to their 
babies was  80% [61–95%] and 210 000 new infections were averted due to PMTCT(8) 
Effective PMTCT programmes require women and their infants to receive a cascade of 
interventions including uptake of antenatal services and HIV testing during pregnancy, use of 
ART by pregnant women living with HIV, safe child birth practices, appropriate infant 
feeding, infant prophylaxis, and HIV testing and other postnatal health care services (9). As 
the WHO PMTCT guidelines have been evolving over time, the key indicators included in 
the PMTCT cascade have also changed (3-6). The steps along the cascade expanded as new 
interventions to prevent HIV transmission were introduced and access to ART improved (10). 
A commonly used surrogate marker for programme effectiveness is programme coverage.  
For PMTCT this would be the proportion of HIV-infected women and exposed infants in a 
population that access the different components of the PMTCT programmatic cascade (11). 
Estimates of coverage with PMTCT services among all HIV-infected pregnant women are 
vital to monitor progress relative to targets, and to secure donor funding for PMTCT 
programmes (12). With the endorsement of the new infant HIV infection elimination goal, 
countries target to increase coverage of PMTCT services to ≥95% (13). 
Zambia revised its national PMTCT guidelines in 2010 in accordance with the new WHO 
guidelines and, along with many other developing countries, adopted Option A (14). Under 
Option A, HIV-positive pregnant women with a CD4 count ≥350 cells/µL received ART 
prophylaxis to prevent transmission of HIV to their baby.  This consisted of daily Zidovudine 
from 14 weeks gestation through to one week postpartum, single-dose Nevirapine at delivery, 
and daily Lamivudine from delivery through to one week postpartum. Their infants received 
daily Nevirapine from birth through to one week after the cessation of breastfeeding. Women 
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with CD4≤ 350 cells/µL or WHO clinical stage 3 or 4 disease were initiated onto lifelong 
triple-drug ART, regardless of symptoms (5).  In 2013, after more than two years 
implementing Option A, Zambia announced that it would revise its PMTCT guidelines again 
and adopt Option B+(15). Option B+ recommends that all pregnant and breastfeeding HIV-
infected women, regardless of CD4 cell count, should start and continue ART for life whilst 
their infants receive daily Nevirapine or Zidovudine from birth to 4–6 weeks (6). 
This paper describes trends in the coverage of PMTCT services from 2010 to 2015 using the 
SmartCare database of routine clinical information collected in Zambia. This is the first study 
to have evaluated the effectiveness of implementing post 2010 PMTCT interventions 
nationwide using SmartCare routine data. 
 
5.2 Method 
5.2.1 Study Design 
This was a retrospective cohort study using routinely collected data. The study population 
was all pregnant women attending antenatal care (ANC) from January 2010 to December 
2015 in health facilities using the SmartCare database. 
 
In Zambia over 90% of pregnant women attend ANC services at least once during their 
pregnancy, but only 47% deliver at health facilities (16). Thus it is difficult to ensure that 
eligible pregnant women receive the complete treatment to prevent transmission of HIV to 
their babies. Although more than 75% of the ANC facilities currently provide PMTCT 
services, the majority of these facilities are along the country’s main rail line and in urban 
centres, resulting in geographical inequity (16). 
 
5.2.2 Data Sources 
The study retrospectively analysed the Ministry of Health electronic SmartCare database, 
using routinely collected data from all pregnant women attending ANC from January 2010 to 
December 2015. SmartCare is a Zambian Ministry of Health-led project funded from the 
United States Centre for Disease Control and Prevention (CDC) (17). The SmartCare 
database was developed to improve continuity of care and provide timely data on maternal 
and child health, HIV/AIDS, tuberculosis and malaria interventions for public health 
purposes. Since 2005, the SmartCare database has been deployed in over 800 health facilities, 
 
87 
 
which represents 40% of all facilities in Zambia, including the biggest and busiest health 
facilities. These results come from 886 health facilities from all provinces in Zambia. The 
Southern province had the most number of facilities (254/886) represented in the dataset, 
followed by the Copperbelt (187/886), and Eastern (166/886) provinces. Muchinga and 
Northern provinces had the least number of facilities, 10 and 26, in the analysed dataset. 
 
5.2.3 Data Extraction 
The data was extracted into Excel, without names, but with the unique identity (ID) number, 
and then transferred to Stata 13 for cleaning and analysis. All women enrolled in a facility 
using SmartCare have an electronic health record about their ANC visits which includes 
information collected in each visit. Records are updated at every point of clinical service. 
SmartCare is organised into comprehensive modules and sub-modules.  The information from 
various modules is linked through the unique ID number.  For this study, the ANC data was 
linked to the HIV Client Summary module and the ARV Eligibility Interaction Module to 
identify HIV-positive women. Data from the Obstetric History Module was then used to 
segregate PMTCT clients from general ART clients. The oldest date of HIV testing and ANC 
visit date were used to determine whether women had known their HIV status before the 
ANC visit. The final data were stratified by province using the geography file from the 
Central Statistical Office (CSO) which has a list of all the districts and provinces. 
The first step in data cleaning was to remove duplicate data for repeat visits in the same 
pregnancy (based on parity and gravid status). This was done by keeping the first visit date of 
each pregnancy then populating any empty fields with information captured at later visits in 
the same pregnancy. Records for all the mothers less than 15 years and those above 49 years 
of age were dropped from the sample making our target group to be those between 15-49 
years (reproductive age group). Age groups were categorised as 15-24, 25-34, and 35-49 
years. Marital status was grouped into single, married, divorced, widowed and missing. The 
education status groups were no education, primary education, junior secondary, secondary, 
and tertiary education. 
 
  
 
88 
 
5.2.4 Statistical Analysis 
The data were used to estimate the proportion of HIV-positive pregnant women attending 
ANC by province and year. The study population was divided into three strata: pregnant 
women with a new HIV test result documented in ANC clinic, pregnant women with known 
status but not on ART, and pregnant women who were already on ART. Among the total 
number of pregnant women presenting to ANC clinic in each calendar year; the percentages 
in each group were calculated. 
The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) 
guidelines were used to conduct and report on the findings of this study (18). 
5.2.5 Ethics 
Ethical approval was granted from Zambia Biomedical Research Ethic Committee (Ref 101-
04-16) and the LSHTM Research Ethics Committee (Ref 12086). Permission to use 
SmartCare data was granted by the Zambia Ministry of Health. The Ethics Committees that 
approved the study waived the need for written informed consent to be obtained as this was a 
secondary analysis of previously collected data and the authors had access only to de-
identifiable information.  
 
5.3 Results 
5.3.1 Demographics 
A total of 105,373 pregnant women attended ANC services in SmartCare facilities from 
January 2010 to December 2015 (Figure 5.1). After removal of those aged 14 years or less 
and those above 49 years, there were 104,155 in the final study sample (Table 5.1) with 33% 
recorded in 2010. Most women were from Copperbelt (27%), Southern (21%) and Eastern 
(21%) provinces whilst the fewest were from Luapula and North-western provinces. The 
majority (51%) were between 15 to 24 years and 82% were married. A high proportion had 
attained primary level (34%) and secondary level (39%) education, however educational level 
attainment data was missing for 20% of pregnant women. 
5.3.2 HIV test results  
Overall during the study period 9% of pregnant women tested HIV-positive (Table 5.2) at 
ANC visits whilst 43% had missing HIV test result records. In addition, 34% of the missing 
HIV test results were in 2014, whereas only 2% were in 2011.  More so, over 60% of HIV 
test results were missing in Lusaka and Muchinga provinces. 
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The overall percentage of HIV-positive pregnant women, who tested for the first time at the 
ANC decreased from 13% in 2010 to 5% in 2013 and then to 0.15% in 2015. The percentage 
with missing HIV test results increased from 11% in 2010 to 65% in 2013 and then to 98.8% 
in 2015 (Table 5.2).  
 
5.3.3 ART initiation 
Almost half (47%) of the pregnant women who tested HIV-positive in their ANC visit were 
recorded in 2010 (Figure 5.2). More women knew their HIV-positive status in 2015 (30%) 
than in 2011 (9%).  There was a large increase in the proportion of HIV-positive women who 
were already on ART from 9% of the HIV-positive women seen in 2011 to 74% of the HIV-
positive women seen in 2015. 
 
The overall mean time difference between HIV-positive diagnosis at the first ANC visit and 
ART initiation was 7 months.  If a woman was diagnosed at 14 weeks the analysis suggests 
that most women were not started on ART until after delivery (7-9 months).  However, there 
are notable variations between visit years (Figure 5.3). There were also large differences 
between provinces; for example, in 2010 pregnant women in Luapula province took an 
average of 37 months from diagnosis to treatment whereas in the Copperbelt it took less than 
1 month.  
5.4 Discussion 
Zambia initiated the PMTCT programme in 1999 to address the burden of vertical 
transmission of HIV and to integrate PMTCT in all maternal, newborn and child health 
services throughout the country (14). The results of this study show that, although there is a 
high rate of engagement with PMTCT services, the variability in HIV infection rates, missing 
data and time to initiation of ART suggests there are some underlying health service or 
database issues which require attention.  
 
Our results indicate a progressive increase in the proportion of women HIV-infected who 
were already on ART before registering for ANC in their visit year (from 3% in 2010 to 74% 
in 2015). This is likely to be attributable to the introduction of Option B+ for those women 
with repeat pregnancies and adoption in 2013 of WHO Test and Treat guidelines that 
recommend anyone who tests positive for HIV should be started on treatment, regardless of 
their CD4 count. However, the UNAIDS Prevention Gap report indicated a decline in 
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pregnant women living with HIV who received effective ART from 96% in 2013 to 87% in 
2015 (1).  In a systematic review of literature on the effectiveness of implementing post 2010 
PMTCT guidelines, we concluded that many HIV-infected women who are engaged in care 
during pregnancy are lost to follow-up during the postpartum period (19). 
The increased volume of patients initiating ART due to test-and-treat and Option B+ could 
have threatened  programme performance and negatively affected the HIV continuum of care 
for all HIV–infected patients (20). Mathematical modelling using the Lifelong ART tool 
indicated that the probability of HIV-infected pregnant women initiating ART would increase 
by 80%. It was also suggested that while the shift would generate higher PMTCT costs, it 
would be cost-saving in the long term as it spares future treatment costs by preventing 
infections in infants and partners (21). 
Other studies from Africa have shown that the uptake of PMTCT services could be 
influenced by health system or structural issues such as staffing level, availability and cost of 
ART, capacity of health personnel to prescribe appropriate regimens, shortage of supplies in 
facilities, failure to follow up mothers’ or infants’ status, and giving wrong information or 
suboptimal quality of counselling leading to loss or dropout from the PMTCT cascade (22-
27). In Zambia lack of human resources remains a serious impediment to addressing HIV, so 
that even when physical resources are available, there is often not the healthcare personnel to 
administer them (28). However, knowledge around PMTCT is high: the  Zambia 
Demographic Health Survey (ZDHS) 2013-14, reported that 82% of women and 66% of men 
were aware of the risk of MTCT and that it can be reduced by taking special drugs during 
pregnancy (29). 
 
In our study 65% (983/1501) of the women who were initiated on ART after testing HIV-
positive during their ANC were documented after the adoption of Option B+ (2013-15). 
However, increasing ART initiation coverage does not always translate to programme 
effectiveness: for example, in a surveillance exercise conducted in Lusaka in 2003, 32% of 
HIV-infected women reported not to actually ingest the NVP tablet given to them in ANC 
(30). In addition, the risk of being lost to follow up was higher in ‘B+ pregnant’ compared to 
women on ART for their own health in Mozambique (31). In Malawi where Option B+ was 
first piloted, default and incomplete adherence were more common with Option B+ than with 
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Option A (32). Hence more efforts must be directed to postnatal programs that ensure 
retention in care so that women who are initiated on ART do not disengage. 
 
The SmartCare database offers real time data which can enable the Zambian health policy 
makers to act on urgent PMTCT interventions and improve health care quality and outcomes 
of mothers and their infants. SmartCare is a facility-based approach which is unable to 
account for individuals who do not access ANC services; hence it’s possible that we might 
overestimate PMTCT effectiveness (11). The ANC SmartCare database sample was likely to 
be biased towards the generally better outcomes of those who receive ANC services. 
However, with over 90% pregnant women attending ANC services at least once during their 
pregnancy (29), the results could be a good indicator of program performance.  
These results come from more than 800 health facilities from all provinces in Zambia, and 
hence representative of the population of pregnant women in Zambia, although some 
provinces, such as Lusaka, may be under represented due to data quality. The level of missing 
data on HIV test results indicate that this data must be viewed with caution and hence 
prevents us making meaningful conclusions in the later years (2014-15) where the missing 
data HIV test results is almost 99%.  This was despite the efforts of PEPFAR and the 
Ministry of Community Development, Mother and Child Health to strengthen the Health 
Management Information Systems (HMIS) and linkages with the national electronic health 
record system (33). The main efforts were supposed to be directed towards supporting 
partners to utilize the capability of SmartCare to electronically populate the HMIS. In 
contrast, our study found that the SmartCare database has not been mined and data quality 
has been deteriorating due to the lack of utilization of the data and its findings. We are 
conducting qualitative research to investigate the problems with using the SmartCare system 
and how to improve them.  
 
Our study shows that there are major problems in both the completeness of the collection and 
reporting of data that tracks PMTCT service delivery. The data quality challenges were 
similar to other studies from the region using routinely collected data (12, 20, 34, 35). 
Despite tremendous progress and many country-driven successes achieved during the Global 
Plan, operational challenges in data use, monitoring, and evaluation for PMTCT persist. 
Collecting longitudinal data on mother–baby pairs throughout the PMTCT cascade is 
challenging but necessary to optimize maternal and infant outcomes. However the Global 
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Plan priority countries (which include Zambia) health records are not properly completed, 
hence the need to scale up electronic data systems (36) such as the SmartCare.  
Limitations 
SmartCare data collection is implemented parallel to the main line Ministry of Health HMIS, 
which also collects HIV test results. This has caused high levels of missing HIV test results 
data in the SmartCare as clinicians prefer to enter the information in the HMIS forms 
compared to SmartCare forms which are longer (5-6 pages per interaction). 
Due to data security and confidentiality from data custodians, we were not able to get the 
exact date of birth and the national identity numbers for individuals in the SmartCare 
database. As a result we could not match records of the same individuals in cases where they 
are double registered through change of name, or facility. A commonly used surrogate 
marker for programme effectiveness is programme coverage, i.e. the proportion of HIV-
infected/exposed mother/infant pairs in a population that receive a PMTCT intervention (11). 
In our study the infant-mother pairs could not be linked as infants are registered as separate 
individuals with unique numbers.  
 
The decrease in the number of records for over 30, 000 in 2010 to 10,000 in 2015 is likely to 
have introduced bias and hence affects the external validity of our study. The findings could 
have been triangulated against HMIS data as this could provide an opportunity to identify 
omissions and errors in the dataset.   
 
The data was mainly collected for administrative purposes without research intentions; for 
example, breastfeeding is part of the PMTCT cascade but the database contains no infant 
feeding information. 
5.5 Conclusion 
The implementation of the WHO post 2010 PMTCT guidelines has resulted in an increase in 
the proportion of HIV-infected pregnant women attending ANC who are already on ART. 
The SmartCare database could enable Zambian health policy makers to act on urgent PMTCT 
interventions and improve health care quality and outcomes of mothers and their infants. 
However, there is a need first to improve procedures for data collection and entry. The 
missing data observations indicated the need for further qualitative research to determine why 
it was such a problem. 
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Table 5.1: Demographic Characteristics 
   
Year of Visit 
   
2010 2011 2012 2013 2014 2015 Total 
Age 
Categories 
15 to 24 
yrs 
 N  16,518 7,124 8,181 8,069 8,224 5,382 53,498 
 %  51 51 51 51 53 52          51   
25 to 34 
yrs 
 N  12,486 5,439 6,162 5,873 5,644 3,881 39,485 
 %  38 39 39 37 36 37 38 
35 to 49 
yrs  
 N  3,494 1,424 1,610 1,750 1,716 1,178 11,172 
 %  11 10 10 11 11 11 11 
Marital 
Status 
 Single   N  3,125 1,291 1,393 800 783 1,135 8,527 
   %  10 9 9 5 5 11 8 
 Married   N  27,139 11,774 13,124 12,940 12,727 7,569 85,273 
   %  84 84 82 82 82 72 82 
 Divorced   N  149 61 70 52 48 68 448 
   %  0.5 0.4 0.4 0.3 0.3 0.7 0.4 
 Widowed   N  100 69 59 43 52 50 373 
   %  0.3 0.5 0.0 0.0 0.0 0.5 0.4 
 Missing   N  1,985 792 1,307 1,857 1,974 1,619 9,534 
   %  6 6 8 12 13 16 9 
Education 
Level 
Attained 
No 
Education 
N 1,593 474 1,134 676 657 363 4,897 
% 5 3 7 4 4 3 5 
Primary 
Level 
N 12,309 4,580 5,631 5,441 4,384 3,026 35,371 
% 38 33 35 35 28 29 34 
 
Secondary 
Level 
N 12,770 6,098 6,372 5,291 5,057 4,558 40,146 
% 39 44 40 38 32 44 39 
Tertiary 
N 646 533 434 434 348 392 2,787 
% 2 4 3 3 2 4 3 
Missing 
N 5,180 2,302 2,382 3,850 5,138 2,102 20,954 
% 16 16 15 25 33 20 20 
Total     32,498 13,987 15,953 15,692 15,584 10,441 104,155 
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Table 5.2: HIV test Result 
Result of 
HIV 
Test 
 
Year of Visit 
  2010 2011 2012 2013 2014 2015 Total 
Negative (N) 24,411 10,773 10,209 4,533 348 106 50,380 
  (%) 75 77 64 29 2 1 48 
Positive (N) 4,375 2,133 1,851 858 29 16 9,262 
  (%)  13 15 12 5 0.3 0.2 9 
Not 
Clear (N) 81 16 15 14 0 0 126 
  (%) 0.3 0.1 0.1 0.1 0.0 0.0 0.1 
Missing (N) 3,631 1,065 3,878 10,287 15,207 10,319 44,387 
  (%) 11 8 24 66 98 99 43 
         Total N 32,498 13,987 15,953 15,692 15,584 10,441 104,155 
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Figure 5.1: Sample size data flow 
 
The Data Flow chart represents the flow chart of participants eligible for inclusion in the 
analysis 
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Figure 5.2: Distribution of HIV positive women by year of visit 
 
 
Started ART refers to women who first tested positive during ANC for this pregnancy and 
were started on ART. 
HIV-positive not started on ART refers to women who first tested HIV-positive in this 
pregnancy but were not started on ART because they were pregnant when Option A was in 
place. 
Already on ART refers to pregnant women who were already on ART before seeking ANC 
services for this pregnancy. 
Known HIV-positive status refers to women with known HIV-positive status before ANC for 
this pregnancy so were not tested again but were not started on ART because they were on 
Option A. 
 
2010 2011 2012 2013 2014 2015 
Year of Visit 
Started ART 149  191  178  158  448  377  
Already on ART 52  40  62  96  150  1,155  
Known HIV   (+ve) status (Not 
started on ART) 
305  152  176  264  266  488  
Tested HIV Positive  4,375 2,133 1,851 858 29 16 
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Figure 5.3: Overall time to ART initiation in months 
 
Time to ART initiation is the number of months calculated from the time a woman was 
diagnosed HIV positive to the time they were initiated on ART. 
 
 
 
 
 
 
  
Year 2010 Year 2011 Year 2012 Year 2013 Year 2014 Year 2015 
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Chapter 6: Quantitative paper using data set of HIV- infected infants  
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Abstract 
Background 
Early diagnosis and treatment initiation of HIV-infected infants can greatly reduce the risk of 
infant mortality. The WHO recommends testing HIV-exposed infants at 6 weeks of age and 
immediate initiation of antiretroviral therapy if positive. This study aimed to determine the 
feasibility of using an electronic health records system to evaluate the performance of 
Zambia’s HIV Early Infant Diagnosis services. 
Methods 
 A retrospective analysis of routinely collected data from the Zambian SmartCare database 
was performed for the period January 2006 to December 2016. The study population includes 
all HIV-infected infants (n=32,593) registered during this period on treatment for HIV. 
Univariable logistic regression was conducted to identify factors associated with later infant 
testing and treatment initiation.  
Results 
The mean age at infant HIV test decreased from 10.10 months in 2006 to 3.49 months in 
2016. Infants born in 2015 were almost 4 times more likely to be tested under 2 months of 
age compared to infants born in 2006 (OR: 3.72, p-value: <0.001). The mean time from 
diagnosis to treatment initiation decreased from 220 days in 2006 to 9 days in 2015.  There 
was substantial regional variability with infants in the provinces of Copperbelt, Luapula and 
Southern performing best in outcomes and Eastern, Lusaka and Western performing the 
worst. 
Conclusions 
HIV-exposed infants born more recently have significantly better outcomes than infants born 
a decade ago in Zambia, which could be as a result of increased attention and funding for 
HIV programmes.  
  
Keywords: Early infant diagnosis, HIV, PMTCT 
 
 
106 
 
6.1Background 
Early diagnosis and treatment initiation of HIV-infected infants with antiretroviral therapy 
(ART) can reduce the risk of early infant mortality by 76% [1]. However, treatment for HIV-
infected children lags considerably behind adult treatment and without treatment 
approximately 50% of HIV-infected infants die before the age of two
 
[2]. The World Health 
Organisation (WHO) recommends testing HIV-exposed infants by 6 weeks of age and 
immediate initiation of ART if positive. Despite these recommendations infants are lost at 
every step of the early infant diagnosis cascade
 
[3].  
Zambia has been using the electronic health records system SmartCare for the routine 
collection of HIV data since 2004. SmartCare was developed to improve continuity of care 
and provide timely data on maternal and child health HIV interventions for public health 
purposes. To date no analysis of the paediatric HIV data has been performed. This study was 
a retrospective analysis of routinely collected data from the SmartCare database over the 
period 2006 to 2016, to determine if infants are being tested and initiated on treatment in the 
correct timeframe. This information can be used to inform decisions on improving the 
provision of early infant diagnosis services in Zambia.  
6.2 Methods  
6.2.1 Study design 
This retrospective analysis of routinely collected data was conducted as part of the SEARCH 
(Sustainable Evaluation through the Analysis of Routinely Collected HIV data) project which 
aims to support the utilisation of routinely collected HIV data. The SEARCH project is 
collaboration between the London School of Hygiene and Tropical Medicine and the 
Ministries of Health in Zambia and Tanzania. The data source was SmartCare, one of the 
largest electronic patient monitoring systems in Africa. Introduced as a pilot project in 2004 
by the Zambian Ministry of Health with funding from the US Centers for Disease Control 
(CDC), it has now been rolled out across all ten provinces of Zambia and is used to monitor 
and plan improvements in the country’s HIV services. All facilities in Zambia wishing to 
dispense ART are required to use SmartCare. Since 2005 SmartCare has been deployed to 
over 800 facilities in 94 districts, with an enrolment above 900,000 patients. This represents 
approximately 40% of all clinics in Zambia; these are the largest and busiest ART clinics and 
the requirement to join SmartCare if clinics wish to prescribe ART means that most Zambian 
patients on ART care captured in SmartCare database [4]. 
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Data was extracted by a SEARCH team member from the Zambian SmartCare database 
modules, Paediatric ART and Under 5 Registration, between the years 2006 and 2016 using a 
standardised data extraction form. The study population includes all HIV-infected infants 
registered during this period on treatment for HIV. Age at infant HIV test was determined by 
linking the Under 5 Registration module (which has infant date of birth) and Paediatric ART 
module (which has date of infant HIV test). Infants are registered as independent patients 
from their mothers and the system does not have a link between the mother and infant pairs; 
therefore, information could not be collected on the mother’s treatment, on the proportion of 
HIV-exposed infants who tested HIV-negative, or on HIV-exposed infants who missed both 
testing and provision of ART. For this reason, we are focusing this analysis solely on HIV-
infected infants born between January 2006 and December 2016 who have received ART. 
6.2.2 Statistical methods 
Categorical variables were summarised by frequencies and percentages and continuous 
variables by histograms. Univariable and multivariable logistic regression were conducted 
with “age at HIV test” and “time from diagnosis to treatment initiation” as the dependent 
variables and the following independent variables: infant sex, province, year of birth, and 
season of birth. Season were defined as early dry (June to August); late dry (September to 
November); early rainy (December to February) and late rainy (March to May).  
Odds ratios with 95% confidence intervals were calculated to identify risk factors for age at 
test under 2 months and time from diagnosis to treatment under 2 weeks. For the variable 
‘province’ Lusaka was chosen as the reference group because it is the most populous 
province, and it contains the capital city where the SmartCare project was first rolled out so 
has the largest number of registered infants. Although multivariable analysis was also 
conducted for all variables to display adjusted odds ratios, the results showed little difference 
and so only the univariable analysis results are included in this paper. All analysis was 
performed using STATA 14 and graphics were produced using STATA and Microsoft Excel.  
6.3 Results  
A total of 32,593 HIV-infected infants on ART in Zambia were identified from SmartCare 
over the period 2006 to 2016. The number of infants in the database on ART increased from 
1,761 in 2006 to peak at 3,720 in 2009 and then steadily decreased to 108 in 2016. Main 
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comparisons over time used 2015 since there were too few infants listed in 2016 for age at 
testing and none for time to treatment initiation.  
6.3.1 Age of diagnosis 
For the outcome ‘age at infant HIV testing’, 20,260 (62.16%) infants had complete data 
recorded. Looking at the country as a whole, the mean age at HIV testing has steadily 
decreased from 10.10 months for infants born in 2006 to 3.49 months in 2016 (Fig.6.1). 
Infants born in 2015 were more likely to be tested under 2 months of age compared to infants 
born in 2006 (OR: 3.72, p-value: <0.001). For infants born in 2016 an even greater 
association was found (OR: 5.62, p-value: <0.001), but this result must be viewed with some 
caution as there were far fewer infants in the database for the year 2016 (n=108) than 2015 
(n=386). 
Considering all years together, infants in all provinces, especially Western province (OR: 
0.21, p-value: <0.001) were less likely to be tested under 2 months of age as compared to 
infants in Lusaka; an exception was Southern province which had an increased odds (OR: 
1.83, p-value: 0.001). Fig. 2 shows the percentage of HIV tests performed within 2 months of 
birth in the years 2010 and 2015 by province. All provinces show an overall improvement, 
particularly Copperbelt, Luapula and Southern. The years 2010 to 2015 were chosen for the 
comparison to coincide with the changes in prevention of mother-to-child transmission 
(PMTCT) guidelines in Zambia over this period, as discussed below.   
Infants born in the late dry season were more likely to be tested within 2 months than infants 
born in the early dry season (OR 1.39; p value: <0.001) (Table 6.1). There was no association 
found for sex.  
6.3.2 Time to ART initiation 
For the outcome ‘time from diagnosis to ART initiation’, 10,881 (33.38%) infants had 
complete data recorded. At the country level the mean time from diagnosis to starting 
treatment has decreased significantly from 220 days for infants born in 2006 to 9 days in 
2015 (Fig.6.1). Infants born in 2015 were more likely to start treatment in under 2 weeks 
compared to infants born in 2006 (OR 2.29; p value: <0.001).  
Infants in all provinces had an increased likelihood of starting treatment within 2 weeks as 
compared to Lusaka, despite being less likely to be tested under 2 months. Luapula showed 
the biggest difference (OR: 3.83, p-value: <0.001). The provinces showing the most 
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improvement from 2006 to 2015 were Copperbelt, Central and Northern. Female infants were 
slightly more likely to start treatment in under 2 weeks compared to males (OR: 1.10; p 
value: 0.004). Season showed no significant association.  
6.4 Discussion 
In Zambia the age at infant HIV test has shown a steady decline, with the exception of the 
period 2010 to 2013 which showed a slight increase. This period coincides with the 
implementation of new WHO treatment guidelines for PMTCT. Changes in WHO 
recommendations over the past decade on when to initiate ART in pregnant women have had 
major implications for the delivery of HIV services, and help explain the trends in service 
delivery. From 2010 Zambia adopted Option A, a complex guideline consisting of different 
maternal treatment regimens during pregnancy, labour and postpartum as well as infant 
prophylaxis
 
[5]. This complexity of regimen changes, combined with the need for regular 
clinic visits in early infancy, led to high attrition rates and infants receiving improper doses of 
daily Nevirapine
 
[6].  Option B+ which was adapted in 2013 [7] this barrier by 
recommending treating all pregnant women with lifelong ART regardless of CD4 count. By 
simplifying the process considerably, in Malawi (where it was first trialled), switching to 
Option B+ led to a five-fold increase in the number of pregnant women enrolled on ART in 
the first quarter of implementation
 
[8]. When Zambia announced its policy for universal ART 
in 2015, there was an increase in the volume of patients initiating on ART [9]. Zambia has 
made progress towards elimination of HIV mother-to-child transmission with a reduction in 
new HIV infections among children from 10,000 in 2010 to 8,900 in 2016. This could be as 
result of improved coverage of pregnant women living with HIV accessing antiretroviral 
medicines to 86% [10]. In our study we were not able to calculate the MTCT rate because the 
SmartCare database does not have information on the HIV exposed infants who are not on 
ART. 
All provinces showed a subsequent reduction in age at test between 2013 and 2015 with the 
implementation of Option B+, in which all pregnant women with HIV are offered lifelong 
ART regardless of CD4 count
 
[11]. The progress could also be attributed to Option B+ as 
previous studies have concluded that children born to women who received ART are less 
likely to be lost to follow-up and more likely to be tested for HIV [12-14]. This suggests that 
under Option B+ mothers and their infants are more likely to be attached to the health care 
system. Therefore efforts have to be made to ensure that the infants who are tested and 
initiated are retained in care. In Tanzania, 61% of infants receiving treatment were lost to 
 
110 
 
follow up at the time of review, despite the high proportion of guardians and parents who 
returned for PCR results (92% in 2010 and 98% in 2011) [15]. The results were consistent 
with a study from Malawi where 48% of the HIV-exposed infants were declared lost to 
follow up (LTFU) in the database although 96% of the them in the cohort had their PCR test 
done at 24 months [16]. Hence despite the reduction in the age of testing the progress of EID 
must be enhanced by ensuring continuity in care. In Zambia the estimated percentage of 
children (aged 0–14 years) living with HIV receiving ART, in 2015 was 61% [17], 3% lower 
than the adult coverage. 
An effective EID service should achieve the following: identify all HIV-exposed infants, 
provide HIV testing and ensure return of results in a timely manner; retain HIV-exposed 
infants and their mothers in care; and identify all HIV-infected infants and link them to 
treatment services to ensure timely initiation of ART [18]. Our data set could not allow us to 
effectively analyse all these steps hence our conclusion of the progress of EID could have 
been overestimated as only 33.38% infants had complete data recorded. The poor data quality 
might have an effect on the external validity of the study. Hence the reasons for poor data 
quality have been qualitatively explored (Gumede-Moyo et al submitted). It is also likely that 
poor data entry over these years has impacted the results; SmartCare has evolved from a 
system solely used to track patients into an extensive database of all patients receiving ART 
in the country. This has resulted in a large amount of data being collected for each patient 
which is very time consuming for the clinician, who often omits collecting data for certain 
fields they deem irrelevant to their patient’s care. In addition, power outages in remote areas 
of Zambia are a major problem and can occur for prolonged periods of time during the day, 
limiting the time that data can be entered into the system. This means that data collection is 
often not up to date and this could contribute to the apparently poor performance of Western 
province.  
Our study is the first to attempt to analyse the progress of EID using the SmartCare database 
as a source for exposed infants on ART dataset. A more comprehensive dataset of the HIV 
status of all exposed infants could have been obtained from the ANC and Under 5 paper 
registers. However, the majority of studies using paper based routine data have also 
acknowledged the common problem of missing data [19]. This could be assumed to be one of 
the causes of under-utilisation of routinely collected data which was observed by Munthali et 
al [20]. 
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The best performing provinces in 2015 (Figure 2) for ‘percentage of tests performed within 2 
months of birth’ were Luapula, Southern and Copperbelt; surprisingly Lusaka was the second 
worse performing province after Western. Of the nine provinces of Zambia (excluding 
Muchinga province which was created in 2011 and not included in this database), Lusaka and 
Copperbelt are predominantly urban whereas the remaining are predominantly rural
 
[21]. 
Previous studies have shown that the burden of HIV is highest in Zambia’s ‘urban poor’ [22, 
23], and indeed data from the latest Zambian 2013-14 DHS showed that Lusaka and 
Copperbelt have the highest adult HIV prevalence, at 16.3% and 18.2% respectively
 
[24]. 
Despite the similar HIV prevalence and population sizes, Copperbelt saw a more dramatic 
improvement in age at infant testing between 2013 and 2015 than Lusaka. The stark 
difference between the performance of Copperbelt and Lusaka is also seen in the percentage 
of infants tested under 2 months of age, which was amongst the highest in Copperbelt in 2015 
compared to 2010, but rose much less in Lusaka during the same period. This regional 
variability seen could be attributed to the concentration of donor funded programmes in the 
various provinces. Despite Zambia’s classification as a lower-middle income country, it 
remains heavily dependent on external donors to finance its national HIV response. PEPFAR 
and the Global Fund account for 95% of donor funding for HIV care
 
[25]. Given external aid 
makes up the bulk of HIV funding in Zambia, it is possible that decisions on which areas of 
the country to target may influence the trends in HIV outcomes we have seen at a provincial 
level.   
Infants born in the early dry season tended to be tested earlier compared to infants born in the 
late dry season, although there was no association found between dry and rainy seasons. 
Season was chosen as a variable of interest because previous studies in Sub-Saharan Africa 
have shown an association between being born in the rainy season and poorer outcomes for 
HIV-exposed infants
 
[26, 27]. Reasons suggested for the higher mortality experienced by 
infants born in the rainy season include a more contaminated water supply from the rains and 
food scarcity in the period preceding the harvest
 
[28, 29].  
Study Limitations 
This research has shown that routinely collected data offers a valuable opportunity for the 
near real-time surveillance of large quantities of data. The SmartCare database of registered 
infants receiving ART represents a robust sample of the population under study over the 
stated time period, although we recognise there was a steady decrease in the numbers of 
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infants registered onto SmartCare from 2009 onwards.  The large amounts of missing data 
did not only introduce bias but also compromised the statistical power of a study.  Other 
limitations with using this database are that the database was designed for practical use by 
healthcare workers and not research so the variables collected are limited to those deemed 
most useful for the clinical care of patients. In addition, mother-infant pairs are not linked 
within SmartCare, and so the analysis was restricted to HIV-infected infants on ART and we 
were not able to analyse outcomes for HIV-exposed uninfected infants. This would be 
valuable information for any future assessment of mother-to-child HIV transmission 
prevention and control programs in Zambia.  
 
6.5 Conclusions 
Early infant diagnosis of HIV is essential to achieve prompt treatment initiation and reduce 
infant mortality. Infants born more recently have better clinical HIV care than infants born a 
decade ago in Zambia, which could be as a result of more inclusive treatment eligibility 
guidelines. Provincial variability in the performance of early infant diagnosis services is 
substantial. Further research is needed on the reasons for such stark regional disparities in 
HIV service provision in Zambia, and on addressing missed opportunities for infant testing.  
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6.8 Figure legends 
 
Figure 6.1: 
Figure Name: Mean age at HIV test and time from diagnosis to treatment initiation by year 
of birth 
 
Description of Figure: 
Blue line is Age at HIV Test and the Red line is the Time from diagnosis to treatment 
initiation. 
 
Figure 6.2 
Figure Name: Percentage of HIV tests performed within 2 months of birth by province in 
2010 and 2015 
 
Description of Figure: 
The percentages represent the proportion of infants who were tested within 2 months of birth 
by province in 2010 and 2015 
 
NB//There was no 2015 data for North-Western province. The other missing province is 
Muchinga province which was newly created in 2011 and is not included in this database. 
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Table 6.1: Univariable analysis results for sex, season, province and year of birth 
 
Variable 
  Age at test             
Logistic regression for testing at < 
2 months 
Logistic regression for time from diagnosis to ART < 2 
weeks 
 
<2 months     n (%) 
<2 weeks      n 
(%) 
OR 95% CI P-value OR 95% CI P-value 
Sex         
Male 550/10,537 (5.2) 2,249/10,537 
(21.3) 
1.00 - - 1.00 - - 
Female 603/11,185 (5.4) 
2,568/11,158 
(23.0) 
1.03 0.92, 1.17 
 
0.573 1.10 1.03, 1.17 0.004 
Season         
Early dry 914/5,254 (17.4) 1,478/5,254 
(28.1) 
1.00 - - 1.00 - - 
Late dry 946/4,168 (22.7) 1,135/4,168 
(27.2) 
1.39 1.26, 1.54 <0.001 0.96 0.87, 1.05 0.333 
Early rainy 926/5,364 (17.3) 1,509/5,364 
(28.1) 
0.99 0.90, 1.10 0.856 1.00 0.92, 1.09 0.999 
Late rainy 912/5,474 (16.7) 1,611/5,474 
(29.4) 
0.95 0.86, 1.05 0.311 1.07 0.98, 1.16 0.137 
 
Time from 
diagnosis to 
ART 
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Variable 
  Age at test             
Logistic regression for testing at < 
2 months 
Logistic regression for time from diagnosis to ART < 2 
weeks 
 
<2 months     n (%) 
<2 weeks      n 
(%) 
OR 95% CI P-value OR 95% CI P-value 
Province         
Lusaka 365/5,394 (6.8) 822/5,394 
(15.2) 
1.00 - - 1.00 - - 
Central 94/2,288   (4.1) 688/2,288 
(30.1) 
0.59 0.47, 0.74 <0.001 2.39 2.13, 2.69 <0.001 
Copperbelt 294/4,778 (6.2) 1,648/4,778 
(34.5) 
0.90 0.77, 1.06 0.210 2.93 2.66, 3.22 <0.001 
Eastern 59/2,072    (2.8) 431/2,072 
(20.8) 
0.40 0.31, 0.53 <0.001 1.46 1.28, 1.66 <0.001 
Luapula 56/1,341   (4.2) 547/1,341 
(40.8) 
0.60 0.45, 0.80 0.001 3.83 3.36, 4.37 <0.001 
Northern 57/983      (5.8) 350/983   (35.6) 0.85 0.64, 1.13 0.262 3.08 2.65, 3.57 <0.001 
North-
Western 
25/883      (2.8) 244/883   (27.6) 0.40 0.27, 0.61 <0.001 2.12 1.80, 2.50 <0.001 
Southern 394/3,366 (11.7) 718/3,366 
(21.3) 
1.83 1.57, 2.12 <0.001 1.51 1.35, 1.69 <0.001 
Time from 
diagnosis to 
ART 
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Variable 
  Age at test             
Logistic regression for testing at < 
2 months 
Logistic regression for time from diagnosis to ART < 2 
weeks 
 
<2 months     n (%) 
<2 weeks      n 
(%) 
OR 95% CI P-value OR 95% CI P-value 
Western 24/1,577   (1.5) 285/1,577 
(18.1) 
0.21 0.14, 0.32 <0.001 1.27 1.06, 1.42 0.007 
 
 
Year of birth 
        
2006 220/1,709 (12.9) 340/1,709 
(19.9) 
1.00 - - 1.00 - - 
2007 412/2,619 (15.7) 547/2,619 
(20.9) 
1.26 1.06, 1.51 0.009 1.06 0.91, 1.24 0.430 
2008 528/3,475 (15.2) 790/3,475 
(22.7) 
1.21 1.02, 1.44 0.025 1.18 1.03, 1.37 0.020   
2009 683/3,678    (18.6) 861/3,678 
(23.4) 
1.54 1.31, 1.82 <0.001 1.23 1.07, 1.42 0.004 
2010 675/2,718   (24.8) 726/2,718 
(26.7) 
2.24 1.89, 2.65 <0.001 1.47 1.27, 1.70 <0.001 
2011 446/1,812      (24.6) 612/1,812   
(33.8) 
2.21 1.85, 2.64 <0.001 2.05 1.76, 2.40 <0.001 
Time from 
diagnosis to 
ART 
 
124 
 
 
Variable 
  Age at test             
Logistic regression for testing at < 
2 months 
Logistic regression for time from diagnosis to ART < 2 
weeks 
 
<2 months     n (%) 
<2 weeks      n 
(%) 
OR 95% CI P-value OR 95% CI P-value 
2012 191/1,384      (13.8) 564/1,384   
(40.8) 
1.08 0.88, 1.33 0.450 2.77 2.35, 3.26 <0.001 
2013 186/1,352 (13.8) 605/1,352 
(44.7) 
1.08 0.88, 1.33 0.474 3.26 2.76, 3.85 <0.001 
2014 171/1,019   (16.8) 548/1,019 
(53.8) 
1.36 1.10, 1.70 0.005 4.68 3.90, 5.62 <0.001 
2015 137/386  (35.5) 140/386  (36.3) 3.72 2.87, 4.83 <0.001 2.29 1.80, 2.92 <0.001 
2016 49/108    (45.4) 0/108        (0.0) 5.62 3.71, 8.51 <0.001 - - - 
 
 
 
 
Time from 
diagnosis to 
ART 
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Fig. 6.1: Mean age at HIV test and time from diagnosis to treatment initiation by year of 
birth 
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Figure 6.2: Percentage of HIV tests performed within 2 months of births by province in 2010 and 2015 
2010         
  2015 
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Chapter 7: Qualitative paper on implementation challenges of the SmartCare electronic 
health record system 
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Abstract 
Introduction: Routinely collected clinic data can provide information for surveillance of 
program implementation and impact. In services for the prevention of mother-to-child 
transmission (PMTCT) of HIV among pregnant women in Sub-Saharan Africa, the data 
collection systems often lack immediacy as paper-based records are completed at each 
facility and aggregate data are collated centrally. Electronic Health Records (EHR) could 
present an opportunity to improve accuracy, timeliness and scope of surveillance data. This 
study aimed to investigate the challenges in implementing a Zambian EHR system labelled 
‘SmartCare’ in order to improve PMTCT data.    
Method: Data was collected using in-depth interviews, observations and focus groups 
discussions (FGD) between September and November 2016. Seventeen in-depth interviews 
were held with a range of key informants from the Ministry of Health and local and 
international organisations implementing SmartCare. Four data entry observations and three 
FGDs with 22 pregnant and lactating women seeking PMTCT services were conducted. Data 
was analysed using a thematic content approach. 
Results: The SmartCare system has evolved from various patient tracking systems into a 
multifunctional system. Funding challenges impede data collection due to manpower 
constraints and shortages of data collection supplies. Challenges associated with data 
collection depend on whether a paper- or computer-based system is utilised. There is no 
uniformity in the data quality verification and submission strategies employed by various 
implementing partners. There isn’t much feedback from the EHR system at health facility 
level, which has led to disengagement as stakeholders do not see the importance of the 
system.  
Conclusion: SmartCare has structural challenges which can be traced from its development. 
Funding gaps have resulted in staffing and data collection disparities within implementing 
partners. The lack of feedback from the system has also led to complacency in operational 
level which has resulted in poor data quality in later years.   
(297 words) 
 
 
 
 
131 
 
 
7.1 Introduction 
Routinely collected clinic data can provide much needed information on the prevalence of 
HIV among pregnant women and the uptake of services for prevention of mother-to-child 
transmission (PMTCT) of HIV(1). The use of routinely collected data can be timely and cost-
efficient for decision making as data are already available for analysis (2). Collection of high-
quality routine data on these services and outcomes for HIV-positive mothers and HIV-
exposed infants is essential for monitoring and evaluation of PMTCT programmes, for 
clinical management of patients, and for managing stocks of HIV test kits and drugs  (1) For 
both the clinic staff and health system managers, having access to reliable data that reflects 
the processes of care and clinical outcomes is the first step to ensuring effective delivery of 
an intervention within a health care system(3, 4). However in Zambia there is underutilization 
of routinely collected data in the HIV programmes (5). 
In our systematic review of literature of previous work we noted that the data collection 
systems for PMTCT programs in Africa often lack immediacy as many are paper-based with 
records completed at each facility, and with individual level data that are inaccessible to 
central planners(6). Electronic health records (EHRs) could present an opportunity to 
supplement current sources of routinely collected surveillance data (7).  EHRs are real-time, 
patient-centered records that make information available instantly and securely to authorized 
users (8). While an EHR does contain the medical and treatment histories of patients, an EHR 
system is built to go beyond standard clinical data collected in a provider’s office and can 
include a broader view of a patient’s care (9).  
Various EHR systems are implemented globally (10-12). A systematic of review of literature 
about the effect of EHR systems in resource-constrained settings recommended that it is 
urgent to evaluate barriers to implementation (13). Our own research on extracting 
surveillance data from a Zambian EHR system, SmartCare, has highlighted some deficiencies 
including large amounts of missing data, especially in more recent years, and variable 
performance across the country (14, 15). The overall goal of our study is to improve the 
implementation of an EHR system in Zambia labelled ‘SmartCare’ and address the 
fundamental need for timely and high-quality data. 
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7.2 Methods 
7.2.1 Study design 
This qualitative study included in-depth interviews, observations and focus groups 
discussions (FGDs) conducted between September and November 2016. 
7.2.2 Study Setting 
SmartCare is a Zambian Ministry of Health (MoH)-led project funded by the United States 
Centre for Disease Control and Prevention (CDC). SmartCare was developed to improve 
continuity of care and provide timely data on maternal and child health, HIV/AIDS, 
tuberculosis and malaria interventions for public health purposes, including Health 
Management Information System (HMIS) trend reporting and analysis for health officials and 
clinicians (16).  
The SmartCare database is a derivative of the PTS (patient tracking system) which was 
developed in 2004, based on a health facility-centred EHR system. In 2010, it became a 
national medical health program and was then rolled out throughout the country. It is 
implemented by government, and both international and local organisations primarily for 
patient management. Most of the international organisations were involved in the database 
development, and the local organisations became involved when implementation was rolled 
out throughout the country (after 2009).  
SmartCare is organised into comprehensive modules and sub-modules (Figure 7.1). This was 
mainly influenced by its funders depending on the information they wanted at that particular 
time. The main module groups are: clinical group comprising the following modules – ANC, 
Delivery, Postnatal, ART, Paediatric ART, PMTCT follow up, Under 5 among others – ( 
these are mainly of interest for this research); logistic group which constitute information on 
drug dispensing and orders; monitoring and evaluation groups which includes health 
management information system reports, graphing, data analysis, data merge from facilities 
for MOH; and the continuity of care group which had data from across facilities and within 
facilities. Through the data merge the SmartCare information can be used to obtain data for 
the monthly reports to MOH. 
Data is captured under a number of ‘modules’ across a range of health issues. Records are 
updated at every point of clinical service. SmartCare enables the capture of all patient data 
into one centralised database that can be accessed from any supported health facility. Patients 
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enrolled in the system can have their records accessed at whichever SmartCare-supported 
facility they present to in the country. Patients are issued with Smartcards at their initial 
consultation which contains all their clinical information and treatment details. When they 
present at another facility the health worker simply plugs the Smartcard into the system and 
can access all the patients’ details.  
Data on a range of HIV and pregnancy related outcomes are collected during the patient 
consultation with the clinician, who records the information on paper forms in facilities that 
are paper-based and directly on the computer in the few facilities which are computer-based. 
The paper forms are then entered into the SmartCare database by data entry clerks who have 
been trained in using the SmartCare database. Data is collected from each facility on a 
monthly basis and submitted to a District Health Information Officer, who aggregates and 
sends the data to the province level Senior Health Information Officers. From here the data 
are wired to a national server at MoH headquarters (Figure 7.3) 
For the purposes of this study, routine data is defined as data that are routinely generated 
through antenatal care (ANC) and PMTCT service delivery, and routinely recorded in 
standard SmartCare data tools.   
7.2.3 Sampling 
The implementing partners (IPs) were purposively sampled in consultation with the MoH to 
identify diverse organizations.  These included both well-resourced international 
organizations and less well-resourced local and government-owned organizations. Within 
each of the selected IPs, a diverse range of interviewees were purposively recruited in order 
to give the broadest range of perspectives (17, 18). The approaches to recruitment of 
participants were flexible, being negotiated with key contacts and recommendations from 
managers who were also considered for in-depth interviews. The FGDs were conducted at 
maternal and child health (MCH) departments in health facilities among consenting pregnant 
and lactating HIV-positive women on ART.  
 
Six health facilities from the representative IPs were also purposively selected based on local 
considerations which included, among these facilities: those best performing versus 
struggling; those which are paper- or computer-based; and facilities which had already 
transitioned to ‘test and treat’ for general population HIV care. Most of the facilities sampled 
were in Lusaka City, and only one was peri-urban.  The choice of Lusaka was based on the 
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following considerations: 1) logistics, 2) facilities in Lusaka are busy and have the highest 
case loads, 3) our previous work has shown that facilities in Lusaka show a wide range of 
successes and failures, and 4) overall Lusaka performs poorly compared to the rest of the 
country and therefore it was important to investigate the working of SmartCare in Lusaka 
city. 
7.2.4 Data sources 
Data were generated from 17 in-depth semi-structured interviews, four data entry 
observations and three FGDs with 22 pregnant and lactating women seeking PMTCT services 
from three health facilities (Table 7.1). The face-to-face semi-structured interviews were held 
with a range of key informants from MOH, and local and international organisations 
SmartCare IPs. IP informants were from leadership, operational and implementation levels 
(Figure 7.2). The key informants for implementation levels were based in the 6 sampled 
health facilities, whilst in-depth interviews with leadership and implementation level 
participants were carried out in their work places. For leadership staff and some senior 
operational level stuff the interviews were carried out in their individual offices. For the 
operational level participants who were in shared office space, interviews were carried in 
boardrooms. 
Interviews with key informants were conducted by the first author in English. They lasted 30 
to 60 minutes and consisted of a series of open-ended questions with follow-up question 
probes. The interview guides were specific to the hierarchical levels of operation, namely: 
leadership level (persons involved in the strategic direction of SmartCare); operational level 
(Data Managers and Monitoring and Evaluation personnel); and implementation level (Data 
entry clerks and MCH in-charge clinicians). The interview guides were designed to capture 
information on SmartCare development, implementation procedures, data quality 
management and linkage between SmartCare and PMTCT services. The FGD sessions were 
conducted by the first author and a co-moderator who was fluent in the local languages 
(Bemba and Nyanja). These discussions were guided by an interview guide containing open-
ended questions and lasted for 60 to 90 minutes. The interview guide was designed to capture 
the general knowledge and experience of the PMTCT programme and SmartCare operations 
Two FGDs were carried out in different Lusaka health facilities, and one in the peri-urban 
area. 
 
135 
 
The observations were conducted to familiarise the researcher with the realities of the 
SmartCare data collection and entry environments. These were planned to be conducted in 6 
health facilities through interaction with study participants and relevant actors as well as 
personal reactions to the related events without the use of a specific tool. However in 2 health 
facilities data entry was not taking place on the scheduled visit days due to power outage, 
hence only in-depth interviews were conducted with implementing level stuff. 
7.2.5 Data Management and Analysis 
The in-depth interviews and FGDs were tape-recorded and subsequently transcribed 
verbatim. FGDs were then translated into English. Data was collected aiming to get sufficient 
data from relevant actors/perspectives to ensure it was qualitatively representative (19).  
Detailed field notes were taken on the sites following the observations for analysis.  
Data were collected and analysed without a constraining overarching framework, which 
enabled us to capture the diversity of experiences of the SmartCare implementation efforts. A 
thematic content approach was conducted; this was done by reading the transcribed material 
systematically, line by line, in order to identify the meaning units. Meaning units were 
defined as strings of the text expressing a single coherent thought, up to the point at which the 
coherent thought changed. Thereafter, the meaning units were marked by a code, describing 
what the text unit was about. Coding was done without any pre-conceived ideas. 
The codes were defined and organised so that those referring to the same subject were 
grouped into categories. The interview guide was used as a starting point for grouping the 
information, but during the analysis new categories were developed. When this happened, we 
re-coded. The data was managed manually in Excel sheets. The underlying meanings of the 
categories were formulated into a theme. The original data was re-assessed by an assistant 
(MSc Student) after analysis in order to detect any concepts or information that would have 
been missed. The first author discussed the results with SF, JT and the MSc student. 
7.3 Research ethics 
Written informed consent was obtained from all in-depth interviews participants including 
their consent to record the interviews and publish anonymous quotations. Verbal consent was 
sought for FGD participants. Participation in the study was entirely voluntary and participant 
anonymity was maintained throughout the processes of interview transcription, data analysis 
and presentation by using pseudonyms.  Permission to collect data from the health facilities 
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was granted by the MoH district offices. The study was approved by the Zambia Biomedical 
Ethical Board (Ref 101-04-16) and the LSHTM Research Ethics Committee (Ref 12086).    
 
7.4 Results   
The comments from key informants, observations and the focus group discussions enabled us 
to characterise four fundamental issues that are key in the implementation of SmartCare: 
database development and ownership, funding and staffing, the data collection process, and 
health facility set up. 
7.4.1 Database Development and Ownership   
The development of SmartCare was mainly CDC-led, with the government of Zambia 
through the MoH supporting the process. Multiple stakeholders using various patient tracking 
software were brought together to form SmartCare. Reflecting on the history of SmartCare, 
two IP informants identified the leading role of CDC and the subsequent collaboration with a 
broader group of partners. 
 ‘The initial development was by the American-funded institutions and a few people from the 
MoH because they had gone into partnership. They were developers at MoH and also at 
CDC, the rest of the institutions like us were only required to use the software.’- 
Implementing partner leader. 
‘There were other systems that were used by other partners throughout the country e.g., there 
was a system called the CareWare which was similar to SmartCare but it was just a patient 
summary. Then there was another system which was used in the private sector which l can’t 
remember the name. Lessons were drawn from all these systems and brought into one and 
this is how SmartCare was born.’- Implementing partner leader. 
There was a consensus among the leaders of the SmartCare implementation that the database 
has also evolved from a system to track patients to its current form as a mixture of a patient 
tracking tool, a clinical care tool, a reporting tool, and a surveillance tool. This was as a result 
of different stakeholders who had different data needs which took the form of added modules. 
The changes have however, made it difficult to classify and use the database because it now 
tries to address multiple issues simultaneously.  
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‘I wanted my things as well and partly l wanted things that PEPFAR (The United States 
President's Emergency Plan for AIDS Relief) wanted because our money comes from them. 
If I can't report on PEPFAR indicators, l don't get more money’ –Implementing partner 
leader. 
‘...it was just a mixture of ideas which were clinically required but each person had different 
needs for information, some needed it for research purposes, l needed it for patient follow up, 
another person needed it for forecasting and quantification’- Implementing partner leader 
The resulting SmartCare forms are 6-7 pages for a normal interaction per visit because of 
requirements from its various stakeholders.  In addition, a lot of data has been entered into the 
system making it bulky. This has caused the system to become very slow, and in the 
mornings it takes a very long time to reboot as narrated by operational and implementing 
level participants. Data entry is often interrupted as the system also hangs up because it is so 
bulky. Hence a lot of backlogs are experienced which results in a lot of data not being 
entered. 
‘Because the system is slow they have to wait instead of entering 100 files per day they are 
only able to enter 60 or so.’- Database Manager. 
‘Last year it had serous faults and we were not using it for a while’ – Data Entry Clerk. 
Although there is a SmartCare technical working group, chaired by the MoH where 
operations are discussed, it is not clear who is guiding the process, and what should be added 
into the database to make it work better.  
7.4.2 Funding and staffing 
The database operations are managed by the monitoring and evaluation (M&E) departments 
of the IPs. The structures of the M&E departments differ across the IPs, with international 
organisations having much bigger and better resourced departments. The local IPs have much 
leaner structure, rely mostly on volunteers, and run into problems due to financial constraints. 
This was elaborated by the leadership and implementing level participants. 
‘The positions of data entry clerks in the facilities are actually paid for by the donor. It's not 
sustainable because the moment the donor says we are pulling out, there will not be any data 
entry personnel in these facilities.’- Implementing partner leader. 
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Mostly the people who enter data in the health facilities where we operate are employed by 
us. Apart from that we also provide support through volunteers; in most cases we also 
provide peers and counsellors. –Data Base Manager. 
The manpower constraint in the local partners has resulted in the loss of data during long 
grant negotiations. Data is lost as data entry staff are laid off between funding cycles since 
their salaries are dependent on grants. In addition, these partners have designated personnel 
who enter general ART data whilst PMTCT data is mainly entered when the data entry 
personnel have specific interest or have trained temporary volunteer staff. 
The funding of operations also affects the supplies required for the day to day operations as 
narrated by both operations and implementing personnel. 
‘We normally run out of forms, especially when funding is out. When we don't have funding 
the facilities also have challenges in printing the forms because toner is expensive.’- Data 
Entry Clerk. 
‘....when the computers are down because of the virus, data entry doesn't happen.’- M &E 
Officer. 
In some small facilities where the MoH is solely responsible for data collection and entry, 
there are no data entry clerks and hence clinicians enter the data on the computer after hours. 
This is usually done only by staff that are passionate and so give it time according to a MoH 
leader. 
‘In the government facilities there is no designated person to manage ART data for 
SmartCare; its health workers who just do that on their own. - ‘Implementing partner 
leader.’ 
7.4.3 Data Collection Process  
7.4.3.1 Data entry 
The SmartCare data is collected either directly onto a computer or using a paper-based 
method.  When using the computer-based data collection and entry method, clinicians have to 
enter data directly in the computer; this method is still being piloted in a few facilities mainly 
in the Southern and Lusaka provinces. For the paper-based data method, client information is 
documented in the SmartCare care forms. The papers are then taken to the data entry room 
where the information is entered into the computer. In some facilities which are deep rural 
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(where there is no electricity at all) they are using paper only and the forms are then 
transferred to a location where there are computers and entered into the database.  
With both the computer and the paper-based methods the greatest challenge is incomplete 
forms which translate to missing data in the database. In some facilities which are computer-
based, the data entry clerks noticed that there are also some clinicians who still prefer 
entering data on paper and handing over to the data entry clerks to enter on the computer.  
‘In as much as data is supposed to be entered at each service point, some people prefer 
entering the data on paper and they hand over the data to me.’- Data Entry Clerk 
According to implementing level staff, with the paper-based method, once the client leaves 
the facility it is a challenge to follow up on the missing data on the forms. 
‘There are usually many gaps in the forms; the forms are not fully completed more than half 
of the time.’- Data Entry Clerk. 
‘When the forms are not complete l return them to whoever was supposed to be entering the 
data at that service point but the challenge is that they will tell you the person has gone and 
that can't follow them up and even so in the next visit they will not even bother correcting the 
information’-  Data Entry Clerk. 
One of the MoH participants explained that the incomplete data forms could be a result of the 
competing demands to physically attend to clients and fill out the forms in the high volume 
facilities. 
‘.... It takes 20-30 minutes just to enter the data for one interaction. In clinics where there are 
many patients, how many patients are you going to see in a day?’ – Implementing partner 
leader. 
The implementation challenges of the SmartCare database depend on the data collection and 
entry method used. Power outages were the greatest challenge: under the computer-based 
method, client information is not collected, as some clinicians will be reluctant to use the 
alternative method, whereas with the paper-based method there will be a backlog of work. 
Some well-funded partners have installed solar power systems in the health facilities, and this 
enables them to enter data without interruptions. Despite having good power supply, there is 
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a challenge in these facilities of some clinicians who are not computer literate. Furthermore, 
because of other competing health facility priorities, the power is rarely used for data entry. 
‘......would you want to power theatre activities or you want to power computers for data 
entry? Theatre is life saving and data can be entered anytime.’ – Implementing partner 
leader. 
7.4.3.2 Data quality verification 
Verification of data quality is specific to each implementing partner. The verification process 
involves comparing the patient information on the paper forms and registers against the 
information in the database. The international partners also have verification procedures 
imbedded in the Monitoring and Evaluation strategies as narrated by one of their participants. 
‘We are doing double data entry for 10% of our files.’ – Data Manager. 
On the other hand, verification is rarely done by the local organisation due to manpower 
constraints as indicated by an operational level participant. 
‘When I get time, l check what is in the system versus what is in the registers. However it's 
rare that l get that time because l always have files to enter into the system. In that case l wait 
for the Quality Control people from Head Office to come and do random verifications for 
me.’- Data entry clerk  
All the partners reported that there are some instances where they can't find patient files, 
making it difficult for them to verify the data that is in the computer with the raw data.  
‘There are certain instances where we can't find patient files’. – M&E Officer. 
The patient files will tell me that a facility has 200 clients whilst SmartCare has 300 clients; 
this is because some of these files are kept somewhere,  could be files of staff members or 
people with  prominent positions in that particular area’. – Database Manager 
The SmartCare Database system has reports that are built in the application. However all the 
partners alluded that these reports are very inconsistent and incorrect. 
‘In some cases it will show a large number of people who would have been initiated in a day 
more than what we would have actually done.’– MCH Nurse in Charge. 
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7.4.3.3. Submission of data to the main database  
There is also no uniformity in submission of the data to the main database, although 
according to the MOH the data is supposed to flow from the facility to the district, province 
and then to the main database at head office (Figure 7.2). Some partners wait for MoH to 
request data whilst some submit their data to CDC. 
 ‘They sometimes come to the facilities and collect the data on their own since they are the 
ones who own these facilities as well’ –  M & E officer  
‘We do not follow that procedure as per say because we collect data directly from the sites 
and aggregate it from here and submit to CDC. If MOH requests it, we submit to them but we 
are not that consistent’- Database Manager 
7.4.3.4Feedback from Database 
There is no standardised procedure for reporting data that is collected by IPs. The partners 
normally use the information internally as well as sharing with the donors supporting them.  
‘We also have special reports that we do in a monthly basis such as the PEPFAR report’ – M 
& E Coordinator. 
In contrast, the nurses-in-charge in some of the facilities reported that they have never 
received feedback from the system. 
‘We have not received anything; they don't give us any reports. We would, however, want to 
receive reports so that we would know how we are fairing.’ – MCH Nurse in Charge. 
As viewed by one of the leaders who participated in the study, the lack of feedback from the 
system has led to disengagement and some stakeholders not seeing the importance of 
documenting client information in the SmartCare Database. 
‘A lot of the staff collecting this data do not understand how and why they are collecting this 
data and they are frustrated by it as it also takes lots of their time entering this data’ –  
Implementing partner leader. 
7.4.4 Health Facility setup 
The set up in some health facilities is in such a way that the PMTCT services are offered in 
the ANC department whereas ART services are offered in places designated solely for ART. 
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The nurses in charge in such health facilities narrated that the facility setup could be a great 
challenge in ensuring that the PMTCT data is entered in an efficient manner. 
 ‘Probably if it was housed within the ART department, you could have the same person 
entering the PMTCT data into the SmartCare’ – MCH nurse in charge.   
In addition, the MCH nurses-in-charge indicated that client files sometimes go missing 
between the MCH and the data room. 
‘I am sure when they are sending the files; some are lost during transfer in different 
departments.’ – MCH nurse-in-charge. 
Overall, women seeking PMTCT services did not have concerns on the implementation of 
SmartCare, as according to them the healthcare workers will be doing their job. 
‘The person who is supposed to enter the data does so because he was trained anyway’-
PMTCT FGD Mothers. 
‘We just carry our cards and leave them to do their job’- PMTCT FGD Mothers. 
‘We are here for our lives and that of our babies, we have to comply and be patient’- PMTCT 
FGD Mothers 
7.5 Discussion 
The study has provided evidence on the SmartCare implementation challenges. It has also 
provided insights as to how to improve implementation, and data quality. The main points 
were to collect less, but better data, to engage the clinic staff by providing regular feedback, 
and to improve the software. Fortunately, PMTCT clients appear already satisfied with the 
system. 
 
The design of EMR systems does not always get attention due to pressures related to their 
functionality requirements(10). SmartCare was exposed to pressures as its data model 
evolved from a patient tracking system into a multi-functional system due to demands of 
various stakeholders. In an effort to shape the SmartCare database into a manageable tool that 
can be used for public health purposes, CDC and MOH could streamline the process for 
including and excluding information that is collected. There is a need to cut down on the 
number of fields collected so that less data of high-quality is collected. This could improve 
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the system by: reducing the amount of data so that it takes less time to collect and people 
might more readily do it; and having a less bulky database which will be less likely to be 
affected by computer crashes and faster to use. 
 
SmartCare could be developed into an Open Medical Record System (MRS), which has been 
reported to be successful in other developing countries like Rwanda, and Kenya (20). The 
system could also be upgraded such that: data can be accessible and be shared in multiple 
sites; multiple users can enter data simultaneously; data can be backed up automatically at 
more than one site; information can be communicated between multiple locations; data are 
accessible and shared at multiple sites and the system can be debugged and upgraded over the 
internet without visiting remote sites (10, 21).  
In Ethiopia the quality of data was reported to be affected by dual documentation where both 
paper based and electronic systems were used (22). Learning from the Ethiopian experience, 
it is important that there is uniformity in the implementation of SmartCare throughout the 
country so that everyone will be on the same level. This will allow for comparisons across 
geographic regions and longitudinal analyses. 
In our findings workload affected the documentation, as evidenced by poor data quality in the 
quantitative analysis of SmartCare PMTCT data (14, 15). In low –resource countries there is 
a shortage of a qualified work- force and most health care institutions do not have dedicated 
IT staff for their EMR systems (23). The results of our study are consistent with a systematic 
review of literature on the role of EHR systems in developing countries which pointed to the 
lack of financial and human resources as major challenges in implementing EMR systems 
(24). Therefore, there is a great need for strong commitment from both the government and 
the donors to invest in improving the implementation of the system. 
There was a notable lack of appreciation of the system, and a need to train and support end 
users of the system such as the clinicians who are directly involved in the data collection 
process. For both the clinic staff and health system managers, having access to reliable data 
that reflects the processes of care and clinical outcomes is the first step to ensuring effective 
delivery of an intervention within a health care system(4). Hence, there should be better buy-
in of the staff at the facilities in order to make sure that they fill in the forms regularly and 
accurately. The data from the database should be presented to facility staff as an advocacy 
tool which is needed in their facilities, so that they would appreciate the need for it (25, 26). 
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Similarly, in their description of the rationale and experience in scaling up EMR in Malawi, 
Douglas and colleagues concluded that health workers will not adopt a system if they do not 
find sufficient value in it (27). 
Strengths and Limitations of the study  
 We obtained a rich and nuanced appreciation of the implementation of the SmartCare as we 
sampled from a range of IPs, health facilities, stakeholders and implementation systems. The 
depth of the inquiry enabled us to consider a range of explanatory factors.  Most of these 
factors were related to the EHR system and its implementation. We also considered the 
factors encountered by the PMTCT clients but these did not emerge as major concerns.  
 
There are several limitations of the study, such as the restriction to health facilities in and 
around Lusaka. Lusaka is the capital city of Zambia and therefore the health facilities 
selected could be receiving financial and technical support of an order that is unlikely to be 
offered in remote facilities even by the same IP. However, our previous work on the 
quantitative analysis of PMTCT data does not support this argument as several provinces had 
better data quality than Lusaka (14, 15).  
7.6 Conclusion 
The SmartCare system has structural challenges which can be traced from its development. 
Funding gaps have resulted in staffing and data collection disparities within implementing 
partners. The lack of feedback from the system has also led to complacency in operational 
level which has resulted in poor data quality in later years.  The data from the database, if 
appropriately understood, could be used by health facility staff as an advocacy tool, as well as 
in monitoring the impact of PMTCT programs.  Our research could aid other countries 
wanting to develop their own EHR systems. 
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Summary 
What is known  
 Electronic Health Records (EHR) could present an opportunity to improve accuracy, 
timeliness and scope of surveillance data 
 Data collection systems for PMTCT programs in Africa often lack immediacy as 
many are paper-based with records completed at each facility, and with individual 
level data that are inaccessible to central planners. 
What this study adds on 
 There is need to invest in EHR systems for them to be implemented in a very efficient 
manner. 
 It is important that there is uniformity in the implementation of EHR. 
 Feedback from the system must be presented to stakeholders. 
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Table 7.1: Breakdown of In-depth Interviews and Focus Group Discussions Participants 
Type of respondents Number of respondents Method 
Leadership 3  
 
In-depth interviews 
Database Management 6 
Data Entry Clerks 5 
MCH- Nurse-in charge 3 
Total 17 
 
 
Pregnant Mothers  
 
(>20 years)    2  
 
 
 
 
Focus Group Discussions 
(20-25years)  3 
(26-30 years) 4 
(31-35 years) 2 
(36-40 years) 1 
Total           12 
 
 
 
Lactating  Mothers 
(>20 years)    1 
(20-25years)  2 
(26-30 years) 2 
(31-35 years) 3 
(36-40 years) 2 
Total          10  
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Figure 7.1: SmartCare Model Structure 
 
 
Figure 7.2 - Breakdown of In-depth interviews key informants 
 
Figures in brackets are for the number of people interviewed for that designated level. 
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Figure 7.3: SmartCare Data flow 
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Chapter 8: Health Management Information System (HMIS) Data 
8.1 Introduction 
The main objective of the chapter is to present data from an independent source, the Health 
Management Information System (HMIS), on outcomes similar to those discussed in 
Chapters 5 for the purpose of triangulating findings from the SmartCare data. The HMIS data 
are aggregated by health facilities and submitted monthly through districts to the national 
MoH.  As such the data differ from SmartCare (which records individual level data from the 
patients) and provides specific information about key health conditions in a regular format.    
A well-functioning health information system is one that ensures the production, analysis, 
dissemination and use of reliable and timely information on health determinants, health 
system performance and health status (152). An HMIS is only successful to the extent to 
which it facilitates the production, analysis, dissemination and use of information reliably and 
in a timely fashion (153). Researchers  may also draw upon it to answer critical health system 
questions pertaining to effectiveness or efficiency of health programs (154). 
Zambia has developed a well-integrated health information system providing information for 
evidence-based planning. The HMIS was designed in 1996 under the context of health sector 
reforms in order to provide efficient and effective support to the planning, monitoring and 
evaluation of health care services (155). The HMIS underwent a revision in 2008, which 
enabled the incorporation of facility indicators to monitor progress of health targets, and as a 
result of this, a new web based software, District Health Information System (DHIS-2) was 
developed (156). The DHIS-2, which is supported by WHO, has enhanced capabilities in 
terms of the number of data elements that can be captured, analyses that can be performed 
and reports that can be generated. 
The quality of HMIS data which influences the use of the data generated from HMIS and 
factors affecting its use have been assessed in various settings in Africa (124, 157-161). In 
Zambia before DHIS was developed; there was limited coverage and under-utilisation of the 
HMIS in respect to timeliness, completeness of reports, data usage, and accessibility (155, 
162).  
In the National Health Strategic Plan 2017 – 2021, the MoH admitted that there has been a 
perception of poor data quality from HMIS due to inconsistent primary sources of data 
associated mainly with poor coverage and completeness (156). As a result they committed to 
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incorporate and standardize the monitoring and evaluation (M&E) framework across all 
levels of the health care delivery system and use of data at all levels of decision-making to 
facilitate research.  
8.2 Method 
The study design was a retrospective analysis of routine aggregate surveillance data from the 
HMIS database from 2013 to 2016. These years were selected to correspond with SmartCare 
data except that HMIS data prior to 2013 was unavailable.  
8.2.1 Data collection  
The HMIS activities are overseen by the Department of Policy and Planning. The District 
HMIS Officer is responsible for all district data collection and reporting activities. All 
districts and central levels reporting is done through a web-based, open source information 
system (District Health Information System - DHIS 2). However most facilities are still using 
paper forms and report at district level where the data is entered on a computer. 
 
All pregnant women who register for antenatal (ANC) services are given a personalised card 
where all interventions pertaining to their maternal history are entered. Women keep these 
cards and they can access maternal services in any health clinic in the country.  When 
determining the number of women seeking ANC care, only the first visit is considered to 
avoid repeat counts. Deliveries are recorded at the time they occur even though the original 
ANC visit when the card was given may have come from the previous year. 
 
The MoH ANC aggregate data was collected on Excel sheets which were designed by the 
candidate. The data elements of interest were: total number of women seeking ANC services; 
number of pregnant women already on antiretroviral treatment (ART); number of women 
who tested HIV-positive on their ANC visit; and number of women who were initiated on 
ART.  
8.2.2 Outcomes of interest:  
1) The proportion of HIV-positive pregnant women was calculated from the total 
number of all HIV-positive women (i.e., the number of women who first tested HIV-
positive during ANC visit for that particular year, plus women who were already on 
ART before seeking ANC services) / the total number of pregnant women seeking 
ANC services. 
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2) The total proportion of women on ART was calculated from the number of HIV-
infected pregnant women on ART (i.e. the number of HIV-infected pregnant women 
documented to have received ART during ANC (initiated on visit plus already on 
ART prior to visit) / the total number of pregnant women enrolled in ANC clinic with 
either newly documented HIV infection or known prior HIV infection);   
3) The proportion of women already on ART was calculated from the number of women 
who were already on ART before seeking ANC services for this pregnancy/ the total 
number of pregnant women enrolled in ANC clinic with either newly documented 
HIV infection or known prior HIV infection. 
4) The proportion of women who were initiated on ART upon testing HIV-positive was 
calculated from the number of women who were initiated on ART on testing HIV-
positive during their ANC visit / the number of women who tested HIV-positive on 
their ANC visit. 
8.3 Data Analysis 
The quantitative data was analyzed using Microsoft Office Excel in proportions. The results 
were presented in tables and graphs. 
 
8.4 Results 
8.4. 1 HMIS Data 
From the HMIS data, a total of 2,537,785 pregnant women were registered for ANC services 
from 2013 to 2016 across the 10 provinces in Zambia (Table 8.1). The majority of the women 
were from Lusaka (16%); Eastern and Copperbelt (13%); and Central and Southern at 11% 
each. The least number of women were from Muchinga and Northern Provinces at 6% each. 
The total number of women seeking ANC services increased gradually from 2013 to 2016 
according to the HMIS data. 
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Table 8.1: Number of pregnant women who attended ANC services using HMIS data 
Province 
  Year of Visit   
 
2013 2014 2015 2016 Total 
Central 
N 61,868 72,932 74,101 74,091 282,992 
% 11% 11% 11% 11% 11% 
Copperbelt 
N 69,582 82,245 83,279 83,400 318,506 
% 13% 13% 13% 12% 13% 
Eastern 
N 80,671 85,556 84,073 85,046 335,346 
% 15% 13% 13% 13% 13% 
Luapula 
N 43,743 56,092 54,523 53,826 208,184 
% 7.9% 8.6% 8.2% 8.0% 8.2% 
Lusaka 
N 82,881 94,041 102,023 118,035 396,980 
% 15% 14% 15% 17% 16% 
Muchinga 
N 31,439 36,313 37,061 35,920 140,733 
% 5.7% 5.6% 5.6% 5.3% 5.5% 
North-Western 
N 49,552 59,658 59,552 56,837 225,599 
% 9% 9% 9% 8% 9% 
Northern 
N 34,120 41,679 43,502 43,116 162,417 
% 6% 6% 7% 6% 6% 
Southern 
N 57,808 73,398 76,069 77,862 285,137 
% 10.5% 11.3% 11.5% 11.5% 11.2% 
Western 
N 38,742 48,296 47,964 46,889 181,891 
% 7.0% 7.4% 7.2% 6.9% 7.2% 
Total   550,406 650,210 662,147 675,022 2,537,785 
 
8.4.2 SmartCare data 
The SmartCare database showed a decrease over time in the number of records of pregnant 
women who were captured in the electronic health record system (Table 8.2). The 2016 
SmartCare figure was very low, and this resulted in the data for that year being excluded 
from the Chapter 5 analysis. In contrast, in the HMIS dataset 2016 had the highest number of 
women who were registered for ANC services. Despite that SmartCare is representative of 
approximately 40% of the healthcare facilities in Zambia, a comparison of the sample sizes 
indicate that SmartCare only captured 2% of women testing for HIV in ANC from 2013-
2016. Partly this is due to the fact that women already known HIV-positive were not recorded 
in the SmartCare dataset, which suffer from the implementation challenges discussed in 
Chapter 7.     
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Table 8.2: Number of pregnant women who attended ANC services using SmartCare  
Province 
  Year of Visit   
 
2013 2014 2015 2016 Total 
Central 
N 1,938 1,471 310 79 3,798 
% 12% 9% 3% 3% 9% 
Copperbelt 
N 3,390 3,610 2,763 110 9,873 
% 22% 23% 27% 4% 22% 
Eastern 
N 5,448 4,881 1,148 404 11,881 
% 35% 31% 11% 16% 27% 
Luapula 
N 218 110 124 28 480 
% 1.4% 0.7% 1.2% 1.1% 1.1% 
Lusaka 
N 979 1,037 1,801 781 4,598 
% 6% 7% 17% 31% 10% 
North-
Western 
N 78 242 401 8 729 
% 0.5% 1.5% 3.9% 0.3% 1.6% 
Northern 
N 755 758 550 175 2,238 
% 5% 5% 5% 7% 5% 
Southern 
N 2,463 3,330 3,045 891 9,729 
% 16% 21% 29% 35% 22% 
Western 
N 290 71 74 14 449 
% 1.9% 0.5% 0.7% 0.6% 1.0% 
Muchinga  
N 108 105 199 52 464 
% 0.7% 0.7% 1.9% 2.0% 1.0% 
Total   15,667 15,615 10,415 2,542 44,239 
 
8.4.3 Cohort of HIV-infected women  
A total of 115,086 pregnant women tested HIV-positive during their ANC registration; 25% 
of these women were from Lusaka and 20% were from the Copperbelt.  Muchinga and North 
Western provinces had the lowest numbers at 3% and 4 % respectively. During the 4-year 
period of analysis, 87,342 pregnant women seeking ANC services were already on ART 
(Figure 8.1), with 30% of them registered in 2015. The majority of these were from Lusaka 
(25%) and Copperbelt (19%).  Over the same period in the SmartCare data set approximately 
98% of the HIV test results were missing, and this was across all the provinces as outlined in 
Chapter 5. 
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Figure 8.1 Distribution of HIV-infected pregnant women using HMIS data (2013-16) 
 
There were notable disparities in the implementation of the PMTCT services across the 
provinces. The percentages of women who tested HIV-positive during their ANC visit ranged 
from 36.3% in Southern province to 50.6% in North-Western province (Figure 8.2). Among 
HIV-infected women, 48.3% tested HIV-positive in Central province compared to 36.3% in 
Southern which had almost the same number of women who were registered for ANC 
services (Table 8.1). The proportion of women who were initiated on ART was almost 
uniform across the provinces ranging from 22% in Central province to 28% in Copperbelt, 
Luapula, Muchinga, Northern and Western provinces. The Southern and Eastern provinces 
had the highest proportion of women who were already on ART at 39% and 36% 
respectively. Muchinga and North-Western provinces registered the lowest percentages at 23 
and 24% of women who were already on ART.  The similar disparities were also reported 
Chapter 5 results. 
 
  
2013 2014 2015 2016 
Year of Visit 
Already on ART on visit  11,969  24,056  26,361  24,956  
Initiated on ART on visit 4,832  15,507  21,575  10,150  
HIV-Infected not on ART 27,825  12,748  6,717  15,732  
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Figure 8.2 Distribution of HIV-infected women by province (2013-2016) using HMIS 
data 
 
 
8.4.2 ART Initiation  
There was a sharp increase in the percentage of HIV-infected women who were on treatment 
between 2013 and 2014 (38% to 76%) illustrated in Figure 8.3. The increase was proportional 
to the increase in the percentage of women who were initiated on ART on testing which 
increased more than 3 times from 15% to 55% over the same period. Similarly, women who 
were already on ART at their initial ANC pregnancy registration almost doubled moving 
from 27% in 2013 to 46% in 2014.   Overall during the period under review, Lusaka province 
had the highest proportion (25%) of women who were already on treatment upon ANC 
registration followed by Copperbelt at 19%.  However, the Copperbelt province had the 
overall highest percentage (23%) of women initiated on ART on testing HIV-positive, 
whereas Lusaka was 22% despite that it had the largest number of women who tested HIV- 
positive.   
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Figure 8.3 Proportion of pregnant women on treatment (2013-2016) 
 
 
8.5 Discussion  
The HMIS data confirms the conclusion from analysis of SmartCare data that there has been 
an increase in the proportion of pregnant HIV-infected women seeking ANC services who 
are already on treatment. HMIS data analysis complements the findings of SmartCare data 
analysis which was compromised by the poor data quality as elaborated in Chapter 5 & 6.  
 
The HIMS records aggregate data from every health facility whether it has electronic patient 
records (SmartCare), or not.  As such the data represents the whole country, big facilities and 
small facilities, and all provinces.  The data show numbers that are comparable with the 
national census, with more patients in larger provinces as the data have a national focus, then 
the results are generalizable to the whole population. 
 
The sharp increase in the proportion of HIV-infected pregnant women on HIV treatment 
coincided with the adoption of Option B+, an approach which recommends treating all 
pregnant and breastfeeding women with lifelong ART regardless of CD4 count. The WHO 
Test and Treat guidelines that recommend anyone who tests positive for HIV should be 
started on treatment, regardless of their CD4 count was also introduced, during the same 
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period (163). A surge in the number women initiated on ART has also been reported in other 
studies from the region (15, 87, 100, 164). However the implementation of Option B + was 
not immediate and could have been slowed by existing health infrastructure constraints (165). 
The findings of this analysis also indicated a decline in the proportion of pregnant women on 
treatment from 2015 to 2016 (163). It is postulated that Option B+ could have threatened 
programme performance and negatively affected the HIV continuum of care for all HIV–
infected patients (166) as a result of the surge in the number of  HIV-infected individuals 
enrolled for HIV treatment.  .   
The quality of HMIS data was not assessed, and hence its accuracy, completeness and 
timeliness cannot be fully confirmed. This is also against the background that the MoH 
admitted that the HMIS could be affected by poor data quality (156). It is therefore 
recommended that for future use the HMIS data quality should be assessed. This could be 
done through 1) cross- checking of selected registers and client/patients’ cards to investigate 
deviations between reported patient statistics and those in the appropriate registers; and 2) 
conducting key informant interviews with the health facility managers and data management 
officers on factors influencing the observed data quality. 
8.6 Conclusion  
The HMIS data complemented the SmartCare data analysis and confirmed that that there has 
been an increase in the proportion of pregnant HIV-infected women seeking ANC services 
who are already on treatment. 
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Chapter 9: Discussion 
9.1 Introduction 
This chapter aims to synthesize the findings of the studies in the 4 chapters presented as 
papers and the triangulation chapter. A view of what has been achieved and a discussion on 
how the research questions were addressed are highlighted. The chapter finally discusses the 
policy implications of the findings, and proposes recommendations and suggestions for future 
research. 
 9.2 Summary of Findings 
The study aimed at evaluating the implementation of the post 2010 WHO PMTCT guidelines 
using routinely collected data. The research gaps in the use of routinely collected data for 
evaluation of PMTCT programs were identified following a systematic review of literature. 
The implementation effectiveness of WHO PMTCT guidelines was evaluated by analysing 
data from a cohort of 104,155 pregnant woman seeking ANC services in 886 health facilities 
throughout the 10 provinces in Zambia. Among these pregnant women a subset of HIV-
infected women were followed down the PMTCT cascade. The results from the ANC dataset 
were triangulated against the HMIS data from 2013 to 2016. These years had a drastic 
decrease in the SmartCare records of women seeking ANC services and an increase in 
missing HIV test results. The progress of early infant diagnosis was analysed using a dataset 
of 32,593 HIV-infected infants born pre- and post- the 2010 guidelines. The implementation 
challenges of the SmartCare EHR system, which was the source of data, was also 
investigated to address the fundamental need for timely, complete, high-quality data.  
The critical findings of this research are: 1) decrease in MTCT rates in SSA, but poor quality 
routinely collected data; 2) an increase in the proportion of HIV-infected pregnant women 
attending ANC in Zambia who know their status, and are already on ART; 3) HIV-exposed 
infants born more recently have significantly better care and treatment than infants born a 
decade ago; 4) The SmartCare database has large amounts of missing data and 5) SmartCare 
implementation is affected by structural challenges, funding gaps, and lack of feedback from 
the system. 
9.2.1 Decrease in MTCT rates in SSA, but poor quality routinely collected data 
The systematic review of literature (chapter 4), showed a continued decline in the incidence 
of HIV among children, as indicated by low MTCT rates. However, very few studies 
investigated the implementation of Option B+, which is now fully implemented in the 22 
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priority countries with a high burden of HIV(14). South African studies reported low MTCT 
rates under Option A implementation, which further suggests that Options A and B have 
similar efficacy (37). The argument should however take into consideration that the South 
African health system is better resourced than in most countries in Sub-Saharan Africa. 
Furthermore, there is a need to investigate the impact of implementing Option B+, on these 
poorly resourced health systems. In Malawi Option B+ programs reported a rapid increase in 
the number of pregnant and breastfeeding women on ART (43). Hence an investigation is 
needed of how these countries could be coping with the surge in coverage percentages, likely 
to be exerting pressure. Chung et al postulated that in Zambia Option B+ could have 
threatened  program performance and negatively affected the HIV continuum of care for all 
HIV–infected patients (166). 
The early studies on retention and adherence of Option B + also revealed that retention in 
care of HIV-infected and lactating mothers is poor and driven by early losses (70, 167-171).  
Similarly, default and incomplete adherence were more common in the Option B+ cohort 
compared to the pre-Option B cohort (71) and  also tended to decrease during the postpartum 
period (112). For the PMTCT guidelines to be effective there is a need to rethink ways of 
ensuring optimal adherence to ART for maximal suppression of viral replication and 
avoidance of drug resistance. In addition there is also need to  adjust operational practices 
related to quality of counselling as it has been indicated to be a predictor of adherence to 
treatment(113). Following women who are lost to follow up  (LTFU) is a great challenge in 
SSA as women may implicitly choose not to be traced by providing a false address at 
enrolment(110).  
 
The major challenge with the data collection systems for PMTCT programs of the studies that 
were included in the analysis was that they often lacked immediacy with considerable data 
quality concerns. This could be as a result of absence of processes such as data-quality checks 
and data-analysis in health facilities.  In most Sub-Saharan countries there seems to be an 
absence of a culture of information use, as a result of lack of trust in the data, and the 
inability of program and facility managers to analyse, interpret and use information (125, 
128). In spite of the demands for quality data, routine health information systems in many 
resource-limited settings continue to perform below expectations, and are often not used for 
their intended purposes of generating accurate and reliable data; where data is generated, the 
information is not sufficiently used for planning and management (124, 125). 
 
162 
 
 
9.2.2 Increase in the proportion of HIV infected women already on treatment 
The results from both the SmartCare and the HMIS data bases indicated a progressive 
increase in the proportion of women who were already on ART before registering for ANC in 
their visit year. This increase demonstrates that Zambia has made progress towards the 
UNAIDS 90–90–90 Targets (90% of people living with HIV who know their status, 90% 
who receive ART, and 90% who have suppressed viral loads)(163). Zambia has also 
managed to increase the proportion of  pregnant women living with HIV who received 
effective antiretroviral medicines to prevent the mother-to-child transmission of HIV to 92% 
in 2017(2). 
Despite that there has been an increase in the proportion of women already on ART from our 
findings; there has also been a decrease in the number of women in the SmartCare database 
between 2010 aand 2015. The decrease in the numbers and increase in the missing data could 
have introduced bias in later years of analysis as the data that was analysed was not 
representative. It could also represent problems with the way that SmartCare data are 
recorded, as indicated in the qualitative research (Chapter 7).  However, these results could 
be a good indicator of program performance since 40% of Zambian health facilities are part 
of SmartCare, and these are the largest and busiest ART clinics. The requirement to join 
SmartCare if clinics wish to prescribe ART means that most Zambian patients on ART 
should be captured in SmartCare database (149).  The trend of gaps in the data quality in 
using data from routine PMTCT programs have also been recently reported in Ethiopia (172). 
The results of this study were also consistent with mathematical modelling using the lifelong 
ART tool that indicated that the probability of HIV-infected pregnant women initiating ART 
would increase by 80% (68). Triangulation of the dataset with nation-wide HMIS aggregate 
data which is more representative also confirmed these findings as the trends followed the 
same patterns. 
The system in Zambia is such that pregnant and lactating women are given ‘VIP’ treatment 
which allows them to be served faster under the ANC department compared to those under 
General ART. In 2014, the General ART program was observed to have had a surge in 
numbers owing to the Test and Treat policy (140) with some clients taking over 6 hours 
waiting to get their medication. Most of the women were not confident on their own ability to 
adhere to life-long ART after weaning their infants or when the infant turns 18 months owing 
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to the long waiting time it takes for those on general ART to get their medication. These 
findings were themes from the qualitative research which were not in the paper but they 
permit better understanding of the overall situation. This was consistent with the Tanzanian 
study where women on Option B+ indicated that they might not adhere to treatment thinking 
that they would be less motivated to take drugs after protecting their child, and fearing the 
drug side effects and the challenges of chronic daily medication (69). Some of the younger 
women even indicated that they would plan having more babies so that they continue to be 
under the PMTCT ‘VIP’ treatment. Therefore there is a need to continuously explore 
strategies to ensure that women on Option B+ are not LTFU once their infants reach 18 
months.  Their counterparts from Uganda, Malawi and Zimbabwe reported that beginning 
treatment is not yet urgent as they are less seriously ill and considered themselves “healthy” 
without treatment (110). 
Although our results show a significant increase in the proportion of mothers who were 
already on treatment during pregnancy,  Zambian mothers are presenting to antenatal care 
late in their pregnancy(173) and only 47% deliver at health facilities (138). In Southern 
Ethiopia, home deliveries were seen as an excuse to avoid the stigma and risk of marital 
break-down associated with disclosure of an HIV-positive status by pregnant women(174).  
This is likely to be a similar possibility in the Zambian women, as MCH – in charge 
interviewed during the qualitative study (Chapter 7) also pointed that they still have cases of 
women who prefer not to disclose their HIV status to their partners. Some of the lactating 
women on PMTCT who were interviewed during focus group discussions mentioned that 
their greatest fears were to disclose the HIV-positive status of their infants to their partners as 
they were likely to be blamed for it. Evidence from my qualitative study revealed that some 
of the pregnant women also go to the extent of hiding their SmartCare cards and even collect 
and take their ARVs without knowledge of their partners or relatives. The pregnant women 
seem to be keen to protect their unborn infants but, after weaning the infant, may not be 
willing to continue taking their medication in secret.  Male partner participation in 
ANC/PMTCT is low in SAA in general SSA (175-179) and may be even lower in Zambia 
compared to the other countries in the region (180). Pregnant women are encouraged to bring 
their partners but the initiative is not heavily enforced. Many women in these countries fear 
violence and divorce if tested positive (175, 176) and MTCT is regarded as only the mother’s 
responsibility (181). 
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The barriers to uptake of ANC have to be addressed, in the context of PMTCT as this is 
important for the success of Option B+ and ‘treat all’ initiatives. In Zambia lack of human 
resources remains a serious impediment to addressing HIV, so that even when physical 
resources are available, there is often not the healthcare personnel to administer them (142). 
The SmartCare forms are 5-6 pages per interaction, which is likely to have created a burden 
on the healthcare personnel and resulted in data gaps. The clinicians, who are responsible for 
collecting SmartCare data either on paper or computer, have to prioritise their duties of 
serving patients to carefully completing the data forms. This further exacerbated by lack of 
feedback from the EHR system. 
Due to inconsistent data collection and entry, this study did not distinguish the analysis of the 
different post 2010 PMTCT options. These were also rolled out at different times throughout 
the country. The coverage analysis of the different PMTCT options could have been key in 
view of the evolving guidelines. As posited by Nicol et al, the changes in PMTCT guidelines 
are often not aligned with data-collection tools such as registers and tally sheets, and there 
may be inadequate mentoring and supervisory support systems to facilitate the use of 
information at facility level (124).  
9.2.3 Progress in the EID  
The consolidated guidelines recommend that HIV-exposed infants be tested for HIV between 
6-8 weeks, at the end of breastfeeding, and at any point they present with illness (3). Our 
results showed the mean age at HIV testing has steadily decreased and the proportion tested 
under 2 months of age increased between 2006 and 2016. The findings are an indication of 
the progress of implementing the revised PMTCT guidelines. In this study it was not possible 
to determine the MTCT rate, because we could not link the infants to their mothers.   
These results have to be viewed with caution as a commonly used surrogate marker for 
program effectiveness is program coverage, i.e. the proportion of HIV-infected/exposed 
mother/infant pairs in a population that receive a PMTCT intervention (4). The analysis was 
restricted to HIV-infected infants on ART as this was what was available. The infants who 
are registered are mainly those who are HIV-positive as these are usually brought to health 
facilities for their medication and are captured under the pharmacy module. When women 
deliver in maternity wards; their records are not automatically taken to SmartCare data rooms 
as these are often located apart.  
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HIV-positive mothers usually bring their infants to be tested at prescribed times (6 weeks, 6 
and 18) months and get messages of their infant test results through Project Mwana. HIV test 
results are transmitted to the caregivers through an SMS-based system which automatically 
notifies caregivers with access to mobile phones that their infants’ test results are ready to be 
picked (18). However Project Mwana, and SmartCare are not linked, hence the information 
for test results of infants who are not initiated on ART is not entered directly into SmartCare. 
These records seem not to flow to SmartCare data room and, as earlier mentioned, the health 
personnel could also be burdened with their workloads and end up not prioritising recording 
these results. In some cases in the database there are also records of infants on ART but their 
test dates or test results are not indicated.  
 
They are also some mothers who deliberatively reported that they register their infants in 
different health facilities from the ones that they usually use for confidentiality reasons as 
they would like to protect their children from stigma. Hence implementing a system that is 
directly linked for both programs is challenging and requires significant human and financial 
resources. The other foreseen challenge is that even after testing HIV-exposed infants, a 
significant proportion of caregivers do not return for the results. In a study that intended to 
determine turnaround time for EID in rural Zambian HIV clinic, only 86% of caregivers 
returned for results and 67% of infants who tested positive started ART by the end of the 
study (146). A more comprehensive dataset of the HIV status of all exposed infants could 
have been obtained from the ANC and Under 5 registers. However, the majority of studies 
using paper based routine data have also acknowledged the common problem of missing data 
as discussed in Chapter 4(45). This could be assumed to be one of the causes of under 
utilisation of routinely collected data which was observed by Munthali et al (7).  
 
9.2.4 Missing Data 
Our study shows that there are major problems in both the completeness of the collection of 
data that tracks PMTCT service delivery.   The data quality from SmartCare seemed to be 
deteriorating over years. For instance in the ANC dataset, the percentage with missing HIV 
test results increased from 11% in 2010 to 65% in 2013 and then to 98.8% in 2015. The poor 
data quality aspect has an effect on the external validity of this study. The missing data could 
have been attributable to the fact that SmartCare data collection is implemented parallel to the 
main line Ministry of Health HMIS which also collects HIV test results. This could have 
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caused high levels of missing HIV test results data in the SmartCare as clinicians prefer to 
enter the information in the HMIS forms compared to SmartCare forms which are longer (5-6 
pages per interaction) and clinicians may omit certain fields they deem irrelevant to their 
patient’s care. Presentation of HMIS data supported this hypothesis as the dataset had HIV 
test results of pregnant women seeking ANC services. The qualitative study also revealed that 
the evolution of the EHR system from various patient tracking systems into a multifunctional 
system has created implementation challenges associated with the model structure of the 
EHR system.  
 
Among other reasons, the lack of feedback from the system mentioned by the implementing 
partner personnel during qualitative data collection has also exacerbated the high levels of 
missing data as shown by the number of infants in the paediatric data set which increased 
from 1,761 in 2006 to peak at 3,720 in 2009 and then steadily decreased to 108 in 2016. Main 
comparisons over time of the study used 2015 since there were too few infants listed in 2016 
for age at testing and none for time to treatment initiation. The proportions of infants missing 
data on either age at testing or time of starting ART was high (34%) but did not differ by 
province or year. In addition, power outages in most areas of Zambia are a major problem 
and can occur for prolonged periods of time during the day, limiting the time that data can be 
entered into the system. This means that data collection is often not up to date and this could 
contribute to the apparently poor data quality. 
 The data quality challenges were similar to other studies from the region using routinely 
collected data (5, 166, 182, 183). Despite tremendous progress and many country-driven 
successes achieved during the Global Plan, operational challenges in data use, monitoring, 
and evaluation for PMTCT persist. Collecting longitudinal data on mother–baby pairs 
throughout the PMTCT cascade is challenging but necessary to optimize maternal and infant 
outcomes. However the Global Plan priority countries (which include Zambia) health records 
are not properly completed, hence the need to scale up electronic data systems (184) such as 
the SmartCare when improved.  
The lack of standardised implementation procedures by various SmartCare partners which 
was evident in the qualitative study is a cause of concern which also fuels poor data quality.  
There is no uniformity in the data quality verification and submission strategies employed by 
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various implementing partners. These strategies are largely determined by the funding which 
also differs across an array of implementing organisations. 
9.3 Study limitations  
The limitations of this PhD research stem from the use of secondary data. The analysis of the 
overall mean time to ART initiation from diagnosis by year of visit showed huge 
interprovincial variations over time. It was therefore difficult to determine whether there has 
been a decrease with time due to increase in the missing HIV test results specifically in the 
later years.  It is also possible that facilities in provinces that have missing data are the ones 
which are performing well. In addition with increase in the missing HIV test data overtime it 
was difficult to determine the time from diagnosis to ART initiation as very few records were 
available.  High statistical power is associated with large sample sizes as it makes it easier to 
establish even the smallest of statistically significant differences .The analysis of HMIS data 
also showed that Lusaka had highest proportion of women who were initiated on ART. 
Missing data was similar across all provinces although our quantitative analysis showed that 
Lusaka province was most likely to have missing.  Since Lusaka has one of the highest HIV 
prevalence rates, this could have also introduced bias into our study and have a negative 
effect on the external validity of the study. 
The Smartcare data examined was from all the 10 provinces across the countries. By using 
the whole country dataset, despite its poor data quality, the candidate was able to show that 
routine data collection systems are vulnerable to other factors in the health care system. If the 
analysis was done for a sample of the data, the candidate was likely to have chosen from best 
performing facilities, from implementing partners which are also well funded and have data 
quality management strategies; however it was not going to be very representative of what 
was happening in the country. 
In the EID study the candidate intended to show variability between provinces and over time. 
If it was possible to have data for all HIV-exposed infants, the MTCT rates at various points 
such as 6 weeks, 6 months, and after weaning could have been calculated.  The association 
between the MTCT rates at various points and the mothers’ characteristics such as age, 
education level and marital status could also have been analysed if there was linkage of 
mother-infant pairs. In addition the association between MTCT rates and infant feeding 
methods could also have been analysed, however the under 5 module which is supposed to 
have infant feeding data was not populated. 
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Given that data security and confidentiality are two important issues associated with the use 
of routinely collected health data. The MOH should come up with a way of scrambling 
national ID numbers to correspond with the unique SmartCare identifiers, so that researchers 
willing to analyse the data are able to identify individuals who register in different facilities.  
 
9. 4 Conclusion  
The implementation of the WHO post 2010 PMTCT guidelines has resulted in an increase in 
the proportion of HIV-infected pregnant women attending ANC who are already on ART. 
Infants born more recently have better clinical HIV care than infants born a decade ago in 
Zambia. The time between HIV diagnosis and ART initiation has greatly reduced however 
there is substantive provincial variability in the performance of PMTCT service.  
The SmartCare system has structural challenges which can be traced from its development. 
Funding gaps have resulted in staffing and data collection disparities within implementing 
partners. The lack of feedback from the system has also led to complacency at the operational 
level which has resulted in poor data quality in later years.  The SmartCare database could 
enable Zambian health policy makers to act on urgent PMTCT interventions and improve 
health care quality and outcomes of mothers and their infants. 
9.5 Recommendations 
 For SmartCare to used to evaluate  national PMTCT health outcomes and present 
comparison across provinces, districts and facilities, the following issues need to be 
addressed: 
1. SmartCare must be able to link data of mother–infant pairs, so that the data 
can be used to evaluate the impact of PMTCT program using MTCT rates 
across different time periods. 
2. The operation procedures of data collection and quality management should be 
standardised across implementation partners. 
3. The database outputs should be made available at facility, district and 
provisional levels so that the implementers could have a better understanding 
of what happens at each level of implementation. 
4.  The system could also be upgraded into a such that: multiple users can enter 
data simultaneously; data can be backed up automatically at more than one 
site; information can be communicated between multiple locations; data are 
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accessible and shared at multiple sites and the system can be debugged and 
upgraded over the internet without visiting remote sites (185, 186). 
9.6 PhD Contribution 
1. This is the first study to have evaluated the implementation post 2010 PMTCT 
interventions nationwide using SmartCare EHR system routine data. There is 
underutilisation of routinely collected PMTCT data in Zambia whereas the SmartCare 
database could present an opportunity to supplement current sources of routinely 
collected surveillance data. The Stata do files generated for data cleaning and analysis 
will be shared with the Ministry Health for their own internal uses.  Since SmartCare 
is being implemented across the whole country, the results of this study can be 
generalizable to the whole population. 
2. The qualitative paper is also the first document to exhaustively investigate the 
implementation of SmartCare since its inception in 2004. Through the qualitative 
research I obtained a rich and nuanced appreciation of the implementation of the 
SmartCare as we sampled from a range of IPs, health facilities, stakeholders and 
implementation systems. The depth of the inquiry enabled us to consider a range of 
explanatory factors. The findings will be shared with the policy makers in order to 
help them to improve the implementation of the EHR system. 
3. Electronic health record systems can have a transformative effect in the health 
systems, however their full potential has not been realised in developing countries. 
The insights from this PhD could aid other countries wanting to develop their own 
EHR systems. 
 
 
 
 
 
  
 
170 
 
10. References 
 UNAIDS. Women and Girls and HIV. Geneva, Switzerland; 2018. 
http://www.aidsdatahub.org/sites/default/files/publication/UNAIDS_Women_and_girls_and_
HIV_2018.pdf. Accessed on 1 August 2018. 
2. UNAIDS. UNAIDS DATA 2018. Geveva; 2018. 
http://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf. Accessed on 
1 August 2018. 
3. UNAIDS. Countdown to Zero: Global Plan Towards the Elimination of new HIV 
Infections among Children by 2015 and Keeping their Mothers Alive 2011-2015. Geneva, 
Switzerland:; 2011. 
http://www.unaids.org/sites/default/files/media_asset/20110609_JC2137_Global-Plan-
Elimination-HIV-Children_en_1.pdf .  Accessed on 15 August 2018. 
4. Stringer E.M. CBH, Chintu N., Creek T.L.,  Ekouevi D. K., Coetzee D., Tih P.,  
Boulle A.,  Dabis F., Shaffer N., Wilfert C.M., and Stringer J.S.A. Monitoring effectiveness 
of programmes to prevent mother-to-child HIV transmission in lower-income countries. 
Bulletin of the World Health Organisation. 2008;86(1):57-62. 
5. Gourlay A, Wringe A, Todd J, Michael D, Reniers G, Urassa M. Challenges with 
routine data sources for PMTCT programme monitoring in East Africa: insights from 
Tanzania. Global health action. 2015;8. 
6. Grzeskowiak LE, Gilbert AL, Morrison JL. Methodological challenges in using 
routinely collected health data to investigate long-term effects of medication use during 
pregnancy. Ther Adv Drug Saf. 2013;4(1):27-37. 
7. Munthali T. MP, Mee P., Gumede S., Schaap A, Mwinga A., Phiri C., Kapata N., 
Michelo C., and Todd J. Underutilisation of routinely collected data in the HIV programme in 
Zambia: A review of quantitatively analysed peer-reviewed articles. BMC Research Policy 
and Systems. 2017;15(51). 
8. UNAIDS. Prevention Gap Report. 2016. 
http://www.aidsdatahub.org/sites/default/files/publication/UNAIDS-2016-prevention-gap-
report_en.pdf. Accessed on 4 August 2018 
9. UNAIDS. HIV/AIDS Fact Sheet. 2017. 
http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed 
on 16 August 2018 
10. World Health Organisation. PMTCT Strategic Vision 2010- 2015:  Preventing 
mother-to-child transmission of HIV to reach the UNGASS and Millennium Development 
Goals. Geneva, Switzerland; 2010. 
http://www.who.int/hiv/pub/mtct/strategic_vision.pdf?ua=1. Accessed on 5 August 
11. UNAIDS. Political Declaration on HIV and AIDS: On the Fast Track to Accelerating 
the Fight against HIV and to Ending the AIDS Epidemic by 2030. Geneva; 2016. . 
http://www.unaids.org/sites/default/files/media_asset/2016-political-declaration-HIV-
AIDS_en.pdf. Accessed on 2 September 2018. 
12. UNAIDS. Global HIV/AIDS response epidemic update and health sector progress 
towards universal access. 2011 
http://apps.who.int/iris/bitstream/handle/10665/44787/9789241502986_eng.pdf?sequence=1 
Accessed on 2 September 2018. 
13. The Interagency Task Team on the Prevention and Treatment of HIV Infection in 
Pregnant Women MaC. Option B+ countries and PMTCT regimen 2015 [Available from: 
http://emtct-iatt.org/b-countries-and-pmtct-regimen/. 
14. World Health Organisation. Progress Report 2016 Prevents HIV, Test and Treat All: 
WHO Support for Country Impact. Geneva: WHO; 2016. 
 
171 
 
http://apps.who.int/iris/bitstream/handle/10665/251713/WHO-HIV-2016.24-
eng.pdf?sequence=1. Accessed on 2 August 2018. 
15. UNAIDS. AIDSInfo: UNAIDS; 2018 [cited 2018 20 September]. Available from: 
http://aidsinfo.unaids.org/. 
16. UNAIDS. UNAIDS Data 2017. 2017. 
http://www.aidsdatahub.org/sites/default/files/publication/UNAIDS_Global_AIDS_Update_2
017_Data_book_2017_en.pdf. Accessed on 4 August 2018 
17. World Health Organisation. Focus on Innovations in Africa Executive Summary of 
the Report on the Global Health Sector Response to HIV, 2000-2015. 2015. 
http://apps.who.int/iris/bitstream/handle/10665/198148/WHO_HIV_2015.40_eng.pdf?sequen
ce=1 Accessed on 17 August 2018 
18. Seidenberg P, Nicholson S, Schaefer M, Semrau K, Bweupe M, Masese N, et al. 
Early infant diagnosis of HIV infection in Zambia through mobile phone texting of blood test 
results. Bulletin of the World Health Organization. 2012;90(5):348-56. 
19. Edmonds A, Yotebieng M, Lusiama J, Matumona Y, Kitetele F, Napravnik S, et al. 
The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a 
resource-deprived setting: a cohort study. PLoS medicine. 2011;8(6):e1001044. 
20. World Health Organisation. World Health Organization. Consolidated Guidelines on 
the Use of Anti-retroviral Drugs for Treating and Preventing HIV Infection 
Recommendations for a Public Health Approach Geneva: WHO; 2016. 
http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf;jsessionid=
16E6F682F14DD912FE7AC00B0A3551B5?sequence=1 Accessed on 20 September 2018 
21. UNAIDS. UNAIDS Global AIDS Update Data Book. Geveva; 2017. 
http://www.aidsdatahub.org/sites/default/files/publication/UNAIDS_Global_AIDS_Update_2
017_Data_book_2017_en.pdf Accessed on 20 August 2018 
22. Joint United Nations Programme on HIV/AIDS, et al. Women Out Loud: How 
Women Living with HIV will help the World End AIDS. 2012. 
http://www.unaids.org/en/resources/presscentre/featurestories/2012/december/20121211wom
enoutloudv Accessed on 20 August 2018. 
23. Taylor GP, Clayden P, Dhar J, Gandhi K, Gilleece Y, Harding K, et al. British HIV 
Association guidelines for the management of HIV infection in pregnant women 2012. HIV 
medicine. 2012;13 Suppl 2:87-157. 
24. Cooper ER, Charurat M, Burns DN, Blattner W, Hoff R. Trends in antiretroviral 
therapy and mother-infant transmission of HIV. The Women and Infants Transmission Study 
Group. Journal of acquired immune deficiency syndromes (1999). 2000;24(1):45-7. 
25. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. 
Low rates of mother-to-child transmission of HIV following effective pregnancy 
interventions in the United Kingdom and Ireland, 2000-2006. AIDS (London, England). 
2008;22(8):973-81. 
26. McIntyre J. Use of antiretrovirals during pregnancy and breastfeeding in low-income 
and middle-income countries. Current opinion in HIV and AIDS. 2010;5(1):48-53. 
27. Stevens J, Lyall H. Mother to child transmission of HIV: what works and how much 
is enough? The Journal of infection. 2014;69 Suppl 1:S56-62. 
28. World, Health, Organisation. Global Update on the Health Sector Response to HIV. 
Gevena; 2014. http://www.who.int/hiv/pub/global-update.pdf dv Accessed on 4 August 2018. 
29. UNICEF. For Every Child, End AIDS: Seventh Stocktaking Report. New York, USA; 
2016. https://www.unicef.org/publications/index_93427.html Accessed on 4 September 2018. 
30. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality 
of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. 
Lancet. 2004;364(9441):1236-43. 
 
172 
 
31. Sutcliffe CG, Thuma PE, van Dijk JH, Sinywimaanzi K, Mweetwa S, Hamahuwa M, 
et al. Use of mobile phones and text messaging to decrease the turnaround time for early 
infant HIV diagnosis and notification in rural Zambia: an observational study. BMC 
pediatrics. 2017;17(1):66. 
32. Ammann AJ. Is there an acquired immune deficiency syndrome in infants and 
children? Pediatrics. 1983;72(3):430-2. 
33. Centers for Disease C. Recommendations for assisting in the prevention of perinatal 
transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and 
acquired immunodeficiency syndrome. MMWR Morbidity and mortality weekly report. 
1985;34(48):721-6, 31-2. 
34. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum 
and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-
child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 
1999;354(9181):795-802. 
35. Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, et al. 
Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-
dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for 
prevention trials 012 study). The Journal of infectious diseases. 2001;184(7):914-7. 
36. Effect of breastfeeding on infant and child mortality due to infectious diseases in less 
developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of 
Breastfeeding on the Prevention of Infant Mortality. Lancet. 2000;355(9202):451-5. 
37. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, et 
al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. The New England 
journal of medicine. 2010;362(24):2271-81. 
38. Kesho Bora Study G, de Vincenzi I. Triple antiretroviral compared with zidovudine 
and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of 
mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. 
The Lancet Infectious diseases. 2011;11(3):171-80. 
39. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, et al. Triple-
antiretroviral prophylaxis to prevent mother-to-child HIV transmission through 
breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS medicine. 
2011;8(3):e1001015. 
40. Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, et al. 
Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and 
effect of maternal highly active antiretroviral therapy. The Journal of infectious diseases. 
2009;200(10):1490-7. 
41. Mofenson LM. Prevention in neglected subpopulations: prevention of mother-to-child 
transmission of HIV infection. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America. 2010;50 Suppl 3:S130-48. 
42. World, Health, Organization. WHO Recommendations on the Diagnosis of HIV 
Infection in Infants and Children. Geneva, Switzerland:. Geneva, Switzerland; 2010. 
http://apps.who.int/iris/bitstream/handle/10665/44275/9789241599085_eng.pdf?sequence=1 
Accessed on 1 September 2018 
43. Centers for Disease, Control, Prevention. Impact of an innovative approach to prevent 
mother-to-child transmission of HIV--Malawi, July 2011-September 2012. MMWR 
Morbidity and mortality weekly report. 2013;62(8):148-51. 
44. Dryden-Peterson S, Lockman S, Zash R, Lei Q, Chen JY, Souda S, et al. Initial 
programmatic implementation of WHO option B in Botswana associated with increased 
projected MTCT. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 
2015;68(3):245-9. 
 
173 
 
45. Gumede-Moyo S, Filteau S, Munthali T, Todd J, Musonda P. Implementation 
effectiveness of revised (post-2010) World Health Organization guidelines on prevention of 
mother-to-child transmission of HIV using routinely collected data in sub-Saharan Africa: A 
systematic literature review. Medicine (Baltimore). 2017;96(40):e8055. 
46 World Health Organisation. New data on the prevention of mother-to-child 
transmission of HIV and their policy implications: conclusions and recommendations. 
Technical Consultation on behalf of the UNFPA/UNICEF/WHO/UNAIDS Inter-Agency 
Task Team on Mother-to-Child Transmission of HIV. . Geneva: WHO; 2001. 
www.who.int/reproductive-health/publications/new_data_prevention_mtct_hiv/index.html. 
Accessed on 18 August 2018. 
47. World Health Organisation. Antiretroviral Drugs for Antiretroviral Drugs for Treating 
Pregnant Women and Treating Pregnant Women and Preventing HIV Infection in Infants: 
Preventing HIV Infection in Infants: Towards Universal Access Towards Universal Access. 
Recommendations for a public health approach. Geneva, Switzerland; 2006. 
http://www.who.int/hiv/pub/mtct/arv_guidelines_mtct.pdf?ua=1 . Accessed on 17 August 
2018  
48. World Health Organisation. WHO Guidelines on HIV and infant feeding 2010: 
Principles and recommendations for infant feeding in the context of HIV and a summary of 
evidence. Geneva, Switzerland: World Health Organization Departments of Child and 
Adolescent Health and Development and HIV, in collaboration with UNAIDS, UNFPA and 
UNICEF; 2010. http://apps.who.int/iris/bitstream/10665/44345/1/9789241599535_eng.pdf. 
Accesed on 17 August 2018. 
49. World Health Organisation. Consolidated Guidelines on the use of Antiretroviral 
Drugs for Treating and Preventing HIV Infection: Recommendations for a public health 
approach. Geneva, Switzerland WHO; 2013 June 2013. 
http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf. Accessed on 17 
August 2018 
50. UNAIDS. Global Plan towards the Elimination of new HIV Infections among 
Children by 2015 and Keeping their Mothers Alive 2011–2015. 2011. 
http://www.unaids.org/sites/default/files/media_asset/20110609_JC2137_Global-Plan-
Elimination-HIV-Children_en_1.pdf. Accessed on 4 August 2018 
51. Leach-Lemens C. Option B+ cuts mother-to-child HIV transmission dramatically in 
Malawi 2016 [cited 2018 10 October ]. Available from: http://www.aidsmap.com/Option-B-
cuts-mother-to-child-HIV-transmission-dramatically-in-Malawi/page/3038713/. 
52. Zambia MoH. Zambia National PMTCT Protocol Guidelines Lusaka Zambia; 2010. 
53. Government of the Republic of Zambia MoH. Lifelong antiretroviral drugs (ARV’s) 
for all HIV positive pregnant women in Zambia: Policy guidelines for health facilities in 
Zambia. Lusaka, Zambia; 2013. 
54. Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, Bartos M, et al. HIV prevention 
transformed: the new prevention research agenda. Lancet. 2011;378(9787):269-78. 
55. Tudor Car L, van-Velthoven MH, Brusamento S, Elmoniry H, Car J, Majeed A, et al. 
Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with 
other health services for preventing HIV infection and improving HIV outcomes in 
developing countries. The Cochrane database of systematic reviews. 2011(6):Cd008741. 
56. Wettstein C, Mugglin C, Egger M, Blaser N, Vizcaya LS, Estill J, et al. Missed 
opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. 
AIDS (London, England). 2012;26(18):2361-73. 
57. Woldesenbet S, Jackson D, Lombard C, Dinh TH, Puren A, Sherman G, et al. Missed 
Opportunities along the Prevention of Mother-to-Child Transmission Services Cascade in 
 
174 
 
South Africa: Uptake, Determinants, and Attributable Risk (the SAPMTCTE). PloS one. 
2015;10(7):e0132425. 
58. Urban M, Chersich M. Acceptability and utilisation of voluntary HIV testing and 
nevirapine to reduce mother-to-child transmission of HIV-1 integrated into routine clinical 
care. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 
2004;94(5):362-6. 
59. Kinuthia J, Kiarie JN, Farquhar C, Richardson BA, Nduati R, Mbori-Ngacha D, et al. 
Uptake of prevention of mother to child transmission interventions in Kenya: health systems 
are more influential than stigma. Journal of the International AIDS Society. 2011;14:61. 
60. Uwimana J, Zarowsky C, Hausler H, Jackson D. Engagement of non-government 
organisations and community care workers in collaborative TB/HIV activities including 
prevention of mother to child transmission in South Africa: opportunities and challenges. 
BMC health services research. 2012;12:233. 
61. Peltzer K, Mlambo G. Factors determining HIV viral testing of infants in the context 
of mother-to-child transmission. Acta paediatrica (Oslo, Norway : 1992). 2010;99(4):590-6. 
62. Torpey K, Mandala J, Kasonde P, Bryan-Mofya G, Bweupe M, Mukundu J, et al. 
Analysis of HIV early infant diagnosis data to estimate rates of perinatal HIV transmission in 
Zambia. PloS one. 2012;7(8):e42859. 
63. Kohler PK OK, Mills LA, Okanda J, Kinuthia J, Olilo G, Odhiambo F, Laserson KF, 
Zierler B, Voss J, John-Stewart G. Shame, guilt, and stress: Community perceptions of 
barriers to engaging in prevention of mother to child transmission (PMTCT) programs in 
western Kenya. AIDS patient care and STDs. 2014;28(12):643-51. 
64. Madiba S, Letsoalo R. HIV disclosure to partners and family among women enrolled 
in prevention of mother to child transmission of HIV program: implications for infant feeding 
in poor resourced communities in South Africa. Global journal of health science. 
2013;5(4):1-13. 
65. Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating 
factors to the uptake of antiretroviral drugs for prevention of mother-to-child transmission of 
HIV in sub-Saharan Africa: a systematic review. Journal of the International AIDS Society. 
2013;16:18588. 
66. de Walque D, Gertler PJ, Bautista-Arredondo S, Kwan A, Vermeersch C, de Dieu 
Bizimana J, et al. Using provider performance incentives to increase HIV testing and 
counseling services in Rwanda. Journal of health economics. 2015;40:1-9. 
67. Schuster RC, de Sousa O, Reme AK, Vopelak C, Pelletier DL, Johnson LM, et al. 
Performance-Based Financing Empowers Health Workers Delivering Prevention of Vertical 
Transmission of HIV Services and Decreases Desire to Leave in Mozambique. International 
journal of health policy and management. 2018;7(7):630-44. 
68. Ishikawa N ST, Miyano S, Sikazwe  I, Mwango A, Ghidinelli M. N, Syakantu G,. 
Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-
to-child transmission of HIV in Zambia. PloS one. 2014;9(3):e90991. 
69. Ngarina M, Tarimo EA, Naburi H, Kilewo C, Mwanyika-Sando M, Chalamilla G, et 
al. Women's preferences regarding infant or maternal antiretroviral prophylaxis for 
prevention of mother-to-child transmission of HIV during breastfeeding and their views on 
Option B+ in Dar es Salaam, Tanzania. PloS one. 2014;9(1):e85310. 
70. Tweya H, Gugsa S, Hosseinipour M, Speight C, Ng'ambi W, Bokosi M, et al. 
Understanding factors, outcomes and reasons for loss to follow-up among women in Option 
B+ PMTCT programme in Lilongwe, Malawi. Tropical medicine & international health : TM 
& IH. 2014;19(11):1360-6. 
71. Kamuyango AA, Hirschhorn LR, Wang W, Jansen P, Hoffman RM. One-year 
outcomes of women started on antiretroviral therapy during pregnancy before and after the 
 
175 
 
implementation of Option B+ in Malawi: A retrospective chart review. World journal of 
AIDS. 2014;4(3):332-7. 
72. Ngarina M, Popenoe R, Kilewo C, Biberfeld G, Ekstrom AM. Reasons for poor 
adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own 
health: experiences from the Mitra Plus study in Tanzania. BMC public health. 2013;13:450. 
73. Etoori D, Kerschberger B, Staderini N, Ndlangamandla M, Nhlabatsi B, Jobanputra 
K, et al. Challenges and successes in the implementation of option B+ to prevent mother-to-
child transmission of HIV in southern Swaziland. BMC public health. 2018;18(1):374. 
74. Hamilton E, Bossiky B, Ditekemena J, Esiru G, Fwamba F, Goga AE, et al. Using the 
PMTCT Cascade to Accelerate Achievement of the Global Plan Goals. Journal of acquired 
immune deficiency syndromes (1999). 2017;75 Suppl 1:S27-S35. 
75. Doherty K, Ciaranello A. What is needed to eliminate new pediatric HIV infections: 
the contribution of model-based analyses. Current opinion in HIV and AIDS. 2013;8(5):457-
66. 
76. World, Health, Organisation. Consolidated ARV guidelines: What’s the Evidence. 
Geneva, Switzerland; 2013. 
77. World, Health, Organisation. WHO Guidelines Approved by the Guidelines Review 
Committee. Geneva: World Health Organization Copyright (c) World Health Organization 
2015.; 2015. http://apps.who.int/iris/handle/10665/186275?search-
result=true&query=Guideline+on+When+to+Start+Antiretroviral+Therapy+and+on+Pre-
Exposure+Prophylaxis+for+HIV&scope=%2F&filtertype_0=dateIssued&filter_relational_op
erator_0=equals&filter_0=%5B2000+TO+2018%5D&rpp=10&sort_by=score&order=desc 
Accessed on 17 August 2018 
78. World, Health, Organization. WHO Recommendations on the Diagnosis of HIV 
Infection in Infants and Children. Geneva, Switzerland:. Geneva, Switzerland; 2010. 
http://apps.who.int/iris/bitstream/handle/10665/44275/9789241599085_eng.pdf?sequence=1 
Accessed on 1 September 2018. 
79. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. 
Antiretroviral regimens in pregnancy and breast-feeding in Botswana. The New England 
journal of medicine. 2010;362(24):2282-94. 
80. Kim MH, Ahmed S, Buck WC, Preidis GA, Hosseinipour MC, Bhalakia A, et al. The 
Tingathe programme: a pilot intervention using community health workers to create a 
continuum of care in the prevention of mother to child transmission of HIV (PMTCT) 
cascade of services in Malawi. Journal of the International AIDS Society. 2012;15 Suppl 
2:17389. 
81. Kim MH, Ahmed S, Hosseinipour MC, Giordano TP, Chiao EY, Yu X, et al. 
Implementation and operational research: the impact of option B+ on the antenatal PMTCT 
cascade in Lilongwe, Malawi. Journal of acquired immune deficiency syndromes (1999). 
2015;68(5):e77-83. 
82. Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, et al. Increased 
risk of preterm delivery among HIV-infected women randomized to protease versus 
nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. The Journal of 
infectious diseases. 2011;204(4):506-14. 
83. Siberry GK, Williams PL, Mendez H, Seage GR, 3rd, Jacobson DL, Hazra R, et al. 
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected 
infants. AIDS (London, England). 2012;26(9):1151-9. 
84. Ford N CA, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an 
updated systematic review and meta-analysis. AIDS (London, England). 2011(25):2301-4. 
 
176 
 
85. Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, van Widenfelt E, et 
al. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed 
uninfected infants in Botswana. Journal of acquired immune deficiency syndromes (1999). 
2011;56(2):131-8. 
86. Persaud D BA, Ziemniak C, . Slower clearance of nevirapine resistant virus in infants 
failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission. 
AIDS research and human retroviruses. 2011(27):823-9. 
87. Saleska JL, Turner AN, Maierhofer C, Clark J, Kwiek JJ. Use of Antiretroviral 
Therapy During Pregnancy and Adverse Birth Outcomes Among Women Living With HIV-1 
in Low- and Middle-Income Countries: A Systematic Review. Journal of acquired immune 
deficiency syndromes (1999). 2018;79(1):1-9. 
88. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and 
Risks of Antiretroviral Therapy for Perinatal HIV Prevention. The New England journal of 
medicine. 2016;375(18):1726-37. 
89. Kuznik A LM, Hermans S, Castelnuro B, Auerbach B, Semeere A, Sempa M, 
Ssewankambo F, Manabe Y. Evaluating the cost-effectiveness of combination antiretroviral 
therapy for the prevention of mother-to-child transmission of HIV in Uganda. Bull World 
Health Organ. 2012(90):595-603. 
90. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of 
the Panel on Cost-effectiveness in Health and Medicine. Jama. 1996;276(15):1253-8. 
91. Binagwaho A, Pegurri E, Drobac PC, Mugwaneza P, Stulac SN, Wagner CM, et al. 
Prevention of mother-to-child transmission of HIV: cost-effectiveness of antiretroviral 
regimens and feeding options in Rwanda. PloS one. 2013;8(2):e54180. 
92. Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, Rusibamayila A, 
et al. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of 
mother-to-child HIV transmission in Zimbabwe. Clinical Infectious Diseases.56(3):430-46. 
93. Fasawe O, Avila C, Shaffer N, Schouten E, Chimbwandira F, Hoos D, et al. Cost-
effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and 
children in Malawi. PloS one. 2013;8(3):e57778. 
94. Orlando S MM, Mancinelli S, Loitta G, Giglio P, Alumendo E, Ziegler I, Palombi L, 
Shawa M. Cost-effectiveness of using HAART in prevention of mother-to-child transmission 
in the DREAM-Project Malawi. Journal of acquired immune deficiency syndromes (1999). 
2010(55):631-4. 
95. Robberstad B E-OB. Preventing mother to child transmission of HIV with highly 
active antiretroviral treatment in Tanzania--a prospective cost-effectiveness study. Journal of 
acquired immune deficiency syndromes (1999). 2010(55):397-403. 
96. Shah M JB, Abimiku A, Walker DG. . Cost-effectiveness of new WHO 
recommendations for prevention of mother-to-child transmission of HIV in a resource-limited 
setting. AIDS and HIV Research. 2011(25):1093-102. 
97. Schmidt NC R-PJ, Fernandez AD, . Costs and benefits of multidrug, multidose 
antiretroviral therapy for prevention of mother-to-child transmission of HIV in the 
Dominican Republic. . Int J Gynaecol Obstet 2012. 2012(116):219-22. 
98. Kourtis AP, Bulterys M, Nesheim SR, Lee FK. Understanding the timing of HIV 
transmission from mother to infant. Jama. 2001;285(6):709-12. 
99. Sugandhi N, Rodrigues J, Kim M, Ahmed S, Amzel A, Tolle M, et al. HIV-exposed 
infants: rethinking care for a lifelong condition. AIDS (London, England). 2013;27 Suppl 
2:S187-95. 
100. Haas AD, van Oosterhout JJ, Tenthani L, Jahn A, Zwahlen M, Msukwa MT, et al. 
HIV transmission and retention in care among HIV-exposed children enrolled in Malawi's 
 
177 
 
prevention of mother-to-child transmission programme. Journal of the International AIDS 
Society. 2017;20(1):21947. 
101. Rawizza HE, Chang CA, Chaplin B, Ahmed IA, Meloni ST, Oyebode T, et al. Loss to 
Follow-Up within the Prevention of Mother-to-Child Transmission Care Cascade in a Large 
ART Program in Nigeria. Current HIV research. 2015;13(3):201-9. 
102. S Bhardwaj  PB, Y Pillay , L Treger-Slavin, P Robinson, A Goga, G Sherman. 
Elimination of mother-to-child transmission of HIV in South Africa: Rapid scale-up using 
quality improvement. South African Medical Journal. 2014;104(3). 
103. M Ibeto JG, V Cox. Closing the gaps: Steps towards elimination of mother-to-child 
transmission of HIV. Southern African Journal of HIV Medicine. 2014;15(3). 
104. G. Martínez Pérez CM, D. Garone, R. Coulborn,  A. D. Harries, B. Hedt-Gauthier,  
M. Murowa, G. S. Mwenelupembe,  R. Van den Bergh,  and L. Triviño Durán. HIV testing 
and retention in care of infants born to HIV- infected women enrolled in ‘Option B+’, 
Thyolo, Malawi. Public Health Action 2014;4(2):102-4. 
105. Mwendo EM, Mtuy TB, Renju J, Rutherford GW, Nondi J, Sichalwe AW, et al. 
Effectiveness of prevention of mother-to-child HIV transmission programmes in Kilimanjaro 
region, northern Tanzania. Tropical medicine & international health : TM & IH. 
2014;19(3):267-74. 
106. Koye DN, Zeleke BM. Mother-to-child transmission of HIV and its predictors among 
HIV-exposed infants at a PMTCT clinic in northwest Ethiopia. BMC public health. 
2013;13:398. 
107. Sethi AK CD, Gange SJ, Moore RD, Gallant JE. . Association between adherence to 
antiretro- viral therapy and human immunodeficiency virus drug resistance. . Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America. 
2003(37):1112–18. 
108. Nieuwkerk PT SM, Burger DM  Limited patient adherence to highly active 
antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 
2001(161):1962-68. 
109. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. 
Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-
income, and high-income countries: a systematic review and meta-analysis. AIDS (London, 
England). 2012;26(16):2039-52. 
110. Cataldo F., Seeley J., Nkhata M.J., Mupambireyi Z., Tumwesige E., M. GD. She 
Knows That She Will not Come Back: Tracing Patients and New Thresholds of Collective 
Surveillance in PMTCT Option B+. BMC health services research. 2018;76(18). 
111. Kawuma R., Seeley J., Mupambireyi Z., Cowan F., Bernays S. “Treatment is not yet 
necessary”: delays in seeking access to HIV treatment in Uganda and Zimbabwe. African 
Journal of AIDS Research. 2018. 
112. Sumiyo Okawa MC, Naoko Ishikawa, Henry Kapyata, Charles Yekha Msiska, 
Gardner Syakantu, Shinsuke Miyano, Kenichi Komada, Masamine Jimba and Junko 
Yasuoka. Longitudinal adherence to ART drugs for PMTCT of HIV in Zambia. BMC 
Pregnancy and Child Birth. 2015;15(1). 
113. Haftamu Ebuy HY, Mussie Alemayehu. Level of adherence and predictors of 
adherence to the Option B+ PMTCT programme in Tigray, Northern Ethiopia International 
Journal of Infectious Diseases 2015;33:123-9. 
114. Benchimol EI, Smeeth L, Guttmann A, Harron K, Hemkens LG, Moher D, et al. [The 
REporting of studies Conducted using Observational Routinely-collected health Data 
(RECORD) statement]. Z Evid Fortbild Qual Gesundhwes. 2016;115-116:33-48. 
 
178 
 
115. Nicholls SG, Langan SM, Benchimol EI. Routinely collected data: the importance of 
high-quality diagnostic coding to research. CMAJ : Canadian Medical Association journal = 
journal de l'Association medicale canadienne. 2017;189(33):E1054-e5. 
116. Jorm L. Routinely collected data as a strategic resource for research: priorities for 
methods and workforce. Public health research & practice. 2015;25(4):e2541540. 
117. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Routinely collected data and 
comparative effectiveness evidence: promises and limitations. CMAJ : Canadian Medical 
Association journal = journal de l'Association medicale canadienne. 2016;188(8):E158-64. 
118. World, Health, Organization. National eHealth strategy toolkit: International 
Telecommunication Union Who.int. ; 2012 [cited 2019 8 February]. 
119. World, Health, Organisation. Electronic health records: manual for developing 
countries: Wpro.who.int; 2006 [cited 2019 8 February]. 
120. Abiy R, Gashu K, Asemaw T, Mitiku M, Fekadie B, Abebaw Z, et al. A Comparison 
of Electronic Medical Record Data to Paper Records in Antiretroviral Therapy Clinic in 
Ethiopia: What is affecting the Quality of the Data? Online journal of public health 
informatics. 2018;10(2):e212. 
121. Fraser HS, Blaya J. Implementing medical information systems in developing 
countries, what works and what doesn't. AMIA Annu Symp Proc. 2010;2010:232-6. 
122. Saczynski JS, McManus DD, Goldberg RJ. Commonly used data-collection 
approaches in clinical research. The American journal of medicine. 2013;126(11):946-50. 
123. Akanbi MO, Ocheke AN, Agaba PA, Daniyam CA, Agaba EI, Okeke EN, et al. Use 
of Electronic Health Records in sub-Saharan Africa: Progress and challenges. Journal of 
medicine in the tropics. 2012;14(1):1-6. 
124. Nicol E, Dudley L, Bradshaw D. Assessing the quality of routine data for the 
prevention of mother-to-child transmission of HIV: An analytical observational study in two 
health districts with high HIV prevalence in South Africa. Int J Med Inform. 2016;95:60-70. 
125. Chen H, Yu P, Hailey D, Wang N. Methods for assessing the quality of data in public 
health information systems: a critical review. Stud Health Technol Inform. 2014;204:13-8. 
126. Ferguson L, Grant AD, Ong'ech JO, Vusha S, Watson-Jones D, Ross DA. Prevention 
of mother-to-child transmission of HIV: assessing the accuracy of routinely collected data on 
maternal antiretroviral prophylaxis coverage in Kenya. Sexually transmitted infections. 
2012;88(2):120-4. 
127. Hotchkiss DR, Aqil A, Lippeveld T, Mukooyo E. Evaluation of the Performance of 
Routine Information System Management (PRISM) framework: evidence from Uganda. 
BMC health services research. 2010;10:188. 
128. Nicol E, Bradshaw D, Phillips T, Dudley L. Human factors affecting the quality of 
routinely collected data in South Africa. Stud Health Technol Inform. 2013;192:788-92. 
129. Hotchkiss DR, Diana ML, Foreit KG. How can routine health information systems 
improve health systems functioning in low- and middle-income countries? Assessing the 
evidence base. Advances in health care management. 2012;12:25-58. 
130. Aqil A, Lippeveld T, Hozumi D. PRISM framework: a paradigm shift for designing, 
strengthening and evaluating routine health information systems. Health policy and planning. 
2009;24(3):217-28. 
131. Girma M, Wendaferash R, Shibru H, Berhane Y, Hoelscher M, Kroidl A. Uptake and 
performance of prevention of mother-to-child transmission and early infant diagnosis in 
pregnant HIV-infected women and their exposed infants at seven health centres in Addis 
Ababa, Ethiopia. Tropical medicine & international health : TM & IH. 2017;22(6):765-75. 
132. Billong SC, Dee J, Fokam J, Nguefack-Tsague G, Ekali GL, Fodjo R, et al. Feasibility 
Study of HIV Sentinel Surveillance using PMTCT data in Cameroon: from Scientific Success 
to Programmatic Failure. BMC infectious diseases. 2017;17(1):3. 
 
179 
 
133. Sirengo M, Rutherford GW, Otieno-Nyunya B, Kellogg TA, Kimanga D, Muraguri 
N, et al. Evaluation of Kenya's readiness to transition from sentinel surveillance to routine 
HIV testing for antenatal clinic-based HIV surveillance. BMC infectious diseases. 
2016;16:113. 
134. Young PW, Mahomed M, Horth RZ, Shiraishi RW, Jani IV. Routine data from 
prevention of mother-to-child transmission (PMTCT) HIV testing not yet ready for HIV 
surveillance in Mozambique: a retrospective analysis of matched test results. BMC infectious 
diseases. 2013;13:96. 
135. Gonese E, Mushavi A, Mungati M, Mhangara M, Dzangare J, Mugurungi O, et al. Is 
Zimbabwe ready to transition from anonymous unlinked sero-surveillance to using 
prevention of mother to child transmission of HIV (PMTCT) program data for HIV 
surveillance?: results of PMTCT utility study, 2012. BMC infectious diseases. 
2016;16(97):DOI 10.1186/s12879-016-1425-2. 
136. Countrymeters. Zambia Information 2018 [8 August 2018]. Available from: 
http://countrymeters.info/en/Zambia/. 
137. LusakaTimes.Com. Zambian HIV rate prevalence rate reduces- Dr Chilufya. Lusaka 
Times. 2017 23 February 2017. 
138. UNICEF. UNICEF Zambia Fact Sheet  [Available from: 
https://www.unicef.org/zambia/5109_8456.html. 
139. ZAMPHIA. Zambia Population-Based HIV Impact Assessment  2015–2016. 2016. 
140. Zambia, Ministry, of, Health. Zambia Consolidated Guidelines for Treatment and 
Prevention of HIV Infection. Lusaka, Zambia: Directorate of Clinical Care and Diagnostic 
Service; 2016 2 December 2017. 
141. UNAIDS. Update:Zambia offering antiretroviral therapy regardless of CD4 count 
2018 [8 August 2018]. Available from: 
http://www.unaids.org/en/resources/presscentre/featurestories/2017/august/20170818_zambia
. 
142. Zambia, National, AIDS, Council. GARPR Zambia Country Report 2013. 2014. 
143. Touré H AM, Dabis F: . To what extent could performance-based schemes help 
increase the effectiveness of prevention of mother-to-child transmission of HIV (PMTCT) 
programs in resource-limited settings? A summary of the published evidence. . BMC public 
health. 2010(10). 
144. Central Statistical Office. Zambia Demographic and health survey - 2013-14. Lusaka, 
Zambia; 2014. 
145. Republic, of, Zambia, Ministry, of, Health. Zambia Consolidated Guidelines for 
Treatment and Prevention of HIV infection. Zambia; 2016. 
146. Sutcliffe CG, van Dijk JH, Hamangaba F, Mayani F, Moss WJ. Turnaround time for 
early infant HIV diagnosis in rural Zambia: a chart review. PloS one. 2014;9(1):e87028. 
147. Kellerman S, Essajee S. HIV testing for children in resource-limited settings: what are 
we waiting for? PLoS medicine. 2010;7(7):e1000285. 
148. UNICEF, Zambia. ‘Project Mwana: Using mobile technology to improve early infant 
diagnosis of HIV’ 2012 [8 August 2018]. Available from: 
https://www.unicef.org/partners/Partnership_profile_2012_Mwana_Zambia_V2_approved.pd
f. 
149. Muyunda G. Zambia leads the way in SmartCare electronic health records system, a 
benefit to both providers and patients 2011 [Available from: 
https://www.jhpiego.org/success-story/zambia-leads-the-way-in-smartcare-electronic-health-
records-system-a-benefit-to-both-providers-and-patients/. 
 
180 
 
150. Gopalakrishnan S, Ganeshkumar P. Systematic Reviews and Meta-analysis: 
Understanding the Best Evidence in Primary Healthcare. Journal of family medicine and 
primary care. 2013;2(1):9-14. 
151. Creswell J. Research design: Qualitative, quantitative, and mixed method 
approaches. 2nd ed: Sage; 2003. 
152. World, Health, Organisation. Everybody Business: Strengthening Health Systems To 
Improve Health Outcomes: WHO’s Framework For Action. Geneva: WHO Library; 2007. 
153. World, Health, Organisation. Monitoring the Building Blocks of Health Systems: A 
Handbook of Indicators and their Measurement Strategies. Geneva: WHO; 2010. 
154. Sharma A, Rana SK, Prinja S, Kumar R. Quality of Health Management Information 
System for Maternal & Child Health Care in Haryana State, India. PloS one. 
2016;11(2):e0148449. 
155. Republic, of, Zambia. National Health Strategic Plan 2011-2015. Lusaka, 
Zambia2011. 
156. Republic, of, Zambia, Ministry, of, Health. Zambia National Health Strategic Plan 
2017 – 2021. Lusaka,  Zambia2017. 
157. Karengera I, Onzima RAD, Simon-Peter K, Govule K. Quality and Use of Routine 
Healthcare Data in Selected Districts of Eastern Province of Rwanda International Journal of 
Public Health Research. 2016;4(2):5-13. 
158. Hong TT, Phuong Hoa N, Walker SM, Hill PS, Rao C. Completeness and reliability 
of mortality data in Viet Nam: Implications for the national routine health management 
information system. PloS one. 2018;13(1):e0190755. 
159. Kasambara A, Kumwenda S, Kalulu K, Lungu K, Beattie T, Masangwi S, et al. 
Assessment of implementation of the health management information system at the district 
level in southern Malawi. Malawi medical journal : the journal of Medical Association of 
Malawi. 2017;29(3):240-6. 
160. O'Hagan R, Marx MA, Finnegan KE, Naphini P, Ng'ambi K, Laija K, et al. National 
Assessment of Data Quality and Associated Systems-Level Factors in Malawi. Global health, 
science and practice. 2017;5(3):367-81. 
161. Nisingizwe MP, Iyer HS, Gashayija M, Hirschhorn LR, Amoroso C, Wilson R, et al. 
Toward utilization of data for program management and evaluation: quality assessment of 
five years of health management information system data in Rwanda. Global health action. 
2014;7:25829. 
162. Mutemwa RI. HMIS and decision-making in Zambia: re-thinking information 
solutions for district health management in decentralized health systems. Health policy and 
planning. 2006;21(1):40-52. 
163. World, Health, Organisation. WHO Guidelines Approved by the Guidelines Review 
Committee. Geneva: World Health Organization. Copyright (c) World Health Organization 
2016.; 2016. 
http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1 
Accessed on 5 August 
164. Shaffer N, Abrams EJ, Becquet R. Option B+ for prevention of mother-to-child 
transmission of HIV in resource-constrained settings: great promise but some early caution. 
AIDS (London, England). 2014;28(4):599-601. 
165. Chi BH, Mutale W, Winston J, Phiri W, Price JT, Mwiche A, et al. Infant Human 
Immunodeficiency Virus-free Survival in the Era of Universal Antiretroviral Therapy for 
Pregnant and Breastfeeding Women: A Community-based Cohort Study From Rural Zambia. 
The Pediatric infectious disease journal. 2018;37(11):1137-41. 
 
181 
 
166. Chung N.C. B-MC, Chilengi R, Kasaro M. P., Stringer J. S. A and Benjamin H. Chi 
B. H. Patient engagement in HIV care and treatment in Zambia, 2004–2014. Tropical 
Medicine and International Health. 2017;22(3):332-9. 
167. Tenthani L, Haas AD, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F, et al. 
Retention in care under universal antiretroviral therapy for HIV-infected pregnant and 
breastfeeding women ('Option B+') in Malawi. AIDS (London, England). 2014;28(4):589-98. 
168. Koole O, Houben RM, Mzembe T, Van Boeckel TP, Kayange M, Jahn A, et al. 
Improved retention of patients starting antiretroviral treatment in Karonga District, northern 
Malawi, 2005-2012. Journal of acquired immune deficiency syndromes (1999). 
2014;67(1):e27-33. 
169. Woelk G.B. ND, Behan S., Mukaminega M., Nyirabahizi E., Hoffman H.J., 
Mugwaneza P., Ribakare M., Amzel A., Ryan Phelps B. Retention of mothers and infants in 
the prevention of mother-Tochild transmission of HIV programme is associated with 
individual and facility-level factors in Rwanda. . Woelk GB, Ndatimana D, Behan S, 
Mukaminega M, Nyirabahizi E, Hoffman HJ, Mugwaneza P, Ribakare M, Amzel A, Ryan 
Phelps B. 2016;19. 
170. Chan AK, Kanike E, Bedell R, Mayuni I, Manyera R, Mlotha W, et al. Same day HIV 
diagnosis and antiretroviral therapy initiation affects retention in Option B+ prevention of 
mother-to-child transmission services at antenatal care in Zomba District, Malawi. Journal of 
the International AIDS Society. 2016;19(1):20672. 
171. Dzangare J, Takarinda KC, Harries AD, Tayler-Smith K, Mhangara M, Apollo TM, et 
al. HIV testing uptake and retention in care of HIV-infected pregnant and breastfeeding 
women initiated on 'Option B+' in rural Zimbabwe. Tropical medicine & international health 
: TM & IH. 2016;21(2):202-9. 
172. Mirkuzie AH. Implementation and outcomes of guideline revisions for the prevention 
of mother-to-child HIV transmission in Mother Support Programme, Addis Ababa, Ethiopia. 
PloS one. 2018;13(6):e0198438. 
173. Scott CA, Iyer HS, Lembela Bwalya D, Bweupe M, Rosen SB, Scott N, et al. Uptake, 
outcomes, and costs of antenatal, well-baby, and prevention of mother-to-child transmission 
of HIV services under routine care conditions in Zambia. PloS one. 2013;8(8):e72444. 
174. Merdekios B, Adedimeji AA. Effectiveness of interventions to prevent mother-to-
child transmission of HIV in Southern Ethiopia. International journal of women's health. 
2011;3:359-66. 
175. Haile F, Brhan Y. Male partner involvements in PMTCT: a cross sectional study, 
Mekelle, Northern Ethiopia. BMC pregnancy and childbirth. 2014;14:65. 
176. Elias M, Mmbaga EJ, Mohamed AA, Kishimba RS. Male partner involvement in the 
prevention of mother to child transmission of HIV infection in Mwanza Region, Tanzania. 
The Pan African medical journal. 2017;27:90. 
177. Amano A, Musa A. Male involvement in PMTCT and associated factors among men 
whom their wives had ANC visit 12 months prior to the study in Gondar town, North west 
Ethiopia, December, 2014. The Pan African medical journal. 2016;24:239. 
178. Morfaw F, Mbuagbaw L, Thabane L, Rodrigues C, Wunderlich AP, Nana P, et al. 
Male involvement in prevention programs of mother to child transmission of HIV: a 
systematic review to identify barriers and facilitators. Systematic reviews. 2013;2:5. 
179. Manjate Cuco RM, Munguambe K, Bique Osman N, Degomme O, Temmerman M, 
Sidat MM. Male partners' involvement in prevention of mother-to-child HIV transmission in 
sub-Saharan Africa: A systematic review. SAHARA J : journal of Social Aspects of 
HIV/AIDS Research Alliance / SAHARA , Human Sciences Research Council. 2015;12:87-
105. 
 
182 
 
180. Kashitala J, Nyambe N, Mwalo S, Musamba J, Chishinga N, Kasonde P, et al. Is Male 
Involvement in ANC and PMTCT Associated with Increased Facility-Based Obstetric 
Delivery in Pregnant Women? African journal of reproductive health. 2015;19(2):117-24. 
181. Koo K, Makin JD, Forsyth BW. Where are the men? Targeting male partners in 
preventing mother-to-child HIV transmission. AIDS care. 2013;25(1):43-8. 
182. Mate KS, Bennett B, Mphatswe W, Barker P, Rollins N. Challenges for routine health 
system data management in a large public programme to prevent mother-to-child HIV 
transmission in South Africa. PloS one. 2009;4(5):e5483. 
183. Annabelle Gourlay AW, Jim Todd, Caoimhe Cawley,  Denna Michael, Richard 
Machemba,  Benjamin Clark,  Clemens Masesa, Milly Marston,  Mark Urassa and Basia 
Zaba. Uptake of services for prevention of mother-to-child transmission of HIV in a 
community cohort in rural Tanzania from 2005 to 2012. BMC health services research. 
2016;16(4):1249-5. 
184. The Interagency Task Team on the Prevention and Treatment of HIV Infection in 
Pregnant Women MaCI, editor B+ Monitoring & Evaluation Framework Dissemination and 
Country Consultation: Technical Synthesis. 2015; Kampala, Uganda. 
185. Fraser HS, Biondich P, Moodley D, Choi S, Mamlin BW, Szolovits P. Implementing 
electronic medical record systems in developing countries. Inform Prim Care. 2005;13(2):83-
95. 
186. Della Mea V. Internet electronic mail: a tool for low-cost telemedicine. J Telemed 
Telecare. 1999;5(2):84-9. 
 
 
 
 
 
 
 
  
 
183 
 
 
Appendices 
Appendix 1: PhD Timelines 
 
 
 
 
 
 
 
 
 
184 
 
Appendix 2: Data Collection Flow Process 
 
 
 
 
 
 
 
 
 
 
  
 
185 
 
Appendix 3: LSHTM Ethical Clearance 
 
 
186 
 
 
 
  
 
187 
 
Appendix 4: Ministry of Health Permission Letter 
 
 
 
 
 
 
  
 
188 
 
Appendix 5: Zambia SEARCH Project Ethical Clearance 
 
 
 
 
 
 
  
 
189 
 
Appendix 6: LSHTM SEARCH Project Ethical Clearance  
  
 
190 
 
Appendix 7: Qualitative Amendment Clearance  
 
 
 
 
 
 
 
191 
 
 
Appendix 8: FDG Written Informed Consent Waiver 
 
 
 
 
  
 
192 
 
Appendix 9: Informed Consent Forms 
 
9.1 Informed Consent – In-depth Interviews 
 
 
Study purpose 
The study aims to use routinely collected data to give an overview of the effectiveness of post 
2010 WHO PMTCT guidelines implementation and improve decision making in the Zambia 
health care system. The SmartCare Database is the source of routinely collected data  
 
Procedures and duration 
If you agree to take part in the study, we will talk on a one on one basis. The one on one 
discussion will take approximately 30 minutes to 1 hour. You will then be asked questions 
about specific issues related to SmartCare and PMTCT Implementation. The information will 
be audio recorded and then written down on a computer. Nothing you say will be directly 
attributable to you. 
 
Confidentiality 
We will use a participant identification number instead of actual names on the study 
information. The information we collect may be shared with other researchers who are 
involved in this study but if shared, it will be anonymously. These ideas will be published in 
order to improve the understanding of the scientific community about these issues. It will not 
be possible to link any information published in this way to the individuals who told their 
stories. The information may be stored for many years at the LSHTM in London and 
University of Zambia.  
 
Risks 
The risks of participating in this study are small. It is possible that you may feel 
uncomfortable with some of the questions that are asked in which case you do not need to 
answer them. You can withdraw from the study at any time.  
 
Benefits  
You are unlikely to benefit directly from participating in this study. However the information 
that we collect could be used by policy makers to plan and prioritize strategies to address 
identified gaps in implementation of SmartCare and PMTCT programs. 
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Voluntary participation 
We hope that you will take part in this study.  However, you do not have to take part in this 
study if you do not want them to. If you decide that you should take part but then change your 
mind you may withdraw at any time without having to give a reason. 
 
Offer to answer questions 
Before you sign this form, please ask any questions on any aspect of this study that is unclear 
to you.  You may take as much time as necessary to think it over. 
 
For any other questions that you may have about this study, please contact the person in 
charge of the study: Mrs Sehlulekile Moyo on this phone number: 09777 61451 
 
If you have any questions concerning this study or consent form beyond those answered by 
the investigator, including questions about the research, your rights as a research participant 
or research-related injuries; or if you feel that you have been treated unfairly and would like 
to talk to someone other than a member of the research team, please feel free to contact: 
University of Zambia 
Biomedical Research Ethics Committee 
Ridgeway Campus 
Box 50110 
Lusaka, Zambia 
Phone: +260 – 1 - 256067 
AUTHORIZATION 
You are making a decision whether you should participate in this study. Your signature 
indicates that you have read and understood the information provided above, have had all 
your questions answered, and have decided to participate. 
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STATEMENT OF CONSENT TO BE AUDIO-TAPED 
I understand that audio recordings will be taken during the study. (Mark either “Yes” or 
“No”) 
I agree to be audio recorded    
 
Yes   
 
       No  
 
 
    
Name (please print)  Date 
 
     
Signature 
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9.2 Informed Consent – Focus Group Discussions 
 
 
Study purpose 
The study aims to use routinely collected data to give an overview of the effectiveness of post 
2010 WHO PMTCT guidelines implementation and improve decision making in the Zambia 
health care system. The SmartCare Database is the source of routinely collected data  
 
Procedures and duration 
If you agree to take part in the study, we will talk to you in group of 8 to 12 women. The 
focus group discussion will take approximately 2 hours. You will then be asked questions 
about specific issues related to SmartCare and PMTCT Implementation. The information will 
be audio recorded and then written down on a computer. Nothing you say will be directly 
attributable to you. 
 
Confidentiality 
We will use a participant identification number instead of actual names on the study 
information. The information we collect may be shared with other researchers who are 
involved in this study but if shared, it will be anonymously. These ideas will be published in 
order to improve the understanding of the scientific community about these issues. It will not 
be possible to link any information published in this way to the individuals who told their 
stories. The information may be stored for many years at the LSHTM in London and 
University of Zambia.  
 
Risks 
The risks of participating in this study are small. It is possible that you may feel 
uncomfortable with some of the questions that are asked in which case you do not need to 
answer them. You can withdraw from the study at any time.  
 
Benefits  
You are unlikely to benefit directly from participating in this study. However the information 
that we collect could be used by policy makers to plan and prioritize strategies to address 
identified gaps in implementation of SmartCare and PMTCT programs. 
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Voluntary participation 
We hope that you will take part in this study.  However, you do not have to take part in this 
study if you do not want them to. If you decide that you should take part but then change your 
mind you may withdraw at any time without having to give a reason. 
 
Offer to answer questions 
Before you sign this form, please ask any questions on any aspect of this study that is unclear 
to you.  You may take as much time as necessary to think it over. 
 
For any other questions that you may have about this study, please contact the person in 
charge of the study: Mrs Sehlulekile Moyo on this phone number: 09777 61451 
If you have any questions concerning this study or consent form beyond those answered by 
the investigator, including questions about the research, your rights as a research participant 
or research-related injuries; or if you feel that you have been treated unfairly and would like 
to talk to someone other than a member of the research team, please feel free to contact: 
University of Zambia 
Biomedical Research Ethics Committee 
Ridgeway Campus 
Box 50110 
Lusaka, Zambia 
Phone: +260 – 1 - 256067 
 
AUTHORIZATION 
You are making a decision whether you should participate in this study. Your signature 
indicates that you have read and understood the information provided above, have had all 
your questions answered, and have decided to participate. 
 
STATEMENT OF CONSENT TO BE AUDIO-TAPED 
I understand that audio recordings will be taken during the study. (Mark either “Yes” or 
“No”) 
I agree to be audio recorded    
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Yes   
 
       No  
 
 
    
Name (please print)  Date 
 
     
Signature 
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Appendix 10: Chapter 5 Additional Results 
 
10.1 Time to ART initiation per province in months 
 
Province  
Year 
2010 
Year 
2011 
Year 
2012 
Year 
2013 
Year 
2014 
Year 
2015 Mean 
Central 9.5 0.4 3.2 6.4 3.8 3.1 4.4 
Copperbelt 0.0 0.4 9.4 9.3 3.7 4.3 4.5 
Eastern 11.6 0.0 10.3 14.7 4.8 4.3 7.6 
Luapula 37.1 33.7 15.1 23.0 0.4 20.0 21.5 
Lusaka 16.2 32.5 6.1 7.7 8.8 14.1 14.2 
North-Western 17.9 0.3 0.1 3.2 1.8 19.0 7.0 
Northern 7.0   1.2 10.0 4.4 1.4 4.0 
Southern 6.0 6.0 3.7 3.6 3.7 6.3 4.9 
Western 10.1 9.5 7.2 19.0 9.7 2.8 9.7 
Total 8.6 6.4 5.1 7.8 4.6 7.9 6.7 
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Appendix 11: Chapter 6 Additional Results 
11.2 Univariable and multivariable analysis for age at HIV test 
 Age at test Univariable analysis Multivariable analysis 
Variable 
<2 months    n 
(%) 
>2 months    n 
(%) 
OR 95% CI P value aOR* 95% CI 
P 
value 
Sex         
Male 550 (5.22) 9,987 (94.78) 1.00 - - 1.00 - - 
Female 603 (5.39) 
10,582 (94.61) 
1.03 0.92, 
1.17 
0.573 0.97 0.85, 1.11 0.665 
Province         
Lusaka 365 (6.77) 5,029 (93.23) 1.00 - - 1.00 - - 
Central 94 (4.11) 2,194 (95.89) 0.59 0.47, 
0.74 
<0.001 0.46 0.35, 0.59 <0.001 
Copperbelt 294 (6.15) 4,484 (93.85) 0.90 0.77, 
1.06 
0.210 0.69 0.58, 0.83 <0.001 
Eastern 59 (2.85) 2,013 (97.15) 0.40 0.31, 
0.53 
<0.001 0.27 0.20, 0.37 <0.001 
Luapula 56 (4.18) 1,285 (95.82) 0.60 0.45, 
0.80 
0.001 0.44 0.31, 0.61 <0.001 
Northern 57 (5.80) 926 (94.20) 0.85 0.64, 
1.13 
0.262 0.69 0.50, 0.96 0.029 
North-
Western 
25 (2.83) 858 (97.17) 0.40 0.27, 
0.61 
<0.001 0.25 0.15, 0.40 <0.001 
Southern 394 (11.71) 2,972 (88.29) 1.83 1.57, 
2.12 
<0.001 1.36 1.13, 1.63 0.001 
Western 24 (1.52) 1,553 (98.48) 0.21 0.14, 
0.32 
<0.001 0.14 0.08, 0.23 <0.001 
Year of birth         
2006 220 (12.87) 1,489 (87.13) 1.00 - - 1.00 - - 
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 Age at test Univariable analysis Multivariable analysis 
Variable 
<2 months    n 
(%) 
>2 months    n 
(%) 
OR 95% CI P value aOR* 95% CI 
P 
value 
2007 412 (15.73) 2,207 (84.27) 1.26 1.06, 
1.51 
0.009 0.80 0.49, 1.30 0.365 
2008 528 (15.19) 2,947 (84.81) 1.21 1.02, 
1.44 
0.025 0.70 0.46, 1.08 0.106 
2009 683 (18.57) 2,995 (81.43) 1.54 1.31, 
1.82 
<0.001 1.11 0.74, 1.65 0.623 
2010 675 (24.83) 2,043 (75.17) 2.24 1.89, 
2.65 
<0.001 1.31 0.87, 1.96 0.191 
2011 446 (24.61) 1,366 (75.39) 2.21 1.85, 
2.64 
<0.001 2.24 1.50, 3.34 <0.001 
2012 191 (13.80) 1,193 (86.20) 1.08 0.88, 
1.33 
0.450 1.63 1.08, 2.46 0.020 
2013 186 (13.76) 1,166 (86.24) 1.08 0.88, 
1.33 
0.474 2.27 1.51, 3.40 <0.001 
2014 171 (16.78) 848 (83.22) 1.36 1.10, 
1.70 
0.005 2.79 1.85, 4.21 <0.001 
2015 137 (35.49) 249 (64.51) 3.72 2.87, 
4.83 
<0.001 27.03 16.43, 
44.49 
<0.001 
2016 49 (45.37) 59 (54.63) 5.62 3.71, 
8.51 
<0.001 - - - 
Birth quarter         
Jan – March 919 (15.13) 5,154 (84.87) 1.00 - - 1.00 - - 
April – June 968 (16.60) 4,865 (83.40) 1.12 1.01, 
1.23 
0.029 1.29 1.07, 1.56 0.009 
July – Sept 869 (19.37) 3,618 (80.63) 1.35 1.22, 
1.49 
<0.001 1.94 1.60, 2.35 <0.001 
Oct – Dec 942 (24.36) 2,925 (75.64) 1.81 1.63, <0.001 2.90   2.40, 3.50 <0.001 
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 Age at test Univariable analysis Multivariable analysis 
Variable 
<2 months    n 
(%) 
>2 months    n 
(%) 
OR 95% CI P value aOR* 95% CI 
P 
value 
2.00 
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Appendix 11.2: Univariable and multivariable analysis for time from diagnosis to ART 
initiation  
 Time from diagnosis to ART Univariable analysis Multivariable analysis 
Variable <2 weeks      n (%) >2 weeks      n (%) OR 95% CI P value aOR* 95% CI P value 
Sex         
Male 2,249 (21.34) 8,288 (78.66) 1.00 - - 1.00 - - 
Female 2,568 (22.96) 8,617 (77.04) 1.10 1.03, 1.17 0.004 1.06 0.97, 1.16 0.165 
Province         
Lusaka 822 (15.24) 4,572 (84.76) 1.00 - - 1.00 - - 
Central 688 (30.07) 1,600 (69.93) 2.39 2.13, 2.69 <0.001 3.10 2.65, 3.64 <0.001 
   Copperbelt 1,648 (34.49) 3,130 (65.51) 2.93 2.66, 3.22 <0.001 5.05 4.42, 5.78 <0.001 
Eastern 431 (20.80) 1,641 (79.20) 1.46 1.28, 1.66 <0.001 1.21 1.02, 1.43 0.026 
Luapula 547 (40.79) 794 (59.21) 3.83 3.36, 4.37 <0.001 8.69 6.83, 11.05 <0.001 
Northern 350 (35.61) 633 (64.39) 3.08 2.65, 3.57 <0.001 5.03 3.98, 6.37 <0.001 
North-Western 244 (27.63) 639 (72.37) 2.12 1.80, 2.50 <0.001 2.46 1.96, 3.09 <0.001 
Southern 718 (21.33) 2,648 (78.67) 1.51 1.35, 1.69 <0.001 1.35 1.16, 1.56 <0.001 
Western 285 (18.07) 1,292 (81.93) 1.27 1.06, 1.42 0.007 1.25 1.04, 1.51 0.018 
Year of birth         
2006 340 (19.89) 1,369 (80.11) 1.00 - - 1.00 - - 
2007 547 (20.89) 2,072 (79.11) 1.06 0.91, 1.24 0.430 1.10 0.82, 1.48 0.531 
2008 790 (22.73) 2,685 (77.27) 1.18 1.03, 1.37 0.020   1.60 1.23, 2.07 <0.001 
2009 861 (23.41) 2,817 (76.59) 1.23 1.07, 1.42 0.004 2.32 1.81, 2.98 <0.001 
2010 726 (26.71) 1,992 (73.29) 1.47 1.27, 1.70 <0.001 2.56 1.99, 3.30 <0.001 
2011 612 (33.77) 1,200 (66.23) 2.05 1.76, 2.40 <0.001 2.65 2.04, 3.43 <0.001 
2012 564 (40.75) 820 (59.25) 2.77 2.35, 3.26 <0.001 3.23 2.47, 4.21 <0.001 
2013 605 (44.75) 747 (55.25) 3.26 2.76, 3.85 <0.001 3.70 2.84, 4.82 <0.001 
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 Time from diagnosis to ART Univariable analysis Multivariable analysis 
Variable <2 weeks      n (%) >2 weeks      n (%) OR 95% CI P value aOR* 95% CI P value 
2014 548 (53.78) 471 (46.22) 4.68 3.90, 5.62 <0.001 7.78 5.83, 10.38 <0.001 
2015 140 (36.27) 246 (63.73) 2.29 1.80, 2.92 <0.001 15.48 9.44, 25.40 <0.001 
2016 0 (0) 108 (100) 0.00 - <0.001 - - - 
Birth quarter         
Jan - March 1,759 (28.96) 4,314 (71.04) 1.00 - - 1.00 - - 
April - June 1,654 (28.36) 4,179 (71.64) 0.97 0.90, 1.05 0.463 0.92 0.82, 1.04 0.179 
July - Sept 1,296 (28.88) 3,191 (71.12) 0.10 0.91, 1.08 0.928 1.03 0.91, 1.16 0.659 
Oct - Dec 1,024 (26.48) 2,843 (73.52) 0.88 0.81, 0.97 0.007 1.02 0.89, 1.16 0.791 
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Appendix 12: Chapter 8 Additional Results 
Appendix 12.1: HMIS data Summary 
 
Province 
name 
2013 2014 2015 2015 2016 
ANC 
Visits 
Tested 
HIV 
+ve 
Initi
ated 
on 
ART  
Alread
y on 
ART 
ANC 
Visits 
Tested 
HIV 
+ve 
Initiat
ed on 
ART  
Alread
y on 
ART 
ANC 
Visits 
Tested 
HIV 
+ve 
Initiat
ed on 
ART  
Alread
y on 
ART 
ANC 
Visits 
Tested 
HIV 
+ve 
Initiat
ed on 
ART  
Alread
y on 
ART 
ANC 
Visits 
Tested 
HIV 
+ve 
Initiat
ed on 
ART  
Alread
y on 
ART 
Central 61868 3730 325 1183 72932 3269 1201 2567 74101 3093 2767 2715 74101 3093 2767 2715 74091 4981 882 2856 
Copperbel
t 69582 7185 1505 2357 82245 6862 3552 4766 83279 6125 4466 5098 83279 6125 4466 5098 83400 2958 2295 4722 
Eastern 80671 2284 424 956 85556 1899 993 2161 84073 1787 1523 2416 84073 1787 1523 2416 85046 607 494 1633 
Lusaka 82881 7565 1188 2570 94041 6734 3853 6152 102023 7607 4539 6343 102023 7607 4539 6343 118035 7176 2105 6942 
Luapula 43743 2250 213 699 56092 1361 1136 1150 54523 1443 1684 1521 54523 1443 1684 1521 53826 1069 778 1325 
Muchinga 31439 584 103 226 36313 604 422 622 37061 762 694 599 37061 762 694 599 35920 2064 289 571 
North-
Western 49552 1605 167 647 59658 1191 818 663 59552 1227 1133 774 59552 1227 1133 774 56837 2932 569 1059 
Northern 34120 1368 379 875 41679 998 608 966 43502 1152 942 1300 43502 1152 942 1300 43116 1385 442 1026 
Southern 57808 3113 389 1317 73398 2832 1590 3127 76069 2684 1791 3531 76069 2684 1791 3531 77862 1065 890 2874 
Western 38742 2973 139 1139 48296 2505 1334 1882 47964 2412 2036 2064 47964 2412 2036 2064 46889 1645 1406 1948 
Total 550406 32657 4832 11969 650210 28255 15507 24056 662147 28292 21575 26361 662147 28292 21575 26361 675022 25882 10150 24956 
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Appendix 12.2: Proportion of pregnant women across provinces  
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Appendix 13: Qualitative Questionnaires 
 
13.1 Leadership Level Interview Guide 
 
Participants were leaders who have been involved in the SmartCare implementing from 
CDC, Ministry of Health and Implementing partners 
1.0 Basic information 
1. Date of interview: 
2. Interview Participant Unique ID Number: 
 2.0 Introduction  
 Self-introduction and welcoming of participant.   
 Explanation of the general purpose of the interview discussion and why the 
participant was chosen.   
 Explanation of the presence and purpose of recording equipment.  
 Addressing the issue of confidentiality.    
 Signing of the informed consent form. 
3.0 Interview 
SmartCare Development 
1. Can you tell me about the process for the development of the SmartCare Database? 
Probe  
 Who ‘drove’ the process? (Name, institution, role)  
 What was your personal role (or the role of your department/institution process?  
 Who else was involved (service providers, service users etc.)?   
 How was this participation organized? 
2. Is this process documented anywhere? 
Probe: 
E.g. Minutes of meetings – are these publicly accessible? 
3. What were the most contentious issues that were discussed during the development 
process? 
Probe: 
 How these issues were resolved? 
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4. Were there any perspectives not represented that you think it might have been useful 
to include? 
 
5. Was there anything that could have been improved in this process? 
 
6. Was there any opportunity for implementing partners to comment on the database 
development? 
 
SmartCare Implementation 
1. How are SmartCare facilities chosen? 
Probe: 
 What type of support do facilities get on inception? 
 
2. How are facilities allocated to implementing partners? 
 
3. How are people aware of SmartCare at health facility level? 
 
Probe 
 How are people made aware of SmartCare?  
 How are people working at different levels of the same health facility made 
aware?  
4. There is often a difference between how SmartCare implementation guidelines look 
on paper and how they are implemented? 
Probe  
 To what extent is it different for each implementing partner group (international/ 
local /government owned) 
 Mention some key points relevant to implementation 
 
5. What are the most contentious issues in SmartCare implementation? 
 
Probe 
 Obstacles that have risen? 
 
6. What do you think are the needs of implementing partners to facilitate data quality of 
SmartCare? 
 
7. What steps are needed to improve data quality? 
 
Data Quality Assessment 
1. How often do you verify the data that is collected from SmartCare Facilities? 
Probe 
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 Who is responsible for the verification process? 
 Is there a standard verification process tool? 
 What are the challenges? 
 
2. How often is the data collected from facilities submitted to district 
offices/provincial/head office? 
Probe: 
 Who is responsible for the submission process? 
 Is there a standard data submission procedure that you need to follow? 
 What are the challenges of the submission process? 
 
3. Do facilities always have supplies that you need for data collection and entry? 
 
4. How often do you hold implementation review sessions with IPs/ operational level 
staff? 
Probe 
 Training / Frequency? 
 How long are training sessions?  
 
5. Is the program delivered in the same manner by all partners? 
Probe 
 Staffing levels for IPs? 
 Capacity of staff for different IPs? 
 Availability of infrastructure? 
 Support services? 
 
PMTCT Services and SmartCare 
1. Can you tell me a bit about PMTCT services offered in SmartCare facilities? 
Probe: 
 What is the purpose of offering the services?  
 Do women have a choice of being part of the services?  
 How have the PMTCT services affected your work? 
 Your relationship with clients? 
 For facilities with test and treat policy – probe how this has affected the services 
offered? 
 
2. What’s the process for offering PMTCT services in these facilities? 
Probe: 
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 HIV Testing & Counselling? 
 ART Eligibility/Initiation? 
 Early Infant diagnosis ? 
3. What do you think are the main barriers within facilities that make it difficult for 
pregnant women to access PMTCT services if they need them?  
Probe:  
 Availability of some services limited to certain days?  
 Waiting times? 
4. Can you describe to me the current system of linkage between PMTCT and 
SmartCare services? 
Probe: 
 HIV Testing & Counselling? 
 ART Eligibility/Initiation? 
 HIV Prevention? 
 Early Infant diagnosis? 
5. What happens to women once they are registered for SmartCare? 
Probe: 
 Who is responsible to ensure that she is registered for SmartCare 
 How do you ensure that they are registered for SmartCare? 
 What do you do if a woman says that she does not want to be enrolled for 
SmartCare? 
6. What do you think are the main barriers within this facility that make it difficult for 
the linkage between PMTCT and SmartCare? 
Probe  
 Linkages between mothers and infants? 
 Infant Diagnosis test results? 
7. What do you think can be done to improve linkage between PMTCT and SmartCare? 
Closing  
Closing remarks: That’s all the questions I have. Is there anything else that you would like to 
tell me or ask me about?  
Thank you for participating in this discussion.   
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13.2. Operational Level Interview Guide 
 
Participants were operational level staff – M& E Managers, Database Managers 
I. Basic Data  
1. Date of interview: 
2. Implementing Partner Name:  
3. Facility Name / Code: 
4. Facility Location: 
 
II. Introduction  
 Welcome participant and introduce yourself.   
 Explain the general purpose of the interview discussion and why the participant 
was chosen.    
 Explain the presence and purpose of recording equipment. 
 Address the issue of confidentiality.    
 Read the information sheet to the participant 
 Go through informed consent procedures 
Let’s start with a few general questions about you 
1. How long have you worked here? 
2. What’s your current position? 
Probe: 
What do you do on a typical day at work? 
3. What has been your involvement with SmartCare? 
4. What training have you had on SmartCare related issues? 
Probe: 
 How long was the training? 
 Who offered training 
5. Are you adequately‐prepared to work on issues around Smart Care in general? 
 Probe:  
When was the last time you received SmartCare ‐ related training? 
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Let’s talk a little bit about the work that you do relating to PMTCT services 
8. Can you tell me a bit about PMTCT services offered in this facility? 
 Probe:  
 What is the purpose of offering the services?  
 Do women have a choice of being part of the services?  
 How have the PMTCT services affected your work? 
 Your relationship with clients? 
 For facilities with test and treat policy – probe how this has affected the 
services offered? 
9. What’s the process for offering PMTCT services in this facility? 
Probe 
 PMTCT Cascade? 
10. How do you manage your time when there are many clients in this facility? 
11. Do you always have supplies that you need for PMTCT services? 
12. Is there anything that you think can be done to improve PMTCT services in this 
facility? 
 
Let’s talk about SmartCare 
13. When did this facility start implementing SmartCare? 
Probe: 
 How was the facility selected? 
 What type of support did this facility get during inception? 
 Is the SmartCare for this facility Paper based or Computer based? 
 Why does this clinic use this method for data collection?  
 Will this change?   
 What are the problems with the current system?  
 Is it the same system for all clinics and clients in the facility?  
 What happens if a client comes in from another health facility? 
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  Can their records be accessed and managed?  
 How are their data entered?  
14. How often do you verify the data that is collected in this facility? 
Probe 
 Who is responsible for the verification process? 
 Is there a standard verification process tool? 
 What are the challenges? 
15. How often do you submit data that is collected in this facility to district 
offices/provincial/head office? 
Probe: 
 Who is responsible for the submission process? 
 Is there a standard data submission procedure that you need to follow? 
 What are the challenges of the submission process? 
16. Do you always have supplies that you need for data collection and entry? 
 
17. What do you think are the main barriers within this facility that make data collection 
and entry difficult? 
18. What do you think can be done within the health care system to improve data 
collection and entry under SmartCare? 
Probe:  
 What difference do you think this would make for you? For patients? 
Let’s talk about link between PMTCT services and SmartCare 
19. Can you describe to me the current system of linkage between PMTCT and SmartCare 
services? 
Probe: 
 HIV Testing & Counselling? 
 ART Eligibility/Initiation? 
 Early Infant diagnosis? 
20. What happens to her once she registers for SmartCare? 
Probe: 
 Who is responsible to ensure that she is registered for SmartCare? 
 How do you ensure that they are registered for SmartCare? 
 What do you do if a woman says that she does not want to be enrolled for 
SmartCare? 
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21. Can you tell me about a particularly difficult case, mentioning no woman’s or staff’s 
names, that you’ve had where it was hard for you to link an HIV positive woman to 
SmartCare services?  
Probe:  
 How would you do things differently if you were in that situation again? 
22. Are there any aspects of SmartCare service provision that you think could be 
improved? Probe:  
 What difference do you think this would make for you?  
 For patients? 
23. What do you think are the main barriers within this facility that make it difficult for the 
linkage between PMTCT and SmartCare? 
24. Is there anything else that you think could be done by other people within the health 
system to help facilitate this linkage into SmartCare? 
25. Are there things about being a health worker at this facility that you would like to 
improve?   
 Probe:  
 What makes your job easier?  
 What makes it harder?  
What difference do you think this would make for you? For patients? 
 
Closing remarks: That’s all the questions I have. Is there anything else that you would like 
to tell me? 
 
Thank you for participating in this discussion. 
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13.3 Data Entry Level Interview Guide 
 
A. Basic Data  
B. Date of interview: 
C. Implementing Partner Name: 
D. Facility Name / Code: 
E. Facility Location: 
F. Time interview started: 
G. Time interview ended: 
 
B. Introduction  
 Welcome participant and introduce yourself.   
 Explain the general purpose of the interview discussion and why the participant 
was chosen.    
 Explain the presence and purpose of recording equipment. 
 Address the issue of confidentiality.    
 Read the information sheet to the participant 
 Go through informed consent procedures 
Let’s start with a few general questions about you 
1. How long have you worked here? 
2. What’s your current position? 
Probe: 
What do you do on a typical day at work? 
3. What training have you had on SmartCare related issues? 
Probe: 
 How long was the training? 
 Who offered training 
4. Are you adequately‐prepared to work on issues around Smart Care in general? 
 Probe:  
When was the last time you received SmartCare ‐ related training? 
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Let’s talk about Data entry and collection 
5. When did this facility start implementing SmartCare? 
Probe: 
 How was the facility selected? 
 What type of support do they get during inception? 
6. Can you explain to me the data collection and entry process for SmartCare? 
Probe 
 Paper based or Computer based. 
7. How do you manage your time when there are many clients in this facility? 
8. What do you think are the main barriers within this facility that make data collection 
and entry difficult? 
9. Are there any aspects of SmartCare data entry that you think could be improved? 
 Probe:  
 What difference do you think this would make for you? For patients? 
10. How often do you verify the data that is collected in this facility? 
Probe 
 Who is responsible for the verification process? 
 Is there a standard verification process tool? 
 What are the challenges? 
 
11. How often do you submit data that is collected in this facility to district 
offices/provincial/head office? 
Probe: 
 Who is responsible for the submission process? 
 
12. Is there a standard data submission procedure that you need to follow? 
Probe: 
 What are the challenges? 
 
13. Do you always have supplies that you need for data collection and entry? 
 
14. What are the challenges of data collection and entry? 
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15. What do you think can be done within the health care system to improve data 
collection and entry under SmartCare? 
 
Let’s talk a little bit about the work that you do relating to PMTCT services 
16. Can you tell me a bit about PMTCT services offered in this facility? 
 Probe:  
 What is the purpose of offering the services?  
 Do women have a choice of being part of the services?  
 How have the PMTCT services affected your work? 
 Your relationship with clients? 
 For facilities with test and treat policy – probe how this has affected the 
services offered? 
17. What’s the process for offering PMTCT services in this facility? 
18. How do you manage your time when there are many clients in this facility? 
Probe: 
 Do you spend less time on some of the PMTCT Cascade steps? 
19. What do you think are the main barriers within this facility that make it difficult for 
pregnant women to access PMTCT services if they need them?  
Probe:  
 Distance to facilities  
 Availability of some services limited to certain days?  
 Waiting times? 
Let’s talk about link between PMTCT services and SmartCare 
20. Can you describe to me the current system of linkage between PMTCT and 
SmartCare services? 
Probe: 
 HIV Testing & Counselling? 
 ART Eligibility/Initiation? 
 HIV Prevention? 
 Early Infant diagnosis? 
 
21. What happens to her once she registers for SmartCare? 
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Probe: 
 Who is responsible to ensure that she is registered for SmartCare? 
 How do you ensure that they are registered for SmartCare? 
 What do you do if a woman says that she does not want to be enrolled for 
SmartCare? 
22. Can you tell me about a particularly difficult case that you’ve had where it was hard 
for you to link an HIV positive woman to SmartCare services?  
Probe:  
How would you do things differently if you were in that situation again? 
23. What do you think are the main barriers within this facility that make it difficult for 
the linkage between PMTCT and SmartCare? 
24. Are there any aspects of PMTCT SmartCare linkage service provision that you think 
could be improved? Probe:  
What difference do you think this would make for you? For patients? 
25. Are there things about being a health worker at this facility that you would like to 
improve?   
 Probe:  
 What makes your job easier?  
 What makes it harder?  
If necessary, provide examples: need more staff because patient load is high, need 
training, salaries should be paid on time etc. 
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13.4 SmartCare Facility Managers Interview Guide   
I. Basic Data  
 Date of interview: 
 Implementing Partner Name  
 Facility Name / Code 
 Facility Location: 
 Time interview started 
 Time interview ended 
II. Introduction  
 Welcome participant and introduce yourself.   
 Explain the general purpose of the interview discussion and why the participant 
was chosen.    
 Explain the presence and purpose of recording equipment. 
 Address the issue of confidentiality.    
 Read the information sheet to the participant 
 Go through informed consent procedures 
Let’s start with a few general questions about you 
1. How long have you worked here? 
2. What’s your current position? 
Probe: 
What do you do on a typical day at work? 
Let’s talk a little bit about the work that you do relating to PMTCT services 
3. Can you tell me a bit about PMTCT services offered in this facility? 
 Probe:  
 What is the purpose of offering the services?  
 Do women have a choice of being part of the services?  
 How have the PMTCT services affected your work? 
 Your relationship with clients? 
 For facilities with test and treat policy – probe how this has affected the 
services offered? 
4. What’s the process for offering PMTCT services in this facility? 
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Probe 
 PMTCT Cascade? 
5. How do you manage your time when there are many clients in this 
facility? 
Probe: 
 Do you spend less time on some of the PMTCT Cascade steps? 
6. Do you always have supplies that you need for PMTCT services? 
 
7. What do you think are the main barriers within this facility that make it 
difficult for pregnant women to access PMTCT services if they need 
them?  
Probe:  
 Distance to facilities  
 Availability of some services limited to certain days?  
 Waiting times? 
8. Is there anything that you think can be done to improve PMTCT services 
in this facility? 
 
Let’s talk about SmartCare 
9. When did this facility start implementing SmartCare? 
Probe: 
 How was the facility selected? 
 What type of support did this facility get during inception? 
 
10. What has been your involvement with SmartCare? 
11. What training have you had on SmartCare related issues? 
12. Are you adequately‐prepared to work on issues around Smart Care in 
general? 
 Probe:  
 When was the last time you received SmartCare ‐ related training? 
13. Who is responsible for verifying the data collected in this facility? 
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Probe: 
 Roles of those responsible? 
 Frequency of verifications? 
14. Do you always have supplies that you need for SmartCare services? 
15. Is there anything that you think can be done to improve SmartCare 
services in this facility? 
Let’s talk about link between PMTCT services and SmartCare 
16. Can you describe to me the current system of linkage between PMTCT 
and SmartCare services? 
Probe: 
 HIV Testing & Counselling? 
 ART Eligibility/Initiation? 
 Early Infant diagnosis? 
17. What happens to her once she registers for SmartCare? 
Probe: 
 Who is responsible to ensure that she is registered for SmartCare? 
 How do you ensure that they are registered for SmartCare? 
 What do you do if a woman says that she does not want to be enrolled for 
SmartCare? 
18. Can you tell me about a particularly difficult case that you’ve had where it 
was hard for you to link an HIV positive woman to SmartCare services?  
Probe:  
 How would you do things differently if you were in that situation again? 
19. Are there any aspects of SmartCare service provision that you think could 
be improved? Probe:  
 What difference do you think this would make for you?  
 For patients? 
20. Are there things about being a health worker at this facility that you would 
like to improve?   
 Probe:  
 What makes your job easier?  
 What makes it harder?  
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If necessary, provide examples: need more staff because patient load is high, need 
training, salaries should be paid on time etc. 
 Probe: 
 What difference do you think this would make for you? For patients? 
21. What do you think are the main barriers within this facility that make it 
difficult for the linkage between PMTCT and SmartCare? 
22. Is there anything else that you think could be done by other people within 
the health system to help facilitate this linkage into SmartCare? 
Closing remarks: That’s all the questions I have. Is there anything else that you would like 
to tell me? 
 
Thank you for participating in this discussion 
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13.5 Focus Group Discussions Interview Guide - English 
 Date of interview: 
 Implementing Partner Name:  
 Facility Name / Code: 
 Facility Location: 
Objectives:  
 Share different experiences (good and bad) related to the use of SmartCare for 
PMTCT services. 
  Identify the major barriers and facilitating factors that affect women’s Uptake of 
PMTCT services  
Materials:  
Flip chart paper and pens  
Pens for participants to fill out informed consent and demographic information 
 Read and have participants sign consent forms.   (5 minutes) 
 Have participants’ complete information form.   (5 minutes) 
 Explain focus group process.      (5 minutes)  
As explained in the consent form, everything you say here is confidential.  Everything you 
say in this discussion will be kept private.    It is important to us that you give us your honest 
opinions. We will be tape‐recording your comments. The tape will be kept confidential, and 
names will not be used in any quotations that might be included in written reports.  
Our discussion will last about two hours. To cover everything and end on time, I may 
sometimes move the discussion on, but everyone will have an opportunity to speak. Please 
speak clearly, one at a time, and share your opinions. There are no right or wrong answers.   
We are interested in your opinions and you do not have to agree with one another ‐ we are 
interested in hearing different opinions. 
INTRODUCTIONS (5 minutes): Get participants interacting, and prepare for introductions 
and expectations.   Introductions: Ask participants to turn to their neighbour and ask them a 
few things about themselves so that each pair can introduce each other to the larger group. 
Explain that if people don’t want to use their real names they can choose a fake name. Ask 
each person to introduce her partner and two things about them. As part of these 
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introductions, introduce yourself and the note‐taker (and anyone else from the research team 
who is in the room). 
OBJECTIVE (5 minutes): Explain the objectives for the workshop e.g. through this 
discussion, our objective is to find out more about the SmartCare and PMTCT Services. 
We will listen and learn from you to get a better understanding of the services and your 
ideas on how to improve them. 
GROUND RULES (5 minutes):   Say “We would like to hear everyone’s ideas and have a 
good meeting. What rules should we use in working together today?” Give an example of 
one rule (e.g. listen to and respect one another’s views), and then ask for other rules. 
Record suggestions. 
If the group doesn’t mention CONFIDENTIALITY, add it to the list and explain 
“You might want to share personal stories during this discussion, but your stories 
should NOT be shared with anyone else after our discussion is over.” 
Examples of Meeting Rules:  
 Encourage everyone to participate to the extent that they feel 
comfortable. 
 Listen to one another and respect one another’s views 
 Don’t interrupt when a person is speaking  
 Keep things confidential  
 Turn off cell phones 
Once the list is completed, say “These will be our rules for this discussion so that we can all 
be comfortable. 
 
1. Can you describe the process from when the health worker first talked to you about 
PMTCT? 
Probe 
 How did the health worker tell you? 
 What did you talk about? 
 Then what happened? 
2. What do you remember about the health worker? 
Probe:  
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 Can you remember any good things about the interaction with her?  
 And any bad things? No need to mention any staff names. 
3. When were you enrolled under SmartCare?  
PROBE:  
 Where / Which Facility?  
 Who did you talk to?  
 Do they have a SmartCare card? 
 
4. Did the health worker take you to the SmartCare Department? 
Probe:  
 Can you tell me about your experience at the SmartCare Department on that day? 
 What happened when you first arrived? And then what? 
 What services were you given? 
 
5. What did they tell you about SmartCare services? 
Probe:  
 What did s/he say to you about it? 
6. Did you tell anyone that you are enrolled under SmartCare?  
Probe: 
 Who did you tell? 
 When did this happen?  
 How did they react when you told them?  
(Deal with each person to whom they have disclosed individually)  
 Did they understand?  
 Has this changed over time?  
 
7. Can you describe people’s attitude towards SmartCare? 
Probe 
 Did they show anyone their SmartCare cards? 
 
8. How often do you come to this facility? 
Probe  
 Reasons? 
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9. Is this facility accessible? 
Probe 
 Mode of transport? 
 Distance travelled? 
(Deal with each person to whom they have disclosed individually)  
10. How long do you usually take at the facility? 
Probe 
 Waiting time? 
 Waiting area? 
 Privacy? 
 Is it longer for people on SmartCare compared to other general patients? 
(Deal with each person to whom they have disclosed individually)  
11. Do you think that pregnant women who test HIV‐positive want to access to PMTCT 
services?  
Probe:   
 Type of services?  
 Why?  
 Why not? 
(Services along the PMTCT Cascade) 
 
12. Do most women who access PMTCT services disclose their HIV status to their 
partners? And families? 
Probe:  
 Why?  
 Why Not. 
 
13. Does stigma persist as an issue affecting decisions to access PMTCT related services? 
Probe:  
 In what ways? 
  How do some women overcome this?  
  
14. Do you think that people’s partners and families are generally supportive of pregnant 
women accessing PMTCT services if they need them?  
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Probe:  
 Why? Why not?  
 What kind of support do they provide?  
 In what ways are they unsupportive?  
 How about the community? 
15. What are the things that have helped you overcome some of the barriers that we’ve 
talked about and helped you come to access PMTCT services at this facility? 
16. What do you think can be done to make it easier for pregnant women to access 
PMTCT services? 
WRAP‐UP (5 mins): 
 Thank you very much. We’ve now gone through all of our questions for this discussion 
group and we just have a few minutes left. Is there anything else that any of you would 
like to add or to ask? 
Thank you very much for taking part. There is a drink and snack for each of you here and 
please see ……. to collect your compensation for taking part. 
 
Interviewer Notes 
 Comments about respondents 
 Comments on specific questions 
 Any other comments 
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13.6 Bemba Focus Group Discussions Interview Guide 
 Date of interview: 
 Implementing Partner Name: 
 Facility Name / Code: 
 Facility Location: 
Efyotulefyawa 
 Ukulanda ifintu ifingi ifyapusanapusana (ifisuma ne fibi) ifikatishanya 
nobubomfyi bwa SmartCare aya PMTCT 
 Ukumona inshila ishikulu ishilenga bana mayo ukukana poka amafwilisho aya 
PMTCT 
Ifilefyaika: 
Ama pepala ayakulembapo ayakulu naba bopeni 
Amabopeni yabantu abalesendako ulubali ukubomfya ukulembela pafipepala 
ifyakusuminisha nefyo bekala nefyo bakwata. 
 Belenga elyo uleke abalesendako ulubali uku saina ifipepala ifyakusuminisha. (5 minutes) 
 Leka abalesendako ulubali bapwishe ukulemba ichipepa ichilanda pafyo bekala (5 
minutes) 
 Londolola inshila iyaku kulandishanya uku. (5 minutes) 
Kwati efyo twalondolola mwipepala yakusuminisha fyonse efyo twalalanda pano fyalaba 
efya nkama.Fyonse efyo mwalalanda mukulandishanya uku fikasungwa mu 
nkama.Chikankala sana kuli ifwe ikutupelaamatontokanyo yenu ayachine.Tukala mi senda 
amashiwi yenu.Iyi Tape ukasungwa munkama elyo amashina yenu tayakabonfyewepo 
mukulanda ukulikonse pakubomfya mukulemba report. 
Ukulandishanya kwesu kwalasenda inshita iyalakumako kuma hola yabili.Kuti tupwishe 
fyonse munshita,munshita shimbi kuti nasenda ukulandishanya oku,mwisakamana bonse 
mwalapelwa inshita yakulanda.Ndelomba mulelandisha,umuntu umo panshita imo nokulanda 
amatontokanyo yenu.Takuli ubwasuko ububi nangula ubusuma.ifwe tulefyaya fye ama 
tontonkanyo yenu eyo tamufwile ukusuminishanya-tulefwaya ukumfwa amatontonkanyo 
ayapusanapusana. 
 Pakwamba: Leka abalesenda ulubali bale landishanya elyo upekanye ukuishibisha 
nefyo balechetekela.Ukuishibisha: eba abalesendamo ulubali uku lolesha kuli ba 
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nebba babo elyo bepushane ifintu ifinono pali bene pakuti abantu babili babili 
baishibishe kwibumba ilikulu. 
 Eba umuntu nomuntu eshibishe abantu pamunaknwe pafintu fibili pali ena.Londolola 
ukuti nga abantu tabalefwaya ukubomfya amashina yabo ayachine kuti basala 
ukupanga amashina nga inshila yaku ishibisha.Ishibishe na ba kukwafwa ukulemba 
(elyo nomuntu onse owo mulebomba nankwe fya kufwailikisha mumuputule uyu.) 
 Efyo tulefyaya: Londolola ichikulu cha workshop,kwati ukupitila mukulandishanya 
uku,efyotulefywaya kusanga ifingi pamafwilisho ya SmartCare na PMTCT.Twala 
umfwa nokusambilila kuli imwe pakuti tusende ukumfwikisha ukusuma pa ma 
fwilisho elyo nama tontokanyo yenu efyo tunga twala pantanshi amafwilisho aya. 
 Amafunde Yakukonka: Landa tulefwaya ukumfwa amatontokanyo yamuntu onse elyo 
nokukwata meeting isuma.Mafundeshi twalabomfwa pakuti tubombele chapamo 
lelo.Pela ichishibisho cha funde chimo(Kwati. Ukumfwila nokupela umuchinsi 
amatontokanyo yamuntu ulionse) Elyo wipushe yambi amafunde.Lemba efyo 
balelanda. 
 Inga ibumba talilandile INKAMA, lundapo kufyo balandile nokulondolola ukweba ati 
kuti bafwaya ukulanda amashiwi ayakuminefye bena pakulandishanya uku, koma aya 
amashiwi tayafwile ukusabankanyishiwa kumuntu ulionse ngatwapwisha 
ukulandishanya uku. 
Ifishibisho fya mafunde aya meeting: 
 Bakoseleshe bonse ukusendako ulubali pakweba ati bayumfweko 
ukukakuluka. 
 Ukumfwilana noku pela umuchinshi kutontokanyo lyamunenu 
 Takuli ukuputukisha umuntu inga alelanda 
 Sungeni ifintu fyonse munkama. 
 Shimyeni ama lamya. 
Inga babwisha fyonse ukulanda, Landa ati aya eyalaba amafunde yesu mukulandishana uku 
pakweba ati bonse tube abakakuluka. 
1. Ndondololweniko inshila ukwamba elyo mwalandile na babomfi bafyabumi 
akakwambililapo pali PMTCT.  
Ipukisha 
 Bamwebeleshani ababomfi ba fyabumi? 
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 Finshi mwalandilepo? 
 Elyo ninshi ichachitike? 
 Finshi mwibukishapo paba bomfi babumi? 
Ipukisha 
Kuti mwaibukishako ichintu ichisuma mukulanda kwenu mwakwete nabena? 
Inga ichintu ichibi? Tachilefwaika ukulanda amashima yaba bomfi. 
2. Mwailembeshe lwisa ku SmartCare? 
Ipukisha 
 Kwisa/Inchende isa? 
 Mwalandile nabanani? 
 Mwalikwata Kadi iya SmartCare? 
 
3. Bushe ababomfi ba fyabumi balimitwala kuchipao cha SmartCare? 
Ipukisha 
 Njebeniko efyo mwwaumfwile elyomwali kuchipao cha SmartCare bulya 
bushiku? 
 Finshi fwachitike elyo mwafikilefye pakwamba?Elyo finshi fwakonkelepo? 
 Mafwilisho nshi eyo bamipele? 
4. Finshi bamwebele pama fwilisho ya SmartCare? 
Ipukisha 
 Finshi balandile kuli imwe pali ifi? 
5. Bushe mwali ebapo umuntu ulionse ukweba ati mwali ilembesha ku SmartCare? 
Ipukisha 
 Nabanani mwaebele? 
 Nilisa fyachitike ifi?  
 Bachitile shani elyo mwabebele pali ifi? 
 (bomba nomuntu uwo baebele umoumo) 
Bali umfwikisha? 
Bushe fwalichinja nenshita ipitilepo? 
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6. Ndondololweniko imitontonkanyishishe yabantu pali SmartCare? 
Ipukisha 
 Bushe balelanga ama kadi yabo aya SmartCare? 
7. Mwisa imiku inga kunchende eyi? 
Ipukisha 
 Umulandu wanshi? 
8. Bushe iyi nche ilifye apasuma? 
Ipukisha 
 Mubomfya transipoti yashani? 
 Inga Ubutali mukwenda? 
 (bomba nomuntu uwo baebele umoumo) 
9. Musende inshita itali shani panchende apa? 
Ipukisha 
 Inshita yakulolela? 
 Panchende yakulolelela? 
 umwafisamikwa? 
 Bushe chilasenda inshita itali kulibalya ababa pa SmartCare nga mwalinganya na 
balwele bambi?  
(bomba nomuntu uwo baebele umoumo) 
10. Bushe muletontokanya ati banamayo abamafumo abobasanga notushishi twa HIV 
balafwaya uku sendako amafwilisho aya PMTCT? 
Ipukisha 
Mitundu yama fwilisho? 
Ninshi? 
Ninshi pantu? 
 
11. Bushe bana mayo abengi abasenda amafwilisho aya PMTCT balanda efyo babasanga 
kubyena mwabo?naba lupwa? 
Ipukisha 
Ninshi? 
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Ninshi pantu? 
12. Bushe ukwimwenamo echintu ichilenga ukukana ukupoka amafwilisho ubukumine 
PMTCT? 
Ipukisha 
 Munshila nshi? 
  Inga bambi bana mayo bachita shani pali ichi? 
13. Bushe muletontokanya ukweba ati abena mwabo naba lupwa mukumonafye balafwa 
banamayo abamafumo mukusenda amafwilisho aya PMTCT inga baleyafwaya? 
Ipukisha 
 Ninshi?ninshi pantu? 
 Babapela ubwafwilisho bwashani? 
 Munshilanshi esho tabafwila? 
 Inga abantu? 
14. Fintu nshi efyamyafwile ukupitapo ifintu ifikanya efyo twachilalandapo elyo 
nokumyafwa ukusendako amafwilisho pa nchende eyi? 
15. Finshi muletontonkanya ati kuti fya afwako banamayo abamafumoukusendako 
amafwilisho aya PMTCT? 
Pwisha 
Twatotela sana.Natupitamo amepusho yonse aya kulandishanya kwesu mwibumba eli 
elyo tushele fye nakashita akanono.kuliko chiimbi echo mulefwaya ukulundapo nagula 
ukwipusha? 
 
Interviewer Notes 
 Comments about respondents 
 Comments on specific questions 
 Any other comments 
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13.7 Nyanja Focus Group Discussions Interview Guide 
 Date of interview: 
 Implementing Partner Name:  
 Facility Name / Code: 
 Facility Location: 
Chimenetifuna 
 Ku uzana vintu vosiyanasiyana (vabwino na voipa) mukugwilizana 
ndikusebenzesa ma masamaliloyabwino yama tandizo ya PMTCT. 
 Kuona njila zikulu zamene zimalesa azimai kutengako matandizo ya PMTCT 
Zofunikila: 
Mapepala yolembapo yakulu ndi ma bolopeni 
Ma bolopeni niya otengakombali kuti basebenzese kulembela zintu zovomeleza kutengako 
mbali ndi mwamene bankalila  
 Belenga ndiku ona kuti otenga mbali ba saina vipepalo vovomeleza, (5 minutes) 
 Onakuti otengambalai basiliza kulemba pa pepala la nkani (5 minutes) 
 Fotokoza njila yo kambilana uku (5 minutes). 
Monga mwamene tafotokozela mupepala lovomeleza vonse vamene muzakamba kuno 
vizankala vachisinsi.Vonse vamene muzakamba visungidwa mobisika.Nicholinga ngako kuti 
mutipase maganizo yanu ya zoona.Tiza kutengani mau mu tape mayanko yanu, Iyi Tape 
izasungidwa mwachisinsi ndipo mazina yanu siyazakasebenzesewa olo kuikidwa mu report 
yomwe tizalemba. 
Uku kukambilana kwatu kuzatenga ma hola yabili.Kuti tisilize vonse pa ntawi, ntawizina 
ningatenge kukambilana kwatu, koma aliyense azapasiwa mupata okamba.nipemba 
muzikamba konveka,umozi pantawi, ndi kukamba maganizo yanu.Kulibe yanko yachendi ndi 
yanko ya boza.Ise tifuna chabe maganizo yanu ndipo simuyenekela kuvomelezana tifuna 
kunvela maganizo yosiyana siyana. 
CHOYAMBILILA: (ma mineti 5) Ona kuti otenga mbali bakambisana ndi kukonzekela 
kuzifotokoza ndi zamene balindilila kuona.Kuzifotokoza:Uza otenga mbali kuti aliyense 
ayanga nebba wake ndikumufunsa zintu zing’ono pali beve kuti bantu babilibabili 
bazifotokoze ku gulu likulu.Funsa muntu aliyense afotokoze munzake ndikukamba zintu 
zibile palimunzake.Bauze kuti ngati bantu sibafuna kusebenzesa mazina yao yazo ona banga 
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sanke kusebenzesa mazina yozipangila monga mbali yo zifotokoza,zikambe iwe ndi 
kalembela(ndipo na aliyense alimu gulu yanu yo fufuza ali mu chipinda umu) 
Chofunikila (maminati 5): Bauze chamene mwachitila iyiworkshop, monga kupitila mu 
kukambisana kwatu uku, tifuna kuzibilapo vambili pali SmartCare ndi matandizo ya 
PMTC.Tizanvelela ndikupunzila kuchokela kuli imwe monga mwamene tingapelekele 
pasogolo matandizo aya 
Malamulo (maminati 5): Kamba ‘Tifuna kunvela maganizo yamuntu aliyense ndipo 
nilinamalamulo yamene yiyenekela kusebenzesa pamozi lelo?Pasa chisanzo cha lamulo 
limozi (monga, nvelela ndikupasa ulemu ganizo yamunzako), ndipo funsa malamuloyenangu 
ndikulemba zizakambidwa. 
Ngati gulu sizakamba CHISINSI, ifakepo pa mundandanda ndiku bauza kuti munga fune 
kukamba chntu chanu chabe pakukambilana uku koma ichisichiyenekela ku uziwa kumuntu 
aliyense tikasiliza kukambilana uku. 
Zisanzo za Malamulo ya meeting: 
 Ona kuti bonse batengako mbali kufikila kuti bazinvela kumasuka. 
 Nvelelani muntu umozi ndikupasa ulemu maganizo yamunzanu 
 Osajubisa muntu ngati akamba 
 Sungani vintu mwachisinsi 
 Zimyani ma lamya. 
. 
Mukasiliza mundandanda oyu, Kamba ‘aya ndiye yazankala malamulo yatu pakukambilana 
kwatu kuti tonse tinkale omasuka. 
1. Ni fotokozele njila kuyambila pamene banchito ba zaumoyo banakamba 
naimwe pali PMTCT koyamba? 
Funsisisa 
 Banaku uzani bwanji banchito ba zaumoyo? 
 Muna kambisana chani? 
 Manje nichani chinachitika? 
2. Nichani chamene mukumbukila pa banchito bazaumoyo? 
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Funsisisa 
 Mungakumbukileko chintu chilichonse chabwino pakukambisilana kwanu 
ndibeve? 
 Nga vintu voipa? Kulibe chofunikila kukamba na zina yaba nchito aba. 
 Munalembesa liti kunkala pa SmartCare? 
Funsisisa 
 Kuti/dela liti? 
 Munakamba nabandani? 
 Kodi muli nakadi ya SmartCare? 
 
3. Kodi banchito zaumoyo banakupelekani ku chigao cha SmartCare? 
Funsisisa 
 Mungani uze mwamene munakunvelela ku chigao cha  
 Nichani china chitika pamene munayambilila kufika? Manje chinakonkapo? 
 Munapasiwa tandizo yabwanji? 
4. Bana ku uzana chani pa matandizo ya SmartCare?         
Funsisisa 
 Bana ku uzani chani pali ichi? 
5. Muna uzako aliyense kuti ndimwe bolembesewa ku SmartCare? 
Funsisisa 
 Muna Uza Ndani? 
 Ichi chinachitika liti? 
 Bana oneka pamene muna bauza? 
(Sebenza na muntu aliyense wamene bana uza umozindiumozi) 
 Chinvela? 
Kodi ichi chachinja pa ntawi yapita? 
 
6. Mungafotokozani maganizo yabantu pali SmartCare? 
Funsisisa 
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 Benzo langiza aliyense ma SmartCare cards yao? 
 
7. Muma bwela kangati kudela ili? 
Funsisisa 
 Zifukwa? 
 
8. Ili dela lili pafufi nakwanu? 
Funsisisa 
Muma sebenzesa transipoti yabwanji? 
Nipatali bwanji kuyenda? 
 (Sebenza na muntu aliyense wamene bana uza umozindiumozi) 
9. Mumankala ntawi itali bwanji kupadela? 
Funsisisa 
 Ntawi yo lindilila? 
 Pa nchende yo lindilila 
 Kubbisika? 
 Kodi chitenga ntawi  ku bantu baja balipa SmartCare kulinganiza nabantu 
bodwala benangu chabe? 
(Sebenza na muntu aliyense wamene bana uza umozindiumozi) 
10. Muganiza kuti azimai baja bali napakati bamene bapezeka HIV-positive bangafune 
tandizo ya PMTC? 
Funsisisa 
 Matandizo ya bwanji? 
 Chifukwa 
 Chifukwa chachani? 
 
11. Kodi azimai bamene batengako tandizo ya PMTCT bamauzako nkalidwe yao ya HIV 
kuli asumbali bao? Ndi ba banja? 
Funsisisa 
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 Chifukwa. 
 Chifukwa chachani? 
12. Kodi kuzionelamo chingankale nichintu chamene chimalengesa kusa tenga matandizo 
yogwilizana na PMTCT? 
Funsisisa 
 Munjila Bwanji? 
 Nanga bazimai benengu bamachita bwanji kugonjesa ichi? 
13. Muganiza kuti bamuna babantu ndi ba banja bamatandizila kuli bazimai balindipakati 
bamene batenga matandizo ya PMTCT ngati bayafuna? 
Funsisisa 
 Chifukwa? Chifukwa chani? 
 Bamapasa kutandizila kwabwanji? 
 Nimunjila bwanji zamene sibamatandizila? 
 Nanga muma dela yao? 
14. Nivintu bwanji vamene vina kutandizani kugonjesa njila zina zamene zivaliza zamene 
takambapo ndipo zina kutandizani kubwela kutenga ma tandizo ya PMTCT pa dela 
ili? 
 
15. Nivichani vamene muonamonga vingachitiwe kuti vi pepukiseko njila ya azimai bali 
ndipakati kuti bazitengako matandizo ya PMTCT? 
Maliza (mamineti 5): 
Zikomo kwambili.Tapitamo mumafunso yatu yonse mukukambisana kwagulu ili ndipo 
tasala chabe ndi maminati yang’ono.kuliko china chamene mufuna kuikilapo kapena 
kufunsa? 
Interviewer Notes 
 Comments about respondents 
 Comments on specific questions 
 Any other comments 
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13.8 Tonga Focus Group Discussions Interview Guide 
 Ibuzuba bwakubuzya:  
 Izina lya muntu ugwasilizya: 
 Izina lyabusena/chizyibilo: 
 Nkobujanika: 
Nchetuyanda: 
 Kobambila izichito ziindeneneindene (izibi azibotu) zijatikizya eyi SmartCare kulu 
gwasho lwa PMTCT. 
 Yandaula twaambo tupati itukasya bamakaintu ikutola lubazu mu magwasho a 
PMTCT. 
Izibelesho: 
Ipepa lyakusandula ama bopeni 
Ima bopeni ngabasikutola lubazu kutegwa babelashe kulembela imapepa akuzumina a 
mbobapona.  
Kobala alimwi bonakuti basikutola lubazu ba saina izipepa zyakuzumina. (5 minutes) 
 Bona ikuti basikutola lubazu bamanizya kulemba ipepa lya nkani.  (5 minutes) 
 Pandulula nzila ya mubandi oyu  (5 minutes 
Mbuli pepa lyaku zumina mboli pandulula,zyonse zetutambaule ano zilaba zyama 
seseke.Zyonse zyomutaambe mumubandi oyu ziyo bambwa kumbali.Echi chilelede 
kulindiswe loko kulindiswe ikutegwa mwatupa imiyeyo yanu yanchobeni.Tunikubweza 
majwi anu mumubandi.I tepu liyobambwa muma seseke alimwi imazina anu tawobeleshegwi 
kulikonse na kwabelesha muma report ngetutikalembe.  
Imubandi yesu ulatola ima hola atandila kusika kuli obilo.kuti tumazye zyonse akumanizya 
muchiindi.inga muziindi ndini kubweza mubandi oyu, pesi nonse mulapegwa ibusena 
bwakwambaula.Ndalomba kamwambaula kwakuvwika,muntu omwe achiindi chipedwe 
akwamba mizeyo yanu.Kwina bwinguzi buluzi abitaluzi.swebo tuyanda biyo imiyeyo yanu 
alimwi tamwelede ikuzumizyana tuyanda ikunvwa imizeyo indeneindene 
KUTANGUNA :Bona ikuti basikutola lubazu balimukwambauzyana alimwi libambile ikuti 
bali pandulule azyobayeyela.Kutanguna:buzya basikutola lubazu ikutu balange muntu 
ngobatobelana awalo alimwi balibuzye azyintu zishonto alimbabo kutegwa bobilobobilo 
balipandulule kukabungwe konse.Ko ambila muntu amuntu apandulule mwenhinyina azintu 
zyobilo alimbabo.kobapanduluda ikuti na bantu tabayandi kubeesha mazina anchobene inga 
babelsha bazina akulipangila.Mbuli kulipandulula uku,lipandulule asikukulembela (aliwi 
kufumbwa muntu ngomulamwi mukubuzya oku uli abusena obu) 
NCHETUYANDAULA: pandulula nchetuyandaula mukwi ishana oku mbuli kwindila 
mukwambauzyana oku,nchetuyandaula nkuzibilao zinji ali SmartCare amagwasho a 
PMTCT.Tuyaku swilila akwiya kuzwakulindinywe kutegwa kunvwisisya kabotu amagwasho 
azyomuyeya mbutunga twasumpula agwasho aya. 
Imilao yesu: kwaamba ‘tuyanda kunvwa muntu onse zyayeya kutegwa tube amubandi 
mubotu.Tulabeleka imilao yabuti antomwe sunu?’’Kupa chitondezyo cha mulao omwe ( 
Mbuli kuswilila akupa bulemu muntu zyayeya) alimwi buzya imilao imbi akulemba 
zebatambe. 
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Ikuti tibamba MASESEKE,kuibika amundandanda akupandulula.Inga mwayanda 
kutwambila nkani igamide biyo ndinywe mumubandi oyu,pesi nkani yanu tayelede kupegwa 
kumuntu uli onse twamanizya kwambaula oku. 
Zitondezyo zyamilao yamubandi oyu: 
 Kugwasyana tonse ikutolalubazu kutegwa twalinvwa 
kwanguluka. 
 Kuswililana akupa bulemu muzezo wa umbi. 
 Kwina kujata muntu amulomo anikwambaula. 
 Tubambe zintu mumaseseke 
 Kumuzina mawaile 
Bamanizya kwambaula zyonse,amba ‘eyi njitibe milao yesu mumubandi wesu kutegwa tonse 
twanguluke 
1. Kumundipandulwida nzila kuzwa nimwatanguna kwambaula ababelesi bazya 
buummi ali PMTCT 
Kobuzisisya 
 Ino mubelesi wazya bumi wakamwambila buti? 
 Mwakambaula nzi? 
 Mpona ninzi chakachitika? 
2. Ninzi nchomuyeya amubelesi wazyabumi? 
Kobuzisisya 
 Inga mwayeya izintu zibotu akwambauzyana awalo? 
 Ino zintu zibi? Tamwelede kwaamba mazina ababelesi. 
 
3. Mwalilembya lili ku SmartCare? 
Kobuzisisya:  
 Okuli/busena buli? 
 Nguni ngumwakambaula awalo? 
 Sena mula chitupa cha SmartCare? 
 
4. Sena mubelesi wazyabumi wakamutola kuchibela cha SmartCare? 
Kobuzisisya:  
 Kamundambila mbumwakalinvwa buya buzuba nimwakali ku chibela cha 
SmartCare? 
 Ninzi chakachitika chakutanguna nimwakasika? Alimwi chakatobela? 
 Magwasho abuti ngimwakapegwa? 
 
5. Bakamwambila nzi amagwasho a SmartCare? 
Kobuzisisya:  
 Wakamwambila nzi alichechi? 
 
6. Mwakambilako muntu uli onse kuti mwakalilembya aba SmartCare? 
Kobuzisisya: 
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 Mwakambila bani? 
 Echi chakachitika lili? 
 Ino bachita nzi nimwakabambila? 
 Beleka amuntu omwe omwe utambigwe 
 Bakachinvwa echi? 
 Sena chachincha echi nikwaba kaindi? 
 
7. Kamupandulula ibantu mbobalailanga eyi SmartCare? 
Kobuzisisya 
 Balikutondezya izitupa zya SmartCare kumuntu ulionse? 
 
8. Inga mubola zindi zyongaye kubusena obu? 
Kobuzisisya 
 Nkaambo? 
 
9. Mpafwafwi buti abusena ubo? 
Kobuzisisya 
 Mweenda buti? 
 Palamfu buti? 
(Beleka amuntu omwe omwe utambigwe) 
 
10. Inga mubweza chiindi chilamfu buti abusena? 
Kobuzisisya 
 Chiindi chakulindila? 
 Busena bwakulindilila? 
 Bulili siside? 
 Ino chitola chiindi chilamfu a SmartCare mwezyanya aba lwazi bambi mubunji? 
 (Beleka amuntu omwe omwe utambigwe) 
11. Sena muyeya ikuti bamakaintu bamitide banga bajanwa atuuka twa HIV inga 
balayanda kubweza magwasho a PMTCT? 
kobuzisisya:   
 Mishobo ya magwasho? 
 Ino? 
 Ino Kayi? 
 (Magwasho ali antomwe a PMCT) 
 
12. Sena bama kaintu ibabweza magwasho a PMTCT inga balamba kubamalumi babo 
mbobabede akauka ka HIV? A bamukwashi? 
Kobuzisisya:  
 Ino? 
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 Ino Kayi? 
13. Sena kusalululana kulagwashilizya kupa kutayanda kubweza magwasho a PMTCT 
azimbi? 
Kobuzisisya:  
 Munzila nzi? 
 Ino bamwi bama kaintu inga bachiinda buti echi? 
 
14. Sena kuyekuti bamalumi abamukwashi inga balagwashilizya ma makaintu bamitide 
kubweza magwasho a PMTCT na ayandika? 
Kobuzisisya:  
 Ino? Ino Kayi?  
 Ndugwasho nzii inga ndobapa? 
 Inga munzila nzi inga mobatagwashi?  
 Ino mumasena mobazwa? 
 
15. Zintu nzi zyakamugwasha kwiinda zintu zikasha ezi zitwambaula awa alimwi 
zyakamugwasha kujana magwasho a PMTCT abusena buno? 
16. Ninzi chomuyeyela ikuti inga chabambwa ikutegwa chibe chuba kubamakaintu ba 
mitide kuti bajane lugwasho lwa PMTCT. 
WRAP‐UP (5 mins): 
Kuma maninizyo 
Twalumba maningi.twainda mumibuzyo yonse yakwa mabuzyana kwesu.Twasyala biyo 
akaindi kashonto.Kuli chimbi nchemuyanda kuyungihila na kubuzya? 
Twalumba loko mukutola lubazu,Kuli dilinki a kakulya kamuntu onse uli wano. 
 
Interviewer Notes 
 Comments about respondents 
 Comments on specific questions 
 Any other comments 
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Appendix 14: Published Papers 
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Appendix 14.2: Chapter 6 
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